|
|
|
Scientific Literature, corticosteroid
-
Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP.
Curr. Top. Med. Chem. 6: 151-163 (2006).
-
Abad S, Seve P, Dhote R, Brezin AP. Guidelines for the management of uveitis in internal medicine.
Rev. Med. Interne. 30: 492-500 (2009).
-
Abdelli MN, Ben Abdallah H, Houissa F, Bouali MR, Khediri MF. Azathioprine for prevention of postoperative recurrence in Crohn's disease.
Tunis. Med. 85: 569-572 (2007).
-
Abdo AA, Beck P. Diagnosis and management of microscopic colitis.
Can. Fam. Physician 49: 1473-1478 (2003).
-
Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T, Garrity J, Goeken JA, Allen NB. Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s.
J. Rheumatol. 29: 309-316 (2002).
-
Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, Horiike N, Onji M. Drug-induced hepatitis with autoimmune features during minocycline therapy.
Intern. Med. 42: 48-52 (2003).
*
-
Abe M, Onji M, Kawai-Ninomiya K, Michitaka K, Matsuura B, Hiasa Y, Horiike N. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis.
Clin. Gastroenterol. Hepatol. 5: 255-258 (2007).
-
Abely M. Treatment of airway inflammation in cystic fibrosis.
Arch. Pediatr. 14: 1350-1355 (2007).
-
Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD. Antibiotic use and the risk of flare of inflammatory bowel disease.
Clin. Gastroenterol. Hepatol. 3: 459-465 (2005).
*
-
Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.
Gastroenterology 125: 320-327 (2003).
*
-
Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients.
Clin. Gastroenterol. Hepatol. 5: 1070-1075 (2007).
-
Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, Bouhnik Y, Coffin B, Allez M, Lamarque D, Chaussade S. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
Clin. Gastroenterol. Hepatol. 5: 1184-1189 (2007).
-
Abitbol V, Mary JY, Roux C, Soule JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S; Groupe D'etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride.
Aliment. Pharmacol. Ther. 16: 919-927 (2002).
*
-
Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease.
Gastroenterology 108: 417-422 (1995).
*
-
Aboian E, Winter DC, Metcalf DR, Wolff BG. Perineal hernia after proctectomy: prevalence, risks, and management.
Dis. Colon Rectum 49: 1564-1568 (2006).
*
-
Abourazzak FE, Guggenbuhl P, Perdriger A, Meadeb J, Gando-Cocley N, Chevrant-Breton J, Hajjaj-Hassouni N, Chales G. Cutaneous lupus induced by etanercept in rheumatoid arthritis.
Rev. Med. Interne. 29: 744-747 (2008).
-
Abraham NS, El-Serag HB, Johnson ML, Hartman C, Richardson P, Ray WA, Smalley W. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs.
Gastroenterology 129: 1171-1178 (2005).
*
-
Abramovits W, Stevenson LC. Atopic profiles, familial histories, and coexisting conditions associated with hand eczema.
Skinmed. 4: 204-210 (2005).
-
Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians.
Curr. Gastroenterol. Rep. 4: 481-489 (2002).
-
Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children.
Am. J. Gastroenterol. 102: 2271-2279 (2007).
*
-
Ackermann D. Hypercalcemia in sarcoidosis - case report, prevalence, pathophysiology and therapeutic options.
Ther. Umsch. 64: 281-286 (2007).
-
Ackermann D, Mordasini D, Cheval L, Imbert-Teboul M, Vogt B, Doucet A. Sodium retention and ascites formation in a cholestatic mice model: role of aldosterone and mineralocorticoid receptor?
Hepatology 46: 173-179 (2007).
*
-
Actis GC, Fadda M, Pellicano R, David E, Rizzetto M, Sapino A. The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis.
Biomed. Pharmacother. 63: 362-365 (2009).
-
Actis GC, Pellicano R, Bugianesi E, Lagget M, Rizzetto M. Use of corticosteroids, immunomodulators, and Infliximab at a third-level day-hospital service of gastro-hepatology.
Minerva Gastroenterol. Dietol. 54: 239-242 (2008).
-
Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease.
Inflamm. Bowel Dis. 5: 200-211 (1999).
-
Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver.
Annals of Gastroenterology 19: 146-151 (2006). *
-
Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases.
COPD 2: 445-455 (2005).
-
Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L. Understanding and treating patients with alcoholic cirrhosis: an update.
Alcohol Clin. Exp. Res. Apr 21 [Epub ahead of print] (2009).
-
Adema GJ. Dendritic cells from bench to bedside and back.
Immunol. Lett. 122: 128-130 (2009).
-
Adler AI, Gunn E, Haworth CS, Bilton D. Characteristics of adults with and without cystic fibrosis-related diabetes.
Diabet. Med. 24: 1143-1148 (2007).
*
-
Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D. Genetic determinants and epidemiology of cystic fibrosis-related diabetes - results from a British cohort of children and adults.
Diabetes Care 31: 1789-1794 (2008).
*
-
Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo.
Dig. Dis. Sci. 36: 449-453 (1991).
-
Affes N, Mseddi A, Feriani N, Beyrouti MI. Extrahepatic cholestasis secondary to Castleman's disease.
Rev. Med. Interne. 30: 450-452 (2009).
-
Agache I, Duca L, Anghel M, Pamfil G. Antinuclear antibodies in asthma patients- a special asthma phenotype?
Iran. J. Allergy Asthma Immunol. 8: 49-52 (2009).
-
Aggarwal A, Catlett JP. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
South. Med. J. 95: 1209-1212 (2002).
-
Agoumi S, Himdi B, Abidi K, Zeggwagh A, Abouqal R. Acute pancreatitis revealing a systemic lupus erythematous.
Rev. Med. Interne. 27: 799-802 (2006).
-
Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease.
Clin. Gastroenterol. Hepatol. 3: 1215-1220 (2005).
-
Aguirre AL, Center SA, Randolph JF, Yeager AE, Keegan AM, Harvey HJ, Erb HN. Gallbladder disease in Shetland sheepdogs: 38 cases (1995-2005).
J. Am. Vet. Med. Assoc. 231: 79-88 (2007).
-
Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, Schechter GP. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Am. J. Hematol. 77: 171-176 (2004).
*
-
Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?
J. Am. Acad. Dermatol. 54: 55-60 (2006).
-
Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R. Risk of postoperative infection in patients with inflammatory bowel disease.
Korean J. Gastroenterol. 48: 306-312 (2006).
-
Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals.
Ann. N. Y. Acad. Sci. 1056: 218-233 (2005).
*
-
Ajisaka H, Fujita H, Kaji M, Maeda K, Yabushita K, Konishi K, Uchiyama A, Miwa A. Lymphoplasmacytic sclerosing pancreatocholangitis successfully treated by pancreatoduodenectomy.
J. Hepatobiliary Pancreat. Surg. 9: 522-526 (2002).
-
Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity.
Am. J. Med. Sci. 325: 292-295 (2003).
-
Akamatsu S, Tsukazaki H, Inoue K, Nishio Y. A case of lupus cystitis diagnosed from urinary symptoms as the sole initial complaint.
Hinyokika. Kiyo. 51: 685-687 (2005).
-
Akerman L, Mimouni D, Trattner A, David M. Pemphigus vulgaris - an alternative for steroid treatment?
Harefuah. 145: 493-494, 551 (2006).
-
Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
Best Pract. Res. Clin. Rheumatol. 20: 539-557 (2006).
-
Akobeng A, Thomas A. Enteral nutrition for maintenance of remission in Crohn's disease.
Cochrane Database Syst. Rev. 3: CD005984 (2007).
*
-
Akobeng A, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
Cochrane Database Syst. Rev. 1: CD003574 (2004).
*
-
Akobeng AK. Crohn's disease: current treatment options.
Arch. Dis. Child. 93: 787-792 (2008).
-
Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn's disease.
Aliment. Pharmacol. Ther. 27: 11-18 (2008).
*
-
Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
Cochrane Database Syst. Rev. 1: CD003715 (2004).
*
-
Akritidis N, Papadopoulos A, Pappas G. Long-term follow-up of patients with adult-onset Still's disease.
Scand. J. Rheumatol. 35: 395-397 (2006).
*
-
Al Shammeri O, Duerksen DR. Celiac crisis in an adult on immunosuppressive therapy.
Can. J. Gastroenterol. 22: 574-576 (2008).
-
Al-Aghbar MN, Alexander GJ, Neuberger J, Nouri-Aria KT, Eddleston AL, Williams R. The effect of prednisolone in vitro on immunoglobulin production in primary biliary cirrhosis.
Clin. Exp. Immunol. 63: 663-670 (1986).
*
-
Al-Daraji W, Gregory AN, Carlson JA. "Macular arteritis": a latent form of cutaneous polyarteritis nodosa?
Am. J. Dermatopathol. 30: 145-149 (2008).
-
Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG. Allopurinol hepatotoxicity. Report of two cases and review of the literature.
Ann. Intern. Med. 95: 588-590 (1981).
-
Al-Khalidi JA, Czaja AJ. Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis.
Mayo Clin. Proc. 76: 1237-1252 (2001).
*
-
Al-Mutawa SA, Hegab SM. Behcet's disease.
Clin. Exp. Med. 4: 103-131 (2004).
*
-
Al-Osaimi AM, Berg CL. Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature.
Am. J. Gastroenterol. 97: S85 (2002). *
-
Al-toma A, Verbeek WH, Mulder CJ. The management of complicated celiac disease.
Dig. Dis. 25: 230-236 (2007).
-
Al-Toma A, Verbeek WH, Mulder CJ. Update on the management of refractory coeliac disease.
J. Gastrointestin. Liver Dis. 16: 57-63 (2007).
*
-
Alam I, Levenson SD, Ferrell LD, Bass NM. Diffuse intrahepatic biliary strictures in sarcoidosis resembling sclerosing cholangitis. Case report and review of the literature.
Dig. Dis. Sci. 42: 1295-1301 (1997).
*
-
Alexander TH, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE, Harris JP. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease.
Otol. Neurotol. Apr 23 [Epub ahead of print] (2009).
-
Alfadhli A, McDonald J, Feagan B. Methotrexate for induction of remission in refractory Crohn's disease.
Cochrane Database Syst. Rev. 1: CD003459 (2005).
*
-
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease.
Cochrane Database Syst. Rev. 1: CD003459 (2003).
*
-
Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patients - extended report.
Rheumatology (Oxford) 46: 1185-1190 (2007).
*
-
Alsultan A, Goldenberg NA, Kaiser N, Graham DK, Hays T. Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children.
Pediatr. Blood Cancer 52: 626-630 (2009).
-
Alva E, Vasquez J, Frisancho O, Mantilla L, Yabar A, Morales D. Refractary corticosteroids colonic Crohn disease with successful remission with infliximab.
Rev. Gastroenterol. Peru 29: 51-54 (2009).
-
Alvarez F. Round table: controversies in the treatment of autoimmune liver diseases in children. Cyclosporine indication in “autoimmune hepatitis (AIH)”.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 95-96 (2004). *
-
Alves Cde A, Lima DS. Cystic fibrosis-related dyslipidemia.
J. Bras. Pneumol. 34: 829-837 (2008).
-
Amano K, Amano K. Filter leukapheresis for patients with ulcerative colitis: clinical results and the possible mechanism.
Ther. Apher. 2: 97-100 (1998).
-
Amarapurkar DN, Patel ND, Amarapurkar AD. Hepatic sarcoidosis.
Indian J. Gastroenterol. 22: 98-100 (2003).
-
Ament ME, Berquist W, Vargas J. Advances in ulcerative colitis.
Pediatrician 15: 45-57 (1988).
-
Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.
Rheumatology (Oxford) 43: 658-661 (2004).
*
-
Ammar D, Denguezli M, Ghariani N, Sriha B, Belajouza C, Nouira R.. Sweet's syndrome complicating isotretinoin therapy in acne.
Ann. Dermatol. Venereol. 134: 151-154 (2007).
-
Ammouri W, Mezalek ZT, Harmouche H, Aouni M, Adnaoui M, Maaouni A. Myelitis complicating systemic lupus erythematosus: successfully treated with corticosteroids and cyclophosphamide.
South. Med. J. May 29 [Epub ahead of print] (2009).
-
Anavekar NS, Williams R, Chong AH. Sweet's syndrome in an Australian hospital: a retrospective analysis.
Australas. J. Dermatol. 48: 161-164 (2007).
*
-
Andre MF, Aumaitre O, Piette JC, Grateau G, Cardoso MC, Ouchchane L, Kemeny JL, Dastugue B, Delpech M, Creveaux I. Analysis of the NOD2/CARD15 gene in patients affected with the aseptic abscesses syndrome with or without inflammatory bowel disease.
Dig. Dis. Sci. 53: 490-499 (2008).
*
-
Andre MF, Piette JC, Kemeny JL, Ninet J, Jego P, Delevaux I, Wechsler B, Weiller PJ, Frances C, Bletry O, Wismans PJ, Rousset H, Colombel JF, Aumaitre O; and the French Study Group on Aseptic Abscesses. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature.
Medicine (Baltimore) 86: 145-161 (2007).
-
Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis.
Scand. J. Gastroenterol. 32: 1247-1255 (1997).
-
Andus T, Gross V, Caesar I, Schulz HJ, Lochs H, Strohm WD, Gierend M, Weber A, Ewe K, Scholmerich J; German/Austrian Budesonide Study Group. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
Dig. Dis. Sci. 48: 373-378 (2003).
*
-
Angelova-Fischer I, Tsankov N. Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.
Acta Dermatovenerol. Alp. Panonica Adriat. 14: 115-119 (2005).
*
-
Angelucci E, Malesci A, Danese S. Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment.
Curr. Med. Chem. 15: 2527-2535 (2008).
-
Angulo P. Use of ursodeoxycholic acid in patients with liver disease.
Curr. Gastroenterol. Rep. 4: 37-44 (2002).
-
Angulo P, Bharucha AE, Jorgensen RA, DeSotel CK, Sandborn WJ, LaRusso NF, Lindor KD. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study.
Dig. Dis. Sci. 44: 602-607 (1999).
*
-
Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Hepatology 31: 318-323 (2000).
*
-
Angulo P, Lindor KD. Management of primary biliary cirrhosis and autoimmune cholangitis.
Clin. Liver Dis. 2: 333-351, ix (1998).
-
Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study.
Am. J. Gastroenterol. 100: 1370-1375 (2005).
*
-
Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Muller S, Senninger N, Russell J, Jauch J, Bergmann J, Granger DN, Krieglstein CF. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis.
Am. J. Physiol. Gastrointest. Liver Physiol. 290: G1131-G1137 (2006).
*
-
Antonio-Santos AA, Eggenberger ER. Medical treatment options for ocular myasthenia gravis.
Curr. Opin. Ophthalmol. 19: 468-478 (2008).
-
Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, Boumpas DT. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease.
Clin. Exp. Rheumatol. 25: 23-28 (2007).
-
Antoniu SA. Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al.: infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. (2006) 174(7):795-802.
Expert Opin. Investig. Drugs 16: 753-756 (2007).
-
Antoniu SA. Treatment options for refractory Wegener's granulomatosis: a role for rituximab?
Curr. Opin. Investig. Drugs 8: 927-932 (2007).
-
Antoniu SA. Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?
Expert Opin. Investig. Drugs 15: 181-184 (2006).
-
Aoki A, Sato K, Itabashi M, Takei T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K. A case of Mikulicz's disease complicated with severe interstitial nephritis associated with IgG4.
Clin. Exp. Nephrol. Jan 14 [Epub ahead of print] (2009).
-
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, de Bruin PA, Mieremet-Ooms MA, van der Zon JM, van Tol EA, Lamers CB. In vitro cellular cytotoxicity in Crohn's disease and ulcerative colitis: relation with disease activity and treatment, and the effect of recombinant gamma-interferon.
J. Clin. Lab. Immunol. 29: 119-124 (1989).
-
Arai F, Takahashi T, Furukawa K, Matsushima K, Asakura H. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease.
Dig. Dis. Sci. 43: 2071-2079 (1998).
*
-
Arakawa Y, Hashida N, Ohguro N, Yamazaki N, Onda M, Matsumoto S, Ohishi M, Yamabe K, Tano Y, Kurokawa N. Eye-concentrated distribution of dexamethasone carried by sugar-chain modified liposome in experimental autoimmune uveoretinitis mice.
Biomed. Res. 28: 331-334 (2008).
*
-
Arash A, Shirin L. The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid.
J. Oral Pathol. Med. 37: 341-344 (2008).
-
Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn's disease.
Aliment. Pharmacol. Ther. 26: 1303-1312 (2007).
*
-
Ardizzone S. Ulcerative colitis.
Orphanet encyclopedia [http://www.orpha.net/data/patho/GB/uk-UC.pdf] (2003). *
-
Arechalde A, Saurat JH. Management of psoriasis: the position of retinoid drugs.
BioDrugs 13: 327-333 (2000).
-
Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review.
Pediatr. Nephrol. 19: 550-553 (2004).
*
-
Arguelles Arias F, Arguelles Martin F, Caunedo Alvarez A, Rodriguez-Tellez M, Herrerias Gutierrez JM. Utility of capsule endoscopy in pediatric gastroenterology.
An. Pediatr. (Barc.) 59: 586-589 (2003).
-
Arimura Y, Goto A, Yamashita K, Endo T, Ikeda H, Tanaka K, Tsutsumi H, Shinomura Y, Imai K. Intractable colitis associated with chronic granulomatous disease.
J. Med. Microbiol. 55: 1587-1590 (2006).
*
-
Arish N, Eldor R, Fellig Y, Bogot N, Laxer U, Izhar U, Rokach A. Lymphocytic interstitial pneumonia associated with common variable immunodeficiency resolved with intravenous immunoglobulins.
Thorax 61: 1096-1097 (2006).
*
-
Arnold C, von Sanden S, Theilacker C, Blum HE. Ulcerous colitis and infection with cytomegalovirus, herpes simplex virus and Clostridium difficile.
Z. Gastroenterol. 46: 780-783 (2008).
-
Aronoff JS, Korelitz BI, Sohn N, Ky A, Rajapakse R, Weinstein MA, Cohen FS. Anorectal Crohn's disease: surgical and medical management.
BioDrugs 13: 95-105 (2000).
-
Arundel C, Lewis JH. Drug-induced liver disease in 2006.
Curr. Opin. Gastroenterol. 23: 244-254 (2007).
-
Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
Ann. Rheum. Dis. 61: 922-924 (2002).
*
-
Asakura H, Suzuki K, Honma T. Non-surgical therapy for ulcerative colitis.
Nippon Geka Gakkai Zasshi 98: 431-437 (1997).
-
Asashima N, Fujimoto M, Jinnin M, Ihn H, Kikuchi K, Takamizawa M, Tamaki K. A female case of hyper-IgM immunodeficiency syndrome with uncommon skin manifestations.
Nihon Rinsho Meneki Gakkai Kaishi 27: 350-355 (2004).
-
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
BMJ 330: 516 (2005).
*
-
Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome.
Autoimmun. Rev. 6: 64-67 (2006).
-
Ashraf VV, Taly AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study.
Acta Neurol. Scand. 114: 119-123 (2006).
*
-
Ashraf-Benson S, Wall GC, Veach LA. Serum sickness-like reaction associated with efalizumab.
Ann. Pharmacother. 43: 383-386 (2009).
-
Assimakopoulos SF, Michalopoulou S, Melachrinou M, Giannakoulas N, Papakonstantinou C, Lekkou A, Gogos C. Primary Sjogren syndrome complicated by autoimmune hemolytic anemia and pure red cell aplasia.
Am. J. Med. Sci. 334: 493-496 (2007).
-
Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: retrospective study.
Biomed. Pharmacother. 61: 370-376 (2007).
-
Atabek ME, Pirgon O. Unusual cardiac features in cholestatic hepatitis A in an adolescent: improvement with corticosteroid treatment.
J. Infect. 54: e91-e93 (2007).
-
Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab.
J. Clin. Rheumatol. 12: 291-293 (2006).
-
Attwood SE, Lewis CJ, Bronder CS, Morris CD, Armstrong GR, Whittam J. Eosinophilic oesophagitis: a novel treatment using Montelukast.
Gut 52: 181-185 (2003).
*
-
Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, Favalli EG, Marchesoni A, Sarzi-Puttini P. Predicting response to anti-TNF treatment in rheumatoid arthritis patients.
Autoimmun. Rev. 8: 431-437 (2009).
-
Atzori L, Deidda S, Aste N. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
G. Ital. Dermatol. Venereol. 143: 1-8 (2008).
-
Au WY, Kwong YL. Arsenic trioxide: safety issues and their management.
Acta Pharmacol. Sin. 29: 296-304 (2008).
-
Aubart FC, Ouayoun M, Brauner M, Attali P, Kambouchner M, Valeyre D, Nunes H. Sinonasal involvement in sarcoidosis: a case-control study of 20 patients.
Medicine (Baltimore) 85: 365-371 (2006).
-
Augustin M, Radtke M, van Engen A, Ruedig C, Lapp C, Moehling U. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany.
J. Dtsch. Dermatol. Ges. Feb 10 [Epub ahead of print] (2009).
-
Aulakh R, Singh S. Strategies for minimizing corticosteroid toxicity: a review.
Indian J. Pediatr. 75: 1067-1073 (2008).
-
Auth MK, Kim HS, Beste M, Bonzel KE, Baumann U, Ballauff A, Wallot M, Borchers T, Vester U, Grasemann C, Hauffa B, Hoyer PF, Gerken G, Voit T. Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children.
J. Pediatr. Gastroenterol. Nutr. 40: 54-59 (2005).
*
-
Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, Giese T, Loffler T, Buchler MW, Schmidt J. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease.
Gut 54: 944-949 (2005).
*
-
Auwardt RB, Mudge SJ, Chen CG, Power DA. Regulation of nuclear factor kappaB by corticosteroids in rat mesangial cells.
J. Am. Soc. Nephrol. 9: 1620-1628 (1998).
-
Awada H, Abi-Karam G, Fayad F. Musculoskeletal and other extrapulmonary disorders in sarcoidosis.
Best Pract. Res. Clin. Rheumatol. 17: 971-987 (2003).
-
Aydogan K, Karadogan SK, Adim SB, Tunali S. Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus.
Int. J. Dermatol. 45: 1057-1061 (2006).
*
-
Azeroual A, Benomar A, Harmouche H, Daoudi N, Ait Benhaddou EH, Yahyaoui M, Maaouni A. Primary Gougerot-Sjogren's syndrome presenting as a cerebellar syndrome.
Rev. Neurol. (Paris) 163: 1242-1245 (2007).
-
Azizan NZ, Gangaram HB, Hussein SH. A novel therapy for the treatment of pyoderma gangrenosum.
Med. J. Malaysia 63: 51-54 (2008).
-
Azulay JP. The diagnosis of chronic axonal polyneuropathy: the poorly understood chronic polyradiculoneuritides.
Rev. Neurol. (Paris) 162: 1292-1295 (2006).
-
Bachmeyer C, Leclerc-Landgraf N, Laurette F, Coutarel P, Cadranel JF, Medioni J, Dhote R, Mougeot-Martin M. Acute autoimmune sensorineural hearing loss associated with Crohn's disease.
Am. J. Gastroenterol. 93: 2565-2567 (1998).
*
-
Badelon I. Eye and spondylarthropathies.
Rev. Prat. 49: 1995-1998 (1999).
-
Bae SH, Kim JS, Kim DH. Deflazacort for type-1 autoimmune hepatitis in a Korean girl.
J. Korean Med. Sci. 21: 758-760 (2006).
*
-
Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, Porta G, Nishioka M, Simon T, Daehnrich C, Schlumberger W, Galle PR, Lohse AW. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.
Gut 51: 259-264 (2002).
*
-
Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P. Management of ulcerative colitis and Crohn's disease.
Acta Clin. Belg. 59: 304-314 (2004).
-
Bahadori HR, Williams VC, Turner RP, Rumboldt Z, Reigart JR, Fowler SL, Chavis PS, Maria BL. Acute disseminated encephalomyelitis following infectious mononucleosis.
J. Child. Neurol. 22: 324-328 (2007).
-
Bai Y, Gao J, Shi X, Zou D, Li Z. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Pancreatology 8: 504-509 (2008).
-
Baker K, Jewell DP. Cyclosporin for the treatment of severe inflammatory bowel disease.
Aliment. Pharmacol. Ther. 3: 143-149 (1989).
-
Balfour-Lynn IM. Anti-inflammatory approaches to cystic fibrosis airways disease.
Curr. Opin. Pulm. Med. 13: 522-528 (2007).
-
Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis.
Cochrane Database Syst. Rev. 1: CD001915 (2009).
-
Balzola FA, Khan K, Pera A, Bonino F, Pounder RE, Wakefield AJ. Measles IgM immunoreactivity in patients with inflammatory bowel disease.
Ital. J. Gastroenterol. Hepatol. 30: 378-382 (1998).
-
Bandelier C, Guerne PA, Genevay S, Finckh A, Gabay C. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies.
Swiss Med. Wkly. 139: 41-46 (2009).
*
-
Banerjee D, Deb R, Dar L, Mirdha BR, Pati SK, Thareja S, Falodia S, Ahuja V. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country.
Scand. J. Gastroenterol. 44: 325-331 (2009).
*
-
Banerjee S, Bishop WP. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center: role of thiopurine methyltransferase and 6-mercaptopurine metabolite measurements.
J. Pediatr. Gastroenterol. Nutr. 43: 324-330 (2006).
*
-
Banerjee S, Rahhal R, Bishop WP. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis.
J. Pediatr. Gastroenterol. Nutr. 43: 353-356 (2006).
*
-
Bankhurst AD, Nunez SE, Draeger HT, Kettwich SC, Kettwich LG, Sibbitt WL Jr. A randomized controlled trial of the reciprocating procedure device for intraarticular injection of corticosteroid.
J. Rheumatol. 34: 187-192 (2007).
-
Bannwarth B. Drug-induced musculoskeletal disorders.
Drug Saf. 30: 27-46 (2007).
-
Barnes DS. Intrahepatic cholestatic liver disease.
http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *
-
Barnett B, Kruse-Jarres R, Leissinger CA. Current management of acquired factor VIII inhibitors.
Curr. Opin. Hematol. 15: 451-455 (2008).
-
Barritt AS 4th, Zacks SL, Rubinas TC, Herfarth HH. Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature.
Inflamm. Bowel Dis. 14: 1695-1700 (2008).
*
-
Barry PJ, Waterhouse DF, Reilly CM, McKenna TJ, McKone EF, Gallagher CG. Androgens, exercise capacity and muscle function in cystic fibrosis.
Chest 134: 1258-1264 (2008).
-
Barth C, Bosse A, Andus T. Severe acute cholestatic hepatitis by infiltration of monoclonal plasma cells in multiple myeloma.
Z. Gastroenterol. 43: 1129-1132 (2005).
-
Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease.
World J. Gastroenterol. 12: 5680-5686 (2006).
*
-
Bastida G, Munoz F. Systemic corticosteroids in inflammatory bowel disease: are they really effective. What is their real toxicity?
Gastroenterol. Hepatol. 31 Suppl. 3: 3-9 (2008).
-
Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease.
Aliment. Pharmacol. Ther. 22: 775-782 (2005).
*
-
Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis.
Semin. Liver Dis. 21: 437-451 (2001).
-
Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM. Severe ulcerative colitis: present medical treatment strategies.
Expert Opin. Pharmacother. 9: 447-457 (2008).
-
Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.
Gut 40: 470-474 (1997).
*
-
Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
BioDrugs 17: 425-431 (2003).
-
Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber FL Jr. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis.
Arch. Intern. Med. 163: 615-620 (2003).
*
-
Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
Sarcoidosis Vasc. Diffuse Lung Dis. 25: 76-89 (2008).
-
Baughman RP, Lower EE, du Bois RM. Sarcoidosis.
Lancet 361: 1111-1118 (2003).
*
-
Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis.
Cochrane Database Syst. Rev. 3: CD007216 (2008).
*
-
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Lancet 369: 1641-1657 (2007).
*
-
Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus.
J. Rheumatol. 34: 346-352 (2007).
-
Beattie RM. Enteral nutrition as primary therapy in childhood Crohn's disease: control of intestinal inflammation and anabolic response.
JPEN J. Parenter. Enteral Nutr. 29: S151-S159 (2005).
*
-
Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis?
Aliment. Pharmacol. Ther. 20: 143-149 (2004).
*
-
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
J. Clin. Oncol. 24: 2283-2289 (2006).
*
-
Becker H, Gaubitz M, Domschke W, Kucharzik T. Joint involvement in chronic inflammatory bowel disease - current diagnostics and treatment options.
Z. Gastroenterol. 44: 497-502 (2006).
-
Becker H, Weber C, Storch S, Federlin K. Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity.
Clin. Immunol. Immunopathol. 56: 219-225 (1990).
-
Beddy D, Watson RW, Fitzpatrick JM, O'Connell PR. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease.
Br. J. Surg. 91: 72-77 (2004).
*
-
Behm B, Bickston S. Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn's disease.
Cochrane Database Syst. Rev. 1: CD006893 (2008).
*
-
Beishuizen A, van Bodegraven AA, Bronsveld W, Sindram JW. Eosinophilic gastroenteritis - a disease with a wide clinical spectrum.
Neth. J. Med. 42: 212-217 (1993).
-
Beji S, Kaaroud H, Ben Moussa F, Goucha R, Abderrahim E, El Younsi F, Ben Maiz H. Renal amyloidosis complicating the outcome of chronic inflammatory colitis.
Presse. Med. 33: 862-865 (2004).
-
Bejot Y, Osseby GV, Ben Salem D, Beynat J, Muller G, Moreau T, Giroud M. Bilateral optic neuropathy revealing Sjogren's syndrome.
Rev. Neurol. (Paris) 164: 1044-1047 (2008).
-
Belda A, Hinojosa J, Serra B, Garcia L, Merino C, Belda A, Moles JR. Systemic candidiasis and infliximab therapy.
Gastroenterol. Hepatol. 27: 365-367 (2004).
-
Bello C, Goldstein F, Thornton JJ. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease.
Am. J. Gastroenterol. 86: 460-466 (1991).
-
Belmont HM. Treatment of ANCA-associated systemic vasculitis.
Bull. Hosp. Jt. Dis. 64: 60-66 (2006).
*
-
Beltinger J, Froehlich F. Patients with inflammatory bowel disease in specialist gastroenterology practice: a prospective survey.
Schweiz. Rundsch. Med. Prax. 94: 459-465 (2005).
-
Ben Lagha N, Poulesquen V, Roujeau JC, Alantar A, Maman L. Pemphigus vulgaris: a case-based update.
J. Can. Dent. Assoc. 71: 667-672 (2005).
-
Ben Rhouma K, Tebourbi O, Sakly M. Acute hepatotoxicity of DDT: effect on glucocorticoid receptors and serum transcortin.
Indian J. Exp. Biol. 38: 452-456 (2000).
-
Ben-Horin S, Barshack I, Chowers Y, Mouallem M. Flare-up of ulcerative colitis after systemic corticosteroids: a strong case for Strongyloides.
World J. Gastroenterol. 14: 4413-4415 (2008).
*
-
Benchimol E, Seow Ch, Steinhart A, Griffiths A. Traditional corticosteroids for induction of remission in Crohn's disease.
Cochrane Database Syst. Rev. 2: CD006792 (2008).
*
-
Benchimol EI, Turner D, Mann EH, Thomas KE, Gomes T, McLernon RA, Griffiths AM. Toxic megacolon in children with inflammatory bowel disease: clinical and radiographic characteristics.
Am. J. Gastroenterol. 103: 1524-1531 (2008).
*
-
Bergheim I, McClain CJ, Arteel GE. Treatment of alcoholic liver disease.
Dig. Dis. 23: 275-284 (2005).
-
Bermejo F, Lopez-Sanroman A, Hinojosa J, Castro L, Jurado C, Gomez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis.
Rev. Esp. Enferm. Dig. 96: 94-101 (2004).
-
Bermejo F, San Roman AL, Algaba A, Van Domselaar M, Carneros JA, Rivero M, Piqueras B, Paz Valer M. Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab.
Gastroenterol. Hepatol. 31: 629-632 (2008).
-
Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma - meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories.
Rheumatology (Oxford) 46: 690-694 (2007).
*
-
Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, D'Armiento F, Romeo EF, Cucchiara S. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease.
Dig. Liver Dis. 38: 381-387 (2006).
-
Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease.
Curr. Gastroenterol. Rep. 4: 513-516 (2002).
-
Bernstein CN. Neoplasia in inflammatory bowel disease: surveillance and management strategies.
Curr. Gastroenterol. Rep. 8: 513-518 (2006).
-
Bernstein CN, Leslie WD. Osteoporosis and inflammatory bowel disease.
Aliment. Pharmacol. Ther. 19: 941-952 (2004).
*
-
Bernstein CN, Leslie WD. Therapy insight: osteoporosis in inflammatory bowel disease - advances and retreats.
Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 232-239 (2005).
*
-
Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
Inflamm. Bowel Dis. 11: 325-330 (2005).
*
-
Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study.
Aliment. Pharmacol. Ther. 10: 777-786 (1996).
-
Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.
J. Bone Miner. Res. 10: 250-256 (1995).
-
Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease.
Am. J. Gastroenterol. 100: 2031-2035 (2005).
*
-
Berti S, Amato L, Chiarini C, Fabbri P. Case study: an itching and excoriated dermatosis during intrahepatic cholestasis of pregnancy.
Skinmed. 4: 248-249 (2005).
-
Beuers U, Rust C. Overlap syndromes.
Semin. Liver Dis. 25: 311-320 (2005).
-
Bhat G, Jordan J Jr, Sokalski S, Bajaj V, Marshall R, Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia.
J. Clin. Gastroenterol. 27: 74-75 (1998).
-
Bhat RM. Management of pyoderma gangrenosum - an update.
Indian J. Dermatol. Venereol. Leprol. 70: 329-335 (2004).
-
Bianchi L, Terracciano LM. Giant cell hepatitis in adults.
Schweiz. Rundsch. Med. Prax. 83: 1237-1241 (1994).
-
Bianchi ML. How to manage osteoporosis in children.
Best Pract. Res. Clin. Rheumatol. 19: 991-1005 (2005).
-
Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease.
Curr. Gastroenterol. Rep. 5: 518-523 (2003).
-
Bilic M, Bumber Z, Blagaic AB, Batelja L, Seiwerth S, Sikiric P. The stable gastric pentadecapeptide BPC 157, given locally, improves CO(2) laser healing in mice.
Burns 31: 310-315 (2005).
-
Billingsley GD, Walter MA, Hammond GL, Cox DW. Physical mapping of four serpin genes: alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome I4q32.1.
Am. J. Hum. Genet. 52: 343-353 (1993).
*
-
Birand B, Cabre P, Bonnan M, Olindo S, Smadja D. A new case of cerebellar ataxia with anti-GAD antibodies treated with corticosteroids and initially seronegative.
Rev. Med. Interne. 27: 616-619 (2006).
-
Bircan Z, Usluer H. Protracted febrile myalgia mimicking polyarteritis nodosa.
J. Clin. Rheumatol. 14: 222-225 (2008).
-
Biro T, Griger Z, Kiss E, Papp H, Aleksza M, Kovacs I, Zeher M, Bodolay E, Csepany T, Szucs K, Gergely P, Kovacs L, Szegedi G, Sipka S. Abnormal cell-specific expressions of certain protein kinase C isoenzymes in peripheral mononuclear cells of patients with systemic lupus erythematosus: effect of corticosteroid application.
Scand. J. Immunol. 60: 421-428 (2004).
*
-
Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Muhlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease.
Am. J. Gastroenterol. 92: 1157-1163 (1997).
-
Bissuel F, Bizollon T, Dijoud F, Bouletreau P, Cordier JF, Chazot C, Gouillat C, Trepo C. Pulmonary hemorrhage and glomerulonephritis in primary biliary cirrhosis.
Hepatology 16: 1357-1361 (1992).
-
Bittar F, Reynaud-Gaubert M, Thomas P, Boniface S, Raoult D, Rolain JM. Acetobacter indonesiensis pneumonia after lung transplant.
Emerg. Infect. Dis. 14: 997-998 (2008).
*
-
Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease.
Gut 40: 228-233 (1997).
*
-
Black M, Mignogna M, Scully C. Pemphigus vulgaris.
Oral Dis. 11: 119-130 (2005).
*
-
Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, Rothenberg ME. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids.
J. Allergy Clin. Immunol. 120: 1292-1300 (2007).
*
-
Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsoe B, Torp-Pedersen S. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Scand. J. Rheumatol. 35: 341-345 (2006).
*
-
Blonski W, Lichtenstein GR. Safety of biologic therapy.
Inflamm. Bowel Dis. 13: 769-796 (2007).
*
-
Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease.
Curr. Treat. Options Gastroenterol. 9: 221-233 (2006).
-
Blumenstein I, Bock H, Weber C, Rambow A, Tacke W, Kihn R, Pfaff R, Orlemann S, Schaeffer R, Schroder O, DignaB A, Hartmann F, Stein J. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study.
Inflamm. Bowel Dis. 14: 53-60 (2008).
*
-
Boberg KM, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients.
Scand. J. Gastroenterol. 38: 991-995 (2003).
*
-
Bockelmann R, Horn T, Gollnick H, Bonnekoh B. Interferon-gamma-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects.
Skin Pharmacol. Physiol. 18: 42-54 (2005).
-
Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab.
Pharmacoeconomics 23: 875-888 (2005).
-
Bogdanos D, Vergani D, Mieli-Vergani G. Overlap syndromes from pediatrics to adulthood.
J. Gastroenterol. Hepatol. 19: S284-S286 (2004). *
-
Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
Liver Transpl. 11: 61-67 (2005).
*
-
Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, Belaiche J, Cadiot G, Metman EH, Cortot A, Colombel JF; Getaid. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.
Aliment. Pharmacol. Ther. 18: 401-408 (2003).
*
-
Bonfioli AA, Damico FM, Curi AL, Orefice F. Intermediate uveitis.
Semin. Ophthalmol. 20: 147-154 (2005).
-
Bonfioli AA, de Miranda SS, Campos WR, Orefice F. Tuberculosis.
Semin. Ophthalmol. 20: 169-175 (2005).
-
Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, Picard V. MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients.
Transplantation 78: 21-25 (2004).
-
Bonnel AS, Quinque K, Le Roux P, Le Luyer B. Semi-invasive necrotic aspergillosis in a child with cystic fibrosis.
Rev. Mal. Respir. 23: 343-347 (2006).
-
Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus.
Osteoporos. Int. 20: 427-433 (2009).
-
Borchers AT, Keen CL, Gershwin ME. Use and misuse of corticosteroids.
Compr. Ther. 29: 157-165 (2003).
-
Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus.
Autoimmun. Rev. 3: 423-453 (2004).
-
Borgaonkar M, MacIntosh D, Fardy J, Simms L. Anti-tuberculous therapy for maintaining remission of Crohn's disease.
Cochrane Database Syst. Rev. 2: CD000299 (2000).
*
-
Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease.
Am. J. Gastroenterol. 95: 725-729 (2000).
*
-
Borgmann S, Endisch G, Urban S, Sitter T, Fricke H. A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis.
Clin. Immunol. 98: 244-248 (2001).
*
-
Borhani Haghighi A. Treatment of neuro-Behcet's disease: an update.
Expert Rev. Neurother. 9: 565-574 (2009).
-
Borkje B, Vetvik K, Odegaard S, Schrumpf E, Larssen TB, Kolmannskog F. Chronic pancreatitis in patients with sclerosing cholangitis and ulcerative colitis.
Scand. J. Gastroenterol. 20: 539-542 (1985).
-
Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Dig. Liver Dis. 36: 342-347 (2004).
-
Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial.
Clin. Gastroenterol. Hepatol. 4: 744-753 (2006).
-
Bosch X. Hypercalcemia due to endogenous overproduction of 1,25-dihydroxyvitamin D in Crohn's disease.
Gastroenterology 114: 1061-1065 (1998).
*
-
Bosch X, Guilabert A. Kikuchi-Fujimoto disease.
Orphanet J. Rare Dis. 1: 18 (2006).
*
-
Bossa F, Colombo E, Andriulli A, Annese V. Treatment of steroid-naive ulcerative colitis.
Expert Opin. Pharmacother. May 15 [Epub ahead of print] (2009).
-
Botoman VA, Bonner GF, Botoman DA. Management of inflammatory bowel disease.
Am. Fam. Physician 57: 57-68, 71-72 (1998).
-
Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy.
Clin. Rheumatol. 28 Suppl. 1: S53-S55 (2009).
-
Boumpas DT, Sidiropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?
Nat. Clin. Pract. Rheumatol. 1: 22-30 (2005).
*
-
Bourges O, Dorgeret S, Alberti C, Hugot JP, Sebag G, Cezard JP. Low bone mineral density in children with Crohn's disease.
Arch. Pediatr. 11: 800-806 (2004).
-
Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease.
Inflamm. Bowel Dis. 11: 833-839 (2005).
*
-
Bovenschen HJ, Gerritsen WJ, van Rens DW, Seyger MM, de Jong EM, van de Kerkhof PC. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
Arch. Dermatol. Res. 298: 457-463 (2007).
*
-
Boyd AS. Localized chronic cutaneous lupus erythematosus masquerading as pigmented lesions: a new clinical subset?
Lupus 15: 292-295 (2006).
-
Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?
Gastroenterology 129: 735-740 (2005).
*
-
Braegger CP, Torresani T, Murch SH, Savage MO, Walker-Smith JA, MacDonald TT. Urinary growth hormone in growth-impaired children with chronic inflammatory bowel disease.
J. Pediatr. Gastroenterol. Nutr. 16: 49-52 (1993).
-
Brailski Kh, Damianov B. Primary biliary cirrhosis.
Vutr. Boles. 22: 27-37 (1983).
-
Branche J, Cortot A, Bourreille A, Coffin B, de Vos M, de Saussure P, Seksik P, Marteau P, Lemann M, Colombel JF. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy.
Inflamm. Bowel Dis. 15: 1044-1048 (2009).
-
Brandsaeter B, Schrumpf E, Clausen OP, Abildgaard A, Hafsahl G, Bjoro K. Recurrent sclerosing cholangitis or ischemic bile duct lesions - a diagnostic challenge?
Liver Transpl. 10: 1073-1074 (2004).
*
-
Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity.
Autoimmun. Rev. 5: 465-470 (2006).
-
Brandt J, Braun J. Anti-TNF-alpha agents in the treatment of psoriatic arthritis.
Expert Opin. Biol. Ther. 6: 99-107 (2006).
-
Brar P, Lee S, Lewis S, Egbuna I, Bhagat G, Green PH. Budesonide in the treatment of refractory celiac disease.
Am. J. Gastroenterol. 102: 2265-2269 (2007).
*
-
Braucci S, Trappolini F, Angrisani L, Luberti E, Clarice A, Proietta M, Pisani D, Trappolini M. Ulcerative colitis and thrombocytopenia: a clinical case of fortuitous association?
Clin. Ter. 158: 27-30 (2007).
-
Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD.
Clin. Immunol. Mar 23 [Epub ahead of print] (2009).
*
-
Bray GP, Williams R. Immunointervention in primary biliary cirrhosis: an overview.
J. Autoimmun. 5 Suppl. A: 293-300 (1992).
-
Bremner AR, Beattie RM. Recent advances in the medical therapy of Crohn's disease in childhood.
Expert Opin. Pharmacother. 8: 2553-2568 (2007).
-
Bremner AR, Griffiths DM, Beattie RM. Current therapy of ulcerative colitis in children.
Expert Opin. Pharmacother. 5: 37-53 (2004).
-
Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study.
Dig. Liver Dis. 39: 430-434 (2007).
-
Breuer A, Benz SR, Enz T, Deubler G, Mork H. Autoimmune pancreatitis - a rare and difficult differential diagnosis to pancreatic cancer.
Med. Klin. (Munich) 102: 157-162 (2007).
-
Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma.
J. Allergy Clin. Immunol. 121: 5-10 (2008).
*
-
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis.
J. Rheumatol. 30: 211-213 (2003).
-
Brogan PA, Malik M, Shah N, Kilday JP, Ramsay A, Shah V, Murch SH, Thomson MA, Walker-Smith JA, Lindley KJ, Milla PJ, Dillon MJ. Systemic vasculitis: a cause of indeterminate intestinal inflammation.
J. Pediatr. Gastroenterol. Nutr. 42: 405-415 (2006).
*
-
Brookes MJ, Green JR. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
Drugs 64: 1069-1089 (2004).
-
Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10-year experience.
Semin. Arthritis Rheum. 34: 544-548 (2004).
*
-
Brucato A, Maestroni S, Cumetti D, Thiella G, Alari G, Brambilla G, Imazio M, Doria A, Palmieri G, Adler Y. Recurrent pericarditis: infectious or autoimmune?
Autoimmun. Rev. 8: 44-47 (2008).
-
Brunner HI, Kim KN, Ballinger SH, Bowyer SL, Griffin TA, Higgins GC, Mier R, Passo MH, Rennebohm R, Schikler K, Lovell DJ. Current medication choices in juvenile rheumatoid arthritis II - update of a survey performed in 1993.
J. Clin. Rheumatol. 7: 295-300 (2001).
-
Brunner M, Greinix HT, Redlich K, Knobl P, Smolen J, Leitner G, Derfler K, Graninger W, Kalhs P, Machold K. Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report.
Arthritis Rheum. 46: 1580-1584 (2002).
*
-
Brunt EM, Di Bisceglie AM. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis.
Hum. Pathol. 35: 509-512 (2004).
-
Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis.
Int. J. Immunopathol. Pharmacol. 22: 235-238 (2009).
-
Brydak-Godowska J, Moneta-Wielgos J, Pauk-Domanska M, Drobecka-Brydak E, Samsel A, Kecik M, Kowalewski C, Mackiewicz W, Kecik D. Diagnostics and farmacological treatment of ocular cicatrical pemphigoid.
Klin. Oczna. 107: 725-727 (2005).
-
Brynskov J, Feagan BG, Jewell D, McDonald JWD, Stange EF. Cyclosporine for maintenance of remission in Crohn’s disease.
Cochrane Database Syst. Rev. 2: CD004377 (2004). *
-
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M, Font J, Asherson RA. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.
Arthritis Rheum. 54: 2568-2576 (2006).
*
-
Buchman AL. Metabolic bone disease in inflammatory bowel disease.
Curr. Treat. Options Gastroenterol. 5: 173-180 (2002).
-
Buchman AL. Bones and Crohn's: problems and solutions.
Inflamm. Bowel Dis. 5: 212-227 (1999).
-
Buchman AL, Paine MF, Wallin A, Ludington SS. A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content.
Dig. Dis. Sci. 50: 2312-2315 (2005).
*
-
Budimir J, Mihic LL, Situm M, Bulat V, Persic S, Tomljanovic-Veselski M. Oral lesions in patients with pemphigus vulgaris and bullous pemphigoid.
Acta Clin. Croat. 47: 13-18 (2008).
-
Bueverov AO. Treatment of autoimmune hepatic diseases.
Klin. Med. (Mosk.) 82: 62-66 (2004).
-
Buhaescu I, Covic A, Deray G. Treatment of proliferative lupus nephritis - a critical approach.
Semin. Arthritis Rheum. 36: 224-237 (2007).
*
-
Buning C, Lochs H. Conventional therapy for Crohn's disease.
World J. Gastroenterol. 12: 4794-4806 (2006).
*
-
Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis?
Am. J. Gastroenterol. 98: 1155-1158 (2003).
*
-
Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G, Vermeire S, Rutgeerts P, D'Hoore A, Penninckx F, Geboes K, Van Assche G, O'Connell PR. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease.
Inflamm. Bowel Dis. 14: 1197-1204 (2008).
*
-
Burns TM. Neurosarcoidosis.
Arch. Neurol. 60: 1166-1168 (2003).
-
Burt AD. Spectrum of liver pathology in immune mediated liver diseases.
J. Gastroenterol. Hepatol. 19: S353-S355 (2004). *
-
Buskila D. Hepatitis C-associated rheumatic disorders.
Rheum. Dis. Clin. North Am. 35: 111-123 (2009).
-
Bussone G, Ribeiro E, Dechartres A, Viallard JF, Bonnotte B, Fain O, Godeau B, Michel M. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
Am. J. Hematol. 84: 153-157 (2009).
-
Bystryn JC, Rudolph JL. Pemphigus.
Lancet 366: 61-73 (2005).
*
-
Byth BC, Billingsley GD, Cox DW. Physical and genetic mapping of the serpin gene cluster at 14q32.1: allelic association and a unique haplotype associated with alpha 1-antitrypsin deficiency.
Am. J. Hum. Genet. 55: 126-133 (1994).
*
-
Caballero-Uribe CV, Acosta-Velez JG, Hernandez-Ruiz EA, Andrade Rodado FM, Penuela-Epalza M. Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city.
J. Clin. Rheumatol. 14: 153-155 (2008).
-
Cabo-Lopez I, Negueruela-Lopez M, Garcia-Bermejo P, Zamarbide-Capdepon I, Garcia-Ruiz PJ, Duran-Martinez P, Gonzalez-Roiz C. Stiff-person syndrome: a case report.
Rev. Neurol. 47: 249-252 (2008).
-
Cabriada Nuno JL, Hernandez Martin A, Bernal Martinez A, Zabalza Estevez I. Oral budesonide in the treatment of chronic refractory pouchitis.
Gastroenterol. Hepatol. 31: 485-489 (2008).
-
Cagatay AA, Taranoglu O, Alpay N, Tufan F, Karadeniz A, Kapmaz M, Buyukbabani N. Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.
Mycoses 51: 81-82 (2008).
-
Cagiano R, Bera I, Vermesan D, Flace P, Sabatini R, Bottalico L, Auteri P, Santacroce L. Psoriasis disappearance after the first phase of an oncologic treatment: a serendipity case report.
Clin. Ter. 159: 421-425 (2008).
-
Cakir E, Uyan ZS, Ersu RH, Karadag B, Karakoc F, Dagli E. Mucoid impaction: an unusual form of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis.
Pediatr. Pulmonol. 41: 1103-1107 (2006).
-
Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases.
Mol. Nutr. Food Res. 52: 885-897 (2008).
*
-
Callejas-Rubio JL, Lopez-Perez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.
Ther. Clin. Risk Manag. 4: 1305-1213 (2008).
*
-
Callen JP. Management of 'refractory' skin disease in patients with lupus erythematosus.
Best Pract. Res. Clin. Rheumatol. 19: 767-784 (2005).
-
Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, Poupon R. Cholestasis induces major histocompatibility complex class I expression in hepatocytes.
Gastroenterology 102: 1371-1377 (1992).
-
Calmus Y, Poupon R. Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases.
Biochimie 73: 1335-1338 (1991).
-
Campbell R, Marik PE. Severe autoimmune hemolytic anemia treated by paralysis, induced hypothermia, and splenic embolization.
Chest 127: 678-681 (2005).
*
-
Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome.
Dig. Liver Dis. 35: 546-551 (2003).
-
Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kaplan M, Wright F, Kam I. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal.
Liver Transpl. 14: 1281-1286 (2008).
-
Cappell MS, Turkieh A. Chronic pericarditis and pericardial tamponade associated with ulcerative colitis.
Dig. Dis. Sci. 53: 149-154 (2008).
*
-
Caprilli R, Viscido A, Guagnozzi D. Review article: biological agents in the treatment of Crohn's disease.
Aliment. Pharmacol. Ther. 16: 1579-1590 (2002).
*
-
Caramoy A, Lappas A, Fauser S, Kirchhof B. Central scotoma and blurred vision in a patient with Crohn's disease.
Ophthalmologe May 15 [Epub ahead of print] (2009).
-
Carbone J, Escudero A, Mayayo M, Ballesteros M, Perez-Corral A, Sanchez-Ramon S, Sarmiento E, Micheloud D, Fernandez-Cruz E. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
Ann. N. Y. Acad. Sci. 1051: 666-671 (2005).
*
-
Carbonnel F. Management of severe or corticosteroid resistant ulcerative colitis.
Gastroenterol. Clin. Biol. 31: 398-403 (2007).
-
Carcagni MR, De Aloe G, D'Ascenzo G, Rubegni P, Fimiani M. Extracorporeal photopheresis in graft-versus-host disease.
J. Dtsch. Dermatol. Ges. 6: 451-457 (2008).
-
Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study.
Gut 53: 251-255 (2004).
*
-
Carette S. All patients with rheumatoid arthritis should receive corticosteroids as part of their management.
J. Rheumatol. 34: 656-660 (2007).
-
Carrascosa JM, Vanaclocha F, Borrego L, Fernandez-Lopez E, Fuertes A, Rodriguez-Fernandez-Freire L, Zulaica A, Tuneu A, Caballe G, Colome E, Bordas X, Hernanz JM, Brufau C, Herrera E. Update of the topical treatment of psoriaris.
Actas Dermosifiliogr. 100: 190-200 (2009).
-
Carrillo-Esper R, Gonzalez-Avila D, Uribe-Rios M, Mendez-Sanchez N. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report.
Ann. Hepatol. 7: 87-90 (2008).
-
Carsia RV, Weber H, McIlroy PJ, Hock CE. Long-term dietary lipid regimen alters adrenocortical function at the cellular level.
Horm. Metab. Res. 40: 848-853 (2008).
-
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project.
Blood 113: 4834-4840 (2009).
*
-
Carvalho JF, Pereira RM, Shoenfeld Y. Systemic polyarteritis nodosa following hepatitis B vaccination.
Eur. J. Intern. Med. 19: 575-578 (2008).
-
Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children.
Semin. Pediatr. Surg. 16: 164-171 (2007).
-
Castiblanco CP, Adelman RA. Sympathetic ophthalmia.
Graefes Arch. Clin. Exp. Ophthalmol. 247: 289-302 (2009).
-
Castro Junior NP, Almeida CI, Campos CA. Sudden sensorineural hearing loss and vertigo associated with arterial occlusive disease: three case reports and literature review.
Sao Paulo Med. J. 125: 191-195 (2007).
*
-
Castro M, Papadatou B, Ceriati E, Knafelz D, De Angelis P, Ferretti F, Gambarara M, Diamanti A, De Peppo F, Rivosecchi M. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis.
Langenbecks Arch. Surg. 392: 161-164 (2007).
*
-
Cauley JA. Osteoporosis in men: prevalence and investigation.
Clin. Cornerstone 8 Suppl. 3: S20-S25 (2006).
-
Cavailhes A, Ingen-Housz-Oro S, Djennane S, Rafaa M, Fiszenson-Albala F, Weber N, Sigal-Grinberg M. Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab.
Ann. Dermatol. Venereol. 134: 363-367 (2007).
-
Cazanave C, Rakotondravelo S, Morlat P, Blanco P, Bonnet F, Beylot J. Autoimmune hepatitis in a HIV-HCV co-infected patient: diagnostic and therapeutic difficulties.
Rev. Med. Interne. 27: 414-419 (2006).
-
Ceovic R, Pasic A, Lipozencic J, Murat-Susic S, Skerlev M, Husar K, Kostovic K. Treatment of childhood psoriasis.
Acta Dermatovenerol. Croat. 14: 261-264 (2006).
-
Cervera R, Bucciarelli S, Plasín MA, Gomez-Puerta JA, Plaza J, Pons-Estel G, Shoenfeld Y, Ingelmo M, Espinos G, For The Catastrophic Antiphospholipid Syndrome Caps Registry Project Group European Forum On Antiphospholipid Antibodies. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry"
J. Autoimmun. 32: 240-245 (2009).
-
Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, Mougenot JF, Alberti C, Goulet O. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease.
J. Pediatr. Gastroenterol. Nutr. 36: 632-636 (2003).
*
-
Cha SI, Fessler MB, Cool CD, Schwarz MI, Brown KK. Lymphoid interstitial pneumonia: clinical features, associations, and prognosis.
Eur. Respir. J. 28: 364-369 (2006).
-
Chaby G, Viseux V, Poulain JF, De Cagny B, Denoeux JP, Lok C. Topical silver sulfadiazine-induced acute renal failure.
Ann. Dermatol. Venereol. 132: 891-893 (2005).
-
Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.
Lupus 14: 210-214 (2005).
-
Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF Jr, Kalb RE, Hsu S. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation.
J. Am. Acad. Dermatol. 60: 962-971 (2009).
-
Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
Gastroenterol. Clin. North Am. 35: 675-712 (2006).
-
Chan J, Ban EJ, Chun KH, Wang S, Backstrom BT, Bernard CC, Toh BH, Alderuccio F. Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease.
J. Immunol. 181: 7571-7580 (2008).
-
Chan TM. Lupus nephritis: induction therapy.
Lupus 14 Suppl. 1: s27-s32 (2005).
-
Chan YC, Tay YK, Ng SK. Allopurinol hypersensitivity syndrome and acute myocardial infarction - two case reports.
Ann. Acad. Med. Singapore 31: 231-233 (2002).
*
-
Chande N. Microscopic colitis: an approach to treatment.
Can. J. Gastroenterol. 22: 686-688 (2008).
-
Chande N, Macdonald J, McDonald J. Methotrexate for induction of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 4: CD006618 (2007).
*
-
Chande N, McDonald J, Macdonald J. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 2: CD006774 (2008).
*
-
Chang HK. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus.
J. Korean Med. Sci. 20: 883-885 (2005).
*
-
Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, Jih JS, Chen CC, Lee DD, Wang WJ, Lin MW, Liu HN. Epidemiological study of psoriasis in the national health insurance database in Taiwan.
Acta Derm. Venereol. 89: 262-266 (2009).
-
Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease.
Ann. Pharmacother. 39: 1552-1556 (2005).
-
Chaoui Z, Bernoussi A, Belmekki M, Berraho A. Uveitis and chronic intestinal inflammatory diseases: three case studies.
J. Fr. Ophtalmol. 28: 854-856 (2005).
-
Chapman RW. The management of primary sclerosing cholangitis.
Curr. Gastroenterol. Rep. 5: 9-17 (2003).
-
Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, Cohen P, Mouthon L, Guillevin L. Risk factors for major infections in Wegener's granulomatosis: analysis of 113 patients.
Ann. Rheum. Dis. 68: 658-663 (2009).
-
Chaudhary R, Ghosh S. Infliximab in refractory coeliac disease.
Eur. J. Gastroenterol. Hepatol. 17: 603-604 (2005).
-
Chaudhuri A, Behan PO. Myasthenic crisis.
QJM 102: 97-107 (2009).
-
Chavez-Tapia NC, Martinez-Salgado J, Granados J, Uribe M, Tellez-Avila FI. Clinical heterogeneity in autoimmune acute liver failure.
World J. Gastroenterol. 13: 1824-1827 (2007).
*
-
Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Hepatology 28: 296-301 (1998).
*
-
Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
J. Hepatol. 44: 400-406 (2006).
*
-
Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
J. Gastroenterol. Hepatol. 22: 268-274 (2007).
*
-
Chebli JM, Gaburri PD, Meirelles De Souza AF, Pereira Da Silva CE, Pinto JR, Felga GE. Benign intracranial hypertension during corticosteroid therapy for idiopathic ulcerative colitis: another indication for cyclosporine?
J. Clin. Gastroenterol. 38: 827-828 (2004).
-
Cheepsattayakorn A, Cheepsattayakorn R. Human genetic influence on susceptibility of tuberculosis: from infection to disease.
J. Med. Assoc. Thai. 92: 136-141 (2009).
-
Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease.
J. Clin. Gastroenterol. 38: S44-S50 (2004).
-
Chen J, Wang Y, Kunkel G, Zhao H, Xue H, Xie X, Li L, Xu C, Shen L, Gu L. Use of CD34(+) autologous stem cell transplantation in the treatment of children with refractory systemic lupus erythematosus.
Clin. Rheumatol. 24: 464-468 (2005).
*
-
Chen M, Yu F, Zhang Y, Zhao MH. An analysis of multi-system involvement and renal pathology of anti-neutrophil cytoplasmic autoantibodies-related vasculitis.
Zhonghua Nei Ke Za Zhi 44: 828-831 (2005).
-
Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE. Eosinophilic gastroenteritis: clinical experience with 15 patients.
World J. Gastroenterol. 9: 2813-2816 (2003).
*
-
Chen TJ, Lai PC, Yang LC, Kuo TT, Hong HS. Bullous pemphigoid in a renal transplant recipient: a case report and review of the literature.
Am. J. Clin. Dermatol. 10: 197-200 (2009).
-
Chen WD, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis.
Cochrane Database Syst. Rev. 3: CD004036 (2004).
*
-
Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Lazzell-Pannell L, Rashdan A, Temkit M, Lehman GA. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Am. J. Gastroenterol. 101: 139-147 (2006).
*
-
Chernev K, Bakalov V. Clinical-dispensary finding of patients with primary biliary cirrhosis.
Vutr. Boles. 24: 42-46 (1985).
-
Chey WY. Infliximab for patients with refractory ulcerative colitis.
Inflamm. Bowel Dis. 7 Suppl. 1: S30-S33 (2001).
*
-
Chikanza IC, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance.
J. Endocrinol. 179: 301-310 (2003).
*
-
Chinratanapisit S, Tunsuriyawong P, Vichyanond P, Visitsunthorn N, Luangwedchakarn V, Jirapongsananuruk O. Chronic rhinosinusitis and recurrent nasal polyps in two children with IgG subclass deficiency and review of the literature.
J. Med. Assoc. Thai. 88 Suppl. 8: S251-S258 (2005).
-
Chitturi S, Farrell GC. Drug-induced liver disease.
Curr. Treat. Options Gastroenterol. 3: 457-462 (2000).
-
Cho J. Update on inflammatory bowel disease genetics.
Curr. Gastroenterol. Rep. 2: 434-439 (2000).
-
Choi EK, Kim MH, Kim JC, Han J, Oh SI, Jeong WJ, Jeong JY, Lee SS, Seo DW, Lee SK. The long-term follow-up results after steroid treatment in patients with autoimmune chronic pancreatitis.
Korean J. Gastroenterol. 47: 440-448 (2006).
-
Chon CY, Park JY. Primary biliary cirrhosis.
Korean J. Hepatol. 12: 364-372 (2006).
-
Chow DK, Sung JJ, Tsoi KK, Wong VW, Wu JC, Leong RW, L Chan FK. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study.
Aliment. Pharmacol. Ther. 29: 843-854 (2009).
*
-
Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.
Z. Gastroenterol. 45: 605-608 (2007).
-
Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients.
J. Am. Acad. Dermatol. 59: 385-396 (2008).
-
Christensen E. Alcoholic hepatitis - glucocorticosteroids or not?
J. Hepatol. 36: 547-548 (2002).
*
-
Christensen PS, Ostergaard JR. Acute disseminated encephalomyelitis.
Ugeskr. Laeger. 170: 1839-1842 (2008).
-
Chugh S, Dilawari JB, Sawhney IM, Dang N, Radotra BD, Chawla YK. Polymyositis associated with ulcerative colitis.
Gut 34: 567-569 (1993).
*
-
Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, Morgenstern EH, Rubin SD, Sacknoff AG, Gleim GM. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up.
Inflamm. Bowel Dis. 4: 177-181 (1998).
*
-
Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis.
Clin. Rheumatol. 26: 1228-1233 (2007).
*
-
Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.
J. Rheumatol. 34: 1849-1854 (2007).
-
Chung GE, Cheon JH, Lee JY, Ye BD, Kim SG, Kim JS, Jung HC, Song IS. Efficacy of combination of intravenous cyclosporin A and steroid therapy versus prolonged intravenous steroid therapy alone in patients with severe ulcerative colitis refractory to initial intravenous steroid therapy.
Korean J. Gastroenterol. 48: 263-268 (2006).
-
Ciacci C, Maiuri L, Russo I, Tortora R, Bucci C, Cappello C, Santonicola A, Luciani A, Passananti V, Iovino P. Efficacy of budesonide therapy in the early phase of treatment of adult celiac disease patients with malabsorption: an in vivo/in vitro pilot study.
Clin. Exp. Pharmacol. Physiol. May 19 [Epub ahead of print] (2009).
*
-
Cicek D, Kandi B, Demir B, Turgut D. Intrahepatic cholestasis occurring with prurigo of pregnancy.
Skinmed. 6: 298-301 (2007).
-
Clatworthy MR, Jayne DR. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab.
Am. J. Kidney Dis. 47: 680-682 (2006).
-
Claudepierre P, Bagot M. Psoriatic arthritis.
Ann. Dermatol. Venereol. 135 Suppl. 4: S263-S268 (2008).
-
Claussmann C, Offner C, Chevalier Y, Sellal F, Collard M. Encephalopathy and Hashimoto thyroiditis.
Rev. Neurol. (Paris) 150: 166-168 (1994).
-
Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission.
Am. J. Gastroenterol. 104: 1162-1169 (2009).
-
Clegg-Lamptey JN, Tettey Y, Wiredu EK, Kwawukume EY. Eosinophilic enteritis - a diagnostic dilemma.
West Afr. J. Med. 21: 258-259 (2002).
-
Cohen PR. Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis.
Orphanet J. Rare Dis. 2: 34 (2007).
*
-
Cohen RD. Evolving medical therapies for ulcerative colitis.
Curr. Gastroenterol. Rep. 4: 497-505 (2002).
-
Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Inflamm. Bowel Dis. 7 Suppl. 1: S17-S22 (2001).
*
-
Cohen SM, Ahn J. Current diagnosis and management of alcoholic hepatitis.
Aliment. Pharmacol. Ther. Mar 26 [Epub ahead of print] (2009).
*
-
Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, Kerem E. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis.
J. Cyst. Fibros. May 14 [Epub ahead of print] (2009).
-
Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease.
Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).
-
Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease.
Inflamm. Bowel Dis. 13: 1453-1454 (2007).
*
-
Cole BJ, Schumacher HR Jr. Injectable corticosteroids in modern practice.
J. Am. Acad. Orthop. Surg. 13: 37-46 (2005).
-
Colmegna I, Maldonado-Cocco JA. Polyarteritis nodosa revisited.
Curr. Rheumatol. Rep. 7: 288-296 (2005).
-
Colombato LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?
Gastroenterology 107: 1839-1843 (1994).
-
Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Am. J. Gastroenterol. 99: 878-883 (2004).
*
-
Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
J. Rheumatol. 33: 24-30 (2006).
-
Comite de nutrition de la Societe francaise de pediatrie. Nutritional treatment in childhood Crohn's disease.
Arch. Pediatr. 12: 1255-1266 (2005).
-
Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
Arthritis Rheum. 56: 1966-1973 (2007).
*
-
Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy.
Drug Saf. 21: 311-323 (1999).
-
Conrad C, Trueb RM. Pyoderma gangrenosum.
J. Dtsch. Dermatol. Ges. 3: 334-342 (2005).
-
Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Lupus 14 Suppl. 1: s33-s38 (2005).
-
Conway RR. Neuralgic amyotrophy: uncommon but not rare.
Mo. Med. 105: 168-169 (2008).
-
Cooke DM. Inflammatory bowel disease: primary health care management of ulcerative colitis and Crohn's disease.
Nurse Pract. 16: 27-30, 35-36, 38-39 (1991).
-
Copeland BH, Aramide O, Wehbe S, Fitzgerald SM, Krishnaswamy G. Eosinophilia in a patient with cyclical vomiting: a case report.
Clin. Mol. Allergy 2: 7 (2004).
*
-
Coronel-Perez IM, Rodríguez-Rey EM, Perez-Bernal AM, Camacho FM. Epidemiology of pemphigus in Hospital Universitario Virgen Macarena, Seville, Spain, 2005-2006.
Actas Dermosifiliogr. 100: 121-125 (2009).
-
Cosme A, Gil I, Alvarez R, Ruiz I, de Juan MD, Ojeda E, Barrio J. Autoimmune hepatitis with antibodies against liver cytosol (anti-LC1).
Gastroenterol. Hepatol. 21: 280-282 (1998).
-
Costa Carvalho BT, Nagao AT, Arslanian C, Carneiro Sampaio MM, Naspitz CK, Sorensen RU, Leiva L, Sole D. Immunological evaluation of allergic respiratory children with recurrent sinusitis.
Pediatr. Allergy Immunol. 16: 534-538 (2005).
-
Costa M, Colia D. Treating infertility in autoimmune patients.
Rheumatology (Oxford) 47 Suppl. 3: iii38-iii41 (2008).
*
-
Costabel U. Sarcoidosis: clinical update.
Eur. Respir. J. Suppl. 32: 56s-68s (2001).
*
-
Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy.
J. Clin. Gastroenterol. 32: 428-430 (2001).
-
Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease.
J. Pediatr. Gastroenterol. Nutr. 27: 580-583 (1998).
*
-
Crabb DW. Recent developments in alcoholism: the liver.
Recent Dev. Alcohol. 11: 207-230 (1993).
-
Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment.
Arthritis Res. Ther. 8 Suppl. 1: S3 (2006).
*
-
Cuadrado E, Alonso M, de Juan MD, Echaniz P, Arenas JI. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis.
World J. Gastroenterol. 14: 1521-1527 (2008).
*
-
Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, De'Angelis GL, Federici T. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study.
Dig. Liver Dis. 40 Suppl. 2: S260-S264 (2008).
-
Cucurachi L, Cattaneo L, Gemignani F, Pavesi G. Late onset generalized myasthenia gravis presenting with facial weakness and bulbar signs without extraocular muscle involvement.
Neurol. Sci. May 30 [Epub ahead of print] (2009).
-
Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective.
Minerva Pediatr. 58: 139-157 (2006).
-
Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
Gut 48: 642-646 (2001).
*
-
Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease.
Digestion 73: 107-110 (2006).
*
-
Cullen G, O'Toole A, Keegan D, Sheahan K, Hyland JM, O'Donoghue DP. Long-term clinical results of ileocecal resection for Crohn's disease.
Inflamm. Bowel Dis. 13: 1369-1373 (2007).
*
-
Culver DA, Thomassen MJ, Kavuru MS. Pulmonary sarcoidosis: new genetic clues and ongoing treatment controversies.
Cleve. Clin. J. Med. 71: 88, 90, 92 (2004).
*
-
Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH. Estrogens and autoimmune diseases.
Ann. N. Y. Acad. Sci. 1089: 538-547 (2006).
*
-
Cutolo M, Villaggio B, Otsa K, Aakre O, Sulli A, Seriolo B. Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms.
Autoimmun. Rev. 4: 497-502 (2005).
-
Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.
Drugs Aging 25: 219-239 (2008).
-
Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis.
Drugs 57: 49-68 (1999).
-
Czaja AJ. Autoimmune liver disease and rheumatic manifestations.
Curr. Opin. Rheumatol. 19: 74-80 (2007).
-
Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease.
Hepatology 28: 360-365 (1998).
*
-
Czaja AJ. Autoimmune liver disease.
Curr. Opin. Gastroenterol. 21: 293-299 (2005).
-
Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis.
Liver Int. 29: 816-823 (2009).
*
-
Czaja AJ. Variant forms of autoimmune hepatitis.
Curr. Gastroenterol. Rep. 1: 63-70 (1999).
-
Czaja AJ. Autoimmune hepatitis: clinical and laboratory diagnosis.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 52-54 (2004). *
-
Czaja AJ. Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis.
Dig. Dis. Sci. 43: 1725-1731 (1998).
*
-
Czaja AJ. Round table: classification of autoimmune liver diseases and diagnostic criteria. Subgroups of autoimmune hepatitis are irrelevant.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 58-59 (2004). *
-
Czaja AJ. Extrahepatic immunologic features of chronic viral hepatitis.
Dig. Dis. 15: 125-144 (1997).
-
Czaja AJ. The variant forms of autoimmune hepatitis.
Ann. Intern. Med. 125: 588-598 (1996).
*
-
Czaja AJ. Autoimmune liver disease.
Curr. Opin. Gastroenterol. 23: 255-262 (2007).
-
Czaja AJ. Autoimmune liver disease.
Curr. Opin. Gastroenterol. 24: 298-305 (2008).
-
Czaja AJ. Autoimmune hepatitis and viral infection.
Gastroenterol. Clin. North Am. 23: 547-566 (1994).
-
Czaja AJ. The immunoreactive propensity of autoimmune hepatitis: is it corticosteroid-dependent after liver transplantation?
Liver Transpl. Surg. 5: 460-463 (1999).
-
Czaja AJ. Autoimmune liver disease.
Curr. Opin. Gastroenterol. 15: 240-248 (1999).
-
Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis.
Hepatology 11: 1044-1049 (1990).
-
Czaja AJ. Autoimmune liver disease.
Curr. Opin. Gastroenterol. 20: 231-240 (2004).
-
Czaja AJ. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries.
J. Hepatol. 44: 251-252 (2006).
*
-
Czaja AJ. Autoimmune hepatitis - approach to diagnosis.
MedGenMed. 8: 55 (2006).
*
-
Czaja AJ. Current problems in the diagnosis and management of chronic active hepatitis.
Mayo Clin. Proc. 56: 311-323 (1981).
-
Czaja AJ. Autoimmune liver disease.
Curr. Opin. Gastroenterol. 17: 268-275 (2001).
-
Czaja AJ. Progress in the diagnosis and treatment of autoimmune hepatitis.
Minerva Med. 99: 549-568 (2008).
-
Czaja AJ. Autoimmune liver disease.
Curr. Opin. Gastroenterol. 22: 234-240 (2006).
-
Czaja AJ. Treatment strategies in autoimmune hepatitis.
Clin. Liver Dis. 6: 511-536 (2002).
-
Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation.
Liver Transpl. 13: 953-955 (2007).
*
-
Czaja AJ. The autoimmune hepatitis/hepatitis C overlap syndrome: does it exist?
Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 42-43. October 15-16 (2003). *
-
Czaja AJ. Treatment of autoimmune hepatitis.
Semin. Liver Dis. 22: 365-378 (2002).
*
-
Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance.
Liver Transpl. 8: 505-513 (2002).
*
-
Czaja AJ. Current and future treatments of autoimmune hepatitis.
Expert Rev. Gastroenterol. Hepatol. 3: 269-291 (2009).
-
Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis.
J. Hepatol. 51: 161-167 (2009).
-
Czaja AJ, Abdulkarim AS, Carpenter HA, Perez RG, Persing DH, Zein NN. GB virus-C infection in type 1 autoimmune hepatitis.
Mayo Clin. Proc. 73: 412-418 (1998).
*
-
Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission.
Gastroenterology 78: 518-523 (1980).
-
Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.
Gastroenterology 92: 215-219 (1987).
-
Czaja AJ, Beaver SJ, Wood JR, Klee GG, Go VL. Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis.
Gastroenterology 93: 687-692 (1987).
-
Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly.
Hepatology 43: 532-538 (2006).
*
-
Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis.
Hepatology 39: 1631-1638 (2004).
*
-
Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis.
Liver Int. 23: 116-123 (2003).
*
-
Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
J. Clin. Gastroenterol. 39: 819-825 (2005).
-
Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.
J. Hepatol. 40: 646-652 (2004).
*
-
Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.
Hepatology 30: 1381-1386 (1999).
*
-
Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis.
Gastroenterology 105: 1522-1528 (1993).
-
Czaja AJ, Carpenter HA, Moore SB. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.
Liver Int. 26: 552-558 (2006).
*
-
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease.
Hepatology 31: 1231-1238 (2000).
*
-
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis.
Gastroenterology 105: 1502-1507 (1993).
-
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis.
Gastroenterology 104: 1755-1761 (1993).
-
Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis.
Gastroenterology 117: 645-652 (1999).
*
-
Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology.
Gastroenterology 85: 713-717 (1983).
-
Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis.
Hepatology 4: 622-627 (1984).
-
Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis.
Mayo Clin. Proc. 65: 23-30 (1990).
-
Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis.
N. Engl. J. Med. 304: 5-9 (1981).
-
Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis.
Dig. Dis. Sci. 40: 33-40 (1995).
-
Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.
Gastroenterology 103: 1290-1295 (1992).
-
Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
Hepatology 35: 890-897 (2002).
*
-
Czaja AJ, Ming C, Shirai M, Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis.
J. Hepatol. 23: 32-38 (1995).
*
-
Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis.
Hepatology 26: 567-572 (1997).
*
-
Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis.
Liver Int. 24: 322-329 (2004).
*
-
Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis.
Dig. Dis. Sci. 41: 1733-1740 (1996).
-
Czaja AJ, Rakela J, Hay JE, Moore SB. Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis.
Gastroenterology 98: 1587-1593 (1990).
-
Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis.
Gastroenterology 95: 448-453 (1988).
-
Czaja AJ, Shiels MT, Taswell HF, Wood JR, Ludwig J, Chase RC. Frequency and significance of immunoglobulin M antibody to hepatitis B core antigen in corticosteroid-treated severe chronic active hepatitis B.
Mayo Clin. Proc. 63: 119-125 (1988).
-
Czaja AJ, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis.
Dig. Dis. Sci. 49: 611-618 (2004).
*
-
Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis.
Autoimmunity 35: 475-483 (2002).
-
Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis.
Dig. Dis. Sci. 45: 1028-1035 (2000).
*
-
Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.
Hepatology 25: 317-323 (1997).
*
-
Czaja AJ, Taswell HF, Rakela J, Rabe D. Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis.
Gastroenterology 102: 1675-1679 (1992).
-
Czaja AJ, Taswell HF, Rakela J, Schimek CM. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis.
Mayo Clin. Proc. 66: 572-582 (1991).
-
Czaja AJ, Taswell HF, Rakela J, Schimek CM. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated cryptogenic chronic active hepatitis.
Mayo Clin. Proc. 65: 1303-1313 (1990).
-
Czaja AJ, Wang KK, Shiels MT, Katzmann JA. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses.
J. Hepatol. 17: 180-186 (1993).
-
Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features.
Gastroenterology 80: 687-692 (1981).
-
D'Amato G, Salzillo A, Piccolo A, D'Amato M, Liccardi G. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
Ther. Clin. Risk Manag. 3: 613-619 (2007).
-
D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?
Endocr. Metab. Immune Disord. Drug Targets 8: 62-68 (2008).
-
D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus.
Lancet 369: 587-596 (2007).
*
-
D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases.
Gut 56: 725-732 (2007).
*
-
D’Haens G. Pratical use of steroids in IBD.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 30 (2005). *
-
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Lancet 371: 660-667 (2008).
*
-
D'Haens G, Hlavaty T. Advances in medical therapy for Crohn's disease.
Curr. Gastroenterol. Rep. 6: 496-505 (2004).
-
D'Haens G, Suenaert P, Westhovens R, Rutgeerts P. Severe knee pain as the single symptom of CMV infection in acute ulcerative colitis treated with cyclosporine.
Inflamm. Bowel Dis. 4: 27-28 (1998).
-
da Silva AV, Valones MA, Guimaraes RP, de Castro JF, Carvalho Ade A. Pemphigus vulgaris: a therapeutic option for disease control.
Gen. Dent. 56: 700-703 (2008).
-
Dagfinrud H, Heiberg MS, Bakland G, Skomsvoll J, Kvien TK. Ankylosing spondylitis - a consensus on diagnosis and treatment.
Tidsskr. Nor. Laegeforen. 127: 3209-3212 (2007).
-
Daikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture.
Ann. Allergy Asthma Immunol. 90: 23-27 (2003).
-
Dalvi V, Gonzalez EB, Lovett L. Lymphocytic interstitial pneumonitis (LIP) in Sjogren's syndrome: a case report and a review of the literature.
Clin. Rheumatol. 26: 1339-1343 (2007).
-
Danese S, Angelucci E, Malesci A, Caprilli R. Biological agents for ulcerative colitis: hypes and hopes.
Med. Res. Rev. 28: 201-218 (2008).
*
-
Danese S, Angelucci E, Marconi S, Repici A, Malesci A. Oral beclomethasone: a review of its use in inflammatory bowel disease.
Mini Rev. Med. Chem. 8: 1459-1463 (2008).
-
Daneshjoo R, J Talley N. Eosinophilic gastroenteritis.
Curr. Gastroenterol. Rep. 4: 366-372 (2002).
-
Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of TNBS colitis with calcitriol is associated with a change of a Th1/Th17 to a Th2 and regulatory T cell profile.
J. Pharmacol. Exp. Ther. 324: 23-33 (2008).
*
-
Danowski A, Magder L, Petri M. Flares in Lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone.
J. Rheumatol. 33: 57-60 (2006).
-
Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, Pera A. Outcome of a conservative approach in severe ulcerative colitis.
Dig. Liver Dis. 36: 21-28 (2004).
*
-
Darlow SJ, Mandal A, Pick B, Thomas T, Mayberry JF, Robinson RJ. The short-term effects of Eudragit-L-coated prednisolone metasulphobenzoate (Predocol) on bone formation and bone mineral density in acute ulcerative colitis.
Eur. J. Gastroenterol. Hepatol. 16: 1173-1176 (2004).
-
Das M, Chhabra R, Hinton SW. Cutaneous leukocytoclastic vasculitis and myelodysplastic syndrome with little or no evidence of associated autoimmune disorders-a case report and a brief review of the literature.
Am. J. Med. Sci. 336: 368-371 (2008).
-
Davis GL, Czaja AJ. Current concepts in the diagnosis and management of hepatitis B surface antigen-positive chronic active hepatitis.
J. Clin. Gastroenterol. 3: 381-388 (1981).
-
Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis.
Mayo Clin. Proc. 57: 303-309 (1982).
-
Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis.
Gastroenterology 87: 1222-1227 (1984).
-
Davis GL, Czaja AJ, Taswell HF, Ludwig J, Go VL. Hepatitis B virus replication in steroid-treated severe HBsAg-positive chronic active hepatitis.
Dig. Dis. Sci. 30: 97-103 (1985).
-
Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, Bohane TD. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach.
J. Gastroenterol. Hepatol. 21: 1609-1614 (2006).
*
-
Day CP. Treatment of alcoholic liver disease.
Liver Transpl. 13: S69-S75 (2007).
*
-
Day CP. Alcoholic steatohepatitis (ASH).
Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 85-86. October 17 - 19 (2003). *
-
Day CP. Alcoholic liver disease.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 77 (2005). *
-
de Almeida AJ, Campos-de-Magalhaes M, Antonietti CL, Brandao-Mello CE, da Silva ML, de Oliveira RV, do Espírito-Santo MP, Yoshida CF, Lampe E. Autoimmune thrombocytopenia related to chronic hepatitis C virus infection.
Hematology 14: 49-58 (2009).
-
de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, de Boer SY, Derijks LJ, Mulder CJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine.
Eur. J. Gastroenterol. Hepatol. 17: 457-461 (2005).
-
de C Ventura GM, Balloy V, Ramphal R, Khun H, Huerre M, Ryffel B, Plotkowski MC, Chignard M, Si-Tahar M. Lack of MyD88 protects the immunodeficient host against fatal lung inflammation triggered by the opportunistic bacteria Burkholderia cenocepacia.
J. Immunol. Jun 17 [Epub ahead of print] (2009).
-
De Jager ME, Van De Kerkhof PC, De Jong EM, Seyger MM. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals.
J. Dermatolog. Treat. Jan 1 [Epub ahead of print] (2009).
-
de Oliveira RA, Fechine LM, Neto FC, Nicodemus JM, Silva GB Jr, Silva LS. Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis.
Int. Urol. Nephrol. 40: 1095-1098 (2008).
-
de Saussure P, Soravia C, Morel P, Hadengue A. Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis.
Aliment. Pharmacol. Ther. 22: 203-208 (2005).
*
-
De Tommaso AM, Santos DS, Novaes P, Arieta CE, Hessel G. Steroid-induced cataracts in patients with autoimmune hepatitis.
Acta Gastroenterol. Latinoam. 33: 93-97 (2003).
-
De Vos M. Standard and innovative therapy of inflammatory bowel diseases.
Clin. Exp. Rheumatol. 20 (6 Suppl. 28): S95-S100 (2002).
-
De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450.
J. Cyst. Fibros. 2: 72-75 (2003).
-
Dear KL, Compston JE, Hunter JO. Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis.
Clin. Nutr. 20: 541-546 (2001).
-
Degos F, Degott C, Erlinger S. Ineffectiveness of corticosteroids in cholestatic forms of chronic active hepatitis.
Gastroenterol. Clin. Biol. 4: 246-250 (1980).
-
Deji N, Sugimoto T, Fujimoto T, Aoyama M, Takeda N, Sakaguchi M, Uzu T, Kashiwagi A. Emergence of panniculitis and haemophagocytic syndrome in a patient with chronic systemic lupus erythematosus.
Lupus 16: 363-365 (2007).
-
Del Rosso Do JQ. Combination topical therapy for the treatment of psoriasis.
J. Drugs Dermatol. 5: 232-234 (2006).
-
Der G, Love T, Schreck J, Horn M. Primary sclerosing cholangitis: a case presentation.
Gastroenterol. Nurs. 28: 13-16 (2005).
*
-
Derijk R, de Kloet ER. Corticosteroid receptor genetic polymorphisms and stress responsivity.
Endocrine 28: 263-270 (2005).
-
Desilva S, Kaplan G, Panaccione R. Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.
Rev. Gastroenterol. Disord. 8: 109-116 (2008).
-
Deurloo DT, van Esch BC, Hofstra CL, Nijkamp FP, van Oosterhout AJ. CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model.
Am. J. Respir. Cell. Mol. Biol. 25: 751-760 (2001).
*
-
Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy.
Can. J. Gastroenterol. 18: 321-326 (2004).
-
Dhabhai R, Kalla G, Singhi MK, Ghiya BC, Kachhawa D. Dexamethasone-cyclophosphamide pulse therapy in systemic lupus erythematosus.
Indian J. Dermatol. Venereol. Leprol. 71: 9-13 (2005).
*
-
Di Gangi M, Foti R, Leonardi R, Leonetti C, Castellino P. Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFalpha treatment.
Reumatismo 59: 169-172 (2007).
-
Diaz-Valle D, Benitez del Castillo JM, Fernandez Acenero MJ, Pascual Allen D, Moriche Carretero M. Bilateral lid margin ulcers as the initial manifestation of Crohn disease.
Am. J. Ophthalmol. 138: 292-294 (2004).
*
-
Diep JT, Kerr LD, Barton C, Emre S. Musculoskeletal manifestations in liver transplantation recipients.
J. Clin. Rheumatol. 14: 257-260 (2008).
-
Dietrich W, Erbguth F. Neurological complications of inflammatory intestinal diseases.
Fortschr. Neurol. Psychiatr. 71: 406-414 (2003).
-
Diez M, Sanchez E, Garcia Lopez S, Arroyo MT, Gomollon F. Infliximab therapy in ulcerative colitis: initial experience in two referral centers.
Gastroenterol. Hepatol. 30: 449-453 (2007).
-
Diez Pina JM, Vazquez Gomez O, Mayoralas Alises S, García Jimenez JD, Alvaro Alvarez D, Rodriguez Bolado MP. Etanercept as a possible trigger of fatal pulmonary fibrosis.
Arch. Bronconeumol. 44: 393-395 (2008).
*
-
Dijkstra G, Moshage H, Jansen PL. Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease?
Scand. J. Gastroenterol. Suppl. 236: 37-41 (2002).
*
-
Dilger K, Alberer M, Busch A, Enninger A, Behrens R, Koletzko S, Stern M, Beckmann C, Gleiter CH. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease.
Aliment. Pharmacol. Ther. 23: 387-396 (2006).
*
-
Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein.
Inflamm. Bowel Dis. 10: 578-583 (2004).
*
-
Dimachkie MM, Barohn RJ. Idiopathic inflammatory myopathies.
Front. Neurol. Neurosci. 26: 126-146 (2009).
-
Dimagno MJ, Dimagno EP. Chronic pancreatitis.
Curr. Opin. Gastroenterol. Jun 16 [Epub ahead of print] (2009).
-
Dimitri D, Pagnoux C. Pregnancy and inflammatory myopathies.
Presse. Med. 37: 1652-1656 (2008).
-
Dimopoulos MA, Theodorakis M, Kostis E, Papadimitris C, Moulopoulos LA, Anastasiou-Nana M. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine.
Leuk. Lymphoma 25: 187-189 (1997).
-
Din S, Dahele A, Fennel J, Aitken S, Shand AG, Arnott ID, Satsangi J. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience.
Inflamm. Bowel Dis. 14: 756-762 (2008).
*
-
Dinarello CA. Anti-cytokine therapy from the bench to the bedside.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 84-86 (2005). *
-
Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, Naccarato R, Martin A. Evolution of osteopenia in inflammatory bowel disease.
Am. J. Gastroenterol. 94: 1292-1297 (1999).
*
-
Dinic-Uzurov V, Lalosevic V, Milosevic I, Urosevic I, Lalosevic D, Popovic S. Current differential diagnosis of hypereosinophilic syndrome.
Med. Pregl. 60: 581-586 (2007).
-
Dinwiddie R. Anti-inflammatory therapy in cystic fibrosis.
J. Cyst. Fibros. 4 Suppl. 2: S45-S48 (2005).
-
Dite P, Novotny I, Trna J, Sevcikova A. Autoimmune pancreatitis.
Best Pract. Res. Clin. Gastroenterol. 22: 131-143 (2008).
-
Dittrich K, Richter M, Rascher W, Kohler H. Leukocytapheresis in a girl with severe ulcerative colitis refractory to corticosteroids, infliximab, and cyclosporine A.
Inflamm. Bowel Dis. 14: 1466-1467 (2008).
-
Dolev E, Sandman-Goddard G. Eosinophilic gastroenteritis.
Harefuah. 116: 465-466 (1989).
-
Donaldson PT. Basic concepts in PSC.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 73-75 (2005). *
-
Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis.
Clin. Liver Dis. 6: 419-437 (2002).
-
Dooley MA, Falk RJ. Human clinical trials in lupus nephritis.
Semin. Nephrol. 27: 115-127 (2007).
-
Dorner T, Haas J, Loddenkemper C, von Baehr V, Salama A. Implant-related inflammatory arthritis.
Nat. Clin. Pract. Rheumatol. 2: 53-56 (2006).
*
-
Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab.
Chest 127: 1064-1071 (2005).
*
-
Dray X, Joly F, Lavergne-Slove A, Treton X, Bouhnik Y, Messing B. A severe but reversible refractory sprue.
Gut 55: 1210-1211 (2006).
*
-
Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS)…
Rheumatology (Oxford) 42: 235-239 (2003).
*
-
Duane WC, Xiong W, Lofgren J. Transactivation of the human apical sodium-dependent bile acid transporter gene by human serum.
J. Steroid Biochem. Mol. Biol. 108: 137-148 (2008).
-
Dubinsky MC. New patients: should children be treated differently?
Colorectal Dis. 8 Suppl. 1: 15-19 (2006).
-
Dubinsky MC. Diffuse jejunoileitis in adolescence.
Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 70. May 7-8 (2004). *
-
Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease.
Curr. Gastroenterol. Rep. 5: 506-511 (2003).
-
Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes.
Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).
-
Dubus JC, Ravilly S. Inhaled therapies in cystic fibrosis.
Rev. Mal. Respir. 25: 989-998 (2008).
-
Duclos-Vallee JC, Di Martino V, Cazier A, Ballot E, Johanet C, Yamamoto AM, Emile JF, Guettier C, Coutarel P, Cadranel JF. Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids.
Gastroenterol. Clin. Biol. 29: 1173-1176 (2005).
-
Duclos-Vallee JC, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A.
Dig. Dis. Sci. 40: 1069-1073 (1995).
-
Dufour JF, Pradat P, Ruivard M, Hot A, Dumontet C, Broussolle C, Trepo C, Seve P. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases.
Eur. J. Gastroenterol. Hepatol. 21: 245-253 (2009).
-
Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Vitamin K status in patients with Crohn's disease and relationship to bone turnover.
Am. J. Gastroenterol. 99: 2178-2185 (2004).
*
-
Dunn JM, McNair A. Prolonged cholestasis following successful removal of common bile duct stones: beware patients on estrogen therapy.
World J. Gastroenterol. 13: 6277-6280 (2007).
*
-
Dupont B, Dupont C, Justum AM, Piquet MA, Reimund JM. Enteral nutrition in adult Crohn's disease: present status and perspectives.
Mol. Nutr. Food Res. 52: 875-884 (2008).
*
-
Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis.
Aliment. Pharmacol. Ther. 22: 907-916 (2005).
*
-
Durox H, Boumediene A, Genet C, Lo Re P, Rogez JP, Weinbreck P, Denes E. Disseminated aspergillosis after intra-articular corticosteroid infiltrations.
Med. Mal. Infect. 37: 609-612 (2007).
-
Dwarakanath AD, Nash J, Rhodes JM. 'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment.
Gut 35: 1141-1144 (1994).
*
-
Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis.
Gut 37: 585-588 (1995).
*
-
Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children.
Aliment. Pharmacol. Ther. 26: 795-806 (2007).
*
-
Eames T, Landthaler M, Karrer S. Crohn's disease: an important differential diagnosis of granulomatous skin diseases.
Eur. J. Dermatol. May 14 [Epub ahead of print] (2009).
-
Ebert EC, Hagspiel KD, Nagar M, Schlesinger N. Gastrointestinal involvement in polyarteritis nodosa.
Clin. Gastroenterol. Hepatol. 6: 960-966 (2008).
-
Ebert EC, Kierson M, Hagspiel KD. Gastrointestinal and hepatic manifestations of sarcoidosis.
Am. J. Gastroenterol. 103: 3184-3192 (2008).
*
-
Ebinger M, Leidl R, Thomas S, Von Tirpitz C, Reinshagen M, Adler G, Konig HH. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital.
J. Gastroenterol. Hepatol. 19: 192-199 (2004).
*
-
Edgin WA, Pratt TC, Grimwood RE. Pemphigus vulgaris and paraneoplastic pemphigus.
Oral Maxillofac. Surg. Clin. North Am. 20: 577-584 (2008).
-
Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
Clin. Pharmacokinet. 43: 803-821 (2004).
-
Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications.
Semin. Arthritis Rheum. 36: 168-172 (2006).
*
-
Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still's disease.
Semin. Arthritis Rheum. 36: 144-152 (2006).
*
-
Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?
Nat. Clin. Pract. Rheumatol. 3: 328-335 (2007).
*
-
Efthimiou P, Paik P, Bielory L. Diagnosis and management of adult onset Still's disease.
Ann. Rheum. Dis. 65: 564-572 (2006).
*
-
Egan LJ. Mechanism of action of established drugs: cyclosporine, methotrexate and others.
Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 63-64. May 7-8 (2004). *
-
Egesten A, Eliasson M, Olin AI, Erjefält JS, Bjartell A, Sangfelt P, Carlson M. The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids.
Int. J. Colorectal Dis. 22: 1421-1427 (2007).
*
-
Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis.
Inflamm. Bowel Dis. 11: 213-218 (2005).
*
-
Eidelwein AP, Thompson R, Fiorino K, Abadom V, Oliva-Hemker M. Disease presentation and clinical course in black and white children with inflammatory bowel disease.
J. Pediatr. Gastroenterol. Nutr. 44: 555-560 (2007).
*
-
Eisen A, Arnson Y, Dovrish Z, Hadary R, Amital H. Arrhythmias and conduction defects in rheumatological diseases - a comprehensive review.
Semin. Arthritis Rheum. Jun 26 [Epub ahead of print] (2008).
*
-
Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Oral lichen planus: clinical features and management.
Oral Dis. 11: 338-349 (2005).
*
-
Eivindson M, Gronbaek H, Flyvbjerg A, Frystyk J, Zimmermann-Nielsen E, Dahlerup JF. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
Growth Horm. IGF Res. 17: 33-40 (2007).
-
Eivindson M, Gronbaek H, Nielsen JN, Frystyk J, Flyvbjerg A, Jorgensen L, Vind I, Munkholm P, Jensen S, Brandslund I, Hey H. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids.
Scand. J. Gastroenterol. 40: 1214-1221 (2005).
*
-
Eken H, Ozturk H, Ozturk H, Buyukbayram H. Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats.
World J. Gastroenterol. 12: 5379-5383 (2006).
*
-
Eklow C, Makrygiannakis D, Backdahl L, Padyukov L, Ulfgren AK, Lorentzen JC, Malmstrom V. Cellular distribution of the C-type II lectin dendritic cell immunoreceptor (DCIR) and its expression in the rheumatic joint: identification of a subpopulation of DCIR+ T cells.
Ann. Rheum. Dis. 67: 1742-1749 (2008).
-
Ekstrom GM, Andersson SE. Plasma exudation, hyperaemia, and epithelial permeability in rats with oxazolone-induced colitis: modulatory effects of budesonide.
Scand. J. Gastroenterol. 35: 190-197 (2000).
*
-
El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
J. Pediatr. 150: 376-382 (2007).
*
-
El-Shanawany TM, Williams PE, Jolles S. Response of refractory ITP in a patient with common variable immunodeficiency (CVID) to treatment with rituximab.
J. Clin. Pathol. 60: 715-716 (2007).
*
-
Elbek O, Uyar M, Aydin N, Borekci S, Bayram N, Bayram H, Dikensoy O. Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha.
Clin. Rheumatol. 28: 421-426 (2009).
*
-
Elia PP, Fogaca HS, Barros RG, Zaltman C, Elia CS. Descriptive analysis of the social, clinical, laboratorial and anthropometric profiles of inflammatory bowel disease inwards patients from the "Clementino Fraga Filho" University Hospital, Rio de Janeiro, RJ, Brazil.
Arq. Gastroenterol. 44: 332-339 (2007).
-
Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis.
Chest 133: 489-495 (2008).
*
-
Elkayam O, Levartovsky D, Brautbar C, Yaron M, Burke M, Vardinon N, Caspi D. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena.
Am. J. Med. 105: 484-487 (1998).
*
-
Elloumi H, Ben Abdelaziz A, Arfaoui D, Lassoued Y, Letaief R, Jmaa A, Ghannem H, Ajmi S. Predictive factors of surgery in severe attacks of ulcerative colitis.
Tunis. Med. 85: 417-420 (2007).
-
Elloumi H, Ben Abdelaziz A, Derbel F, Jmaa A, Lassoued Y, Arfaoui D, Ben Ali A, Letaief R, Hamida RB, Ghannem H, Ajmi S. Predictive factors of glucocorticosteroid treatment failure in severe acute idiopathic colitis.
Acta Gastroenterol. Belg. 68: 226-229 (2005).
-
Endo H, Rees TD, Matsue M, Kuyama K, Nakadai M, Yamamoto H. Early detection and successful management of oral pemphigus vulgaris: a case report.
J. Periodontol. 76: 154-160 (2005).
-
Engels EA, Cerhan JR, Linet MS, Cozen W, Colt JS, Davis S, Gridley G, Severson RK, Hartge P. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study.
Am. J. Epidemiol. 162: 1153-1161 (2005).
*
-
Ephgrave K. Extra-intestinal manifestations of Crohn's disease.
Surg. Clin. North Am. 87: 673-680 (2007).
-
Erkelens GW, Van Deventer SJ. Endoscopic treatment of strictures in Crohn's disease.
Best Pract. Res. Clin. Gastroenterol. 18: 201-207 (2004).
-
Esber EJ, Ferguson DR. Primary sclerosing cholangitis.
Gastroenterologist 2: 131-146 (1994).
-
Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence.
Inflamm. Bowel Dis. 9: 34-58 (2003).
*
-
Escher JC; European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
Eur. J. Gastroenterol. Hepatol. 16: 47-54 (2004).
-
Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors.
Semin. Thromb. Hemost. 34: 290-294 (2008).
-
Espinosa G, Cervera R. Morbidity and mortality in the antiphospholipid syndrome.
Curr. Opin. Pulm. Med. May 11 [Epub ahead of print] (2009).
-
Espinosa G, Mendizabal A, Minguez S, Ramo-Tello C, Capellades J, Olive A, Cervera R. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients.
Semin. Arthritis Rheum. Nov 18 [Epub ahead of print] (2008).
*
-
Esteve M, Gisbert JP. Severe ulcerative colitis: at what point should we define resistance to steroids?
World J. Gastroenterol. 14: 5504-5507 (2008).
*
-
Estiarte R, Juan J, Colome E, Artes M, Jimenez FJ. Drug utilization study in patients with Crohn's disease in Spain.
Eur. J. Gastroenterol. Hepatol. 15: 355-362 (2003).
-
Estradas J, Pascual-Ramos V, Martinez B, Uribe M, Torre A. Autoimmune hepatitis with giant-cell transformation.
Ann. Hepatol. 8: 68-70 (2009).
*
-
Estrin HM, Hughes RW Jr. Oral manifestations in Crohn's disease: report of a case.
Am. J. Gastroenterol. 80: 352-354 (1985).
-
Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation.
Hepatology 43: 1109-1117 (2006).
*
-
Evereklioglu C. Managing the symptoms of Behcet's disease.
Expert Opin. Pharmacother. 5: 317-328 (2004).
-
Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease.
Surv. Ophthalmol. 50: 297-350 (2005).
-
Evers EA, Pfefferkorn MD, Steiner SJ. Factors predictive of Crohn disease following colectomy in medically refractory pediatric colitis.
J. Pediatr. Gastroenterol. Nutr. 48: 283-286 (2009).
-
Ezzedine K, Simonart T, Candaele M, Malvy D, Heenen M. Concomitant xeroderma pigmentosum and disseminated small plaque psoriasis - the first case of an antinomic association: a case report.
Cases J. 1: 74 (2008).
-
Fahrlander H. Drug treatment of chronic inflammatory intestinal diseases with special reference to 5-azosalicylic acid.
Schweiz. Med. Wochenschr. 117: 1620-1623 (1987).
-
Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience.
Liver Transpl. 10: 1189-1194 (2004).
*
-
Fakhoury M, Lecordier J, Medard Y, Peuchmaur M, Jacqz-Agrain E. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.
Inflamm. Bowel Dis. 12: 745-749 (2006).
*
-
Fan PT, Leong KH. The use of biological agents in the treatment of rheumatoid arthritis.
Ann. Acad. Med. Singapore 36: 128-127 (2007).
-
Fang W, Yang P. Vogt-Koyanagi-Harada syndrome.
Curr. Eye Res. 33: 517-523 (2008).
-
Farrell GC. Drugs and steatohepatitis.
Semin. Liver Dis. 22: 185-194 (2002).
-
Farrell JJ, Garber J, Sahani D, Brugge WR. EUS findings in patients with autoimmune pancreatitis.
Gastrointest. Endosc. 60: 927-936 (2004).
*
-
Farrow SN. Nuclear receptors: doubling up in the lung.
Curr. Opin. Pharmacol. 8: 275-279 (2008).
-
Fartoux L, Serfaty L. Liver cirrhosis in adults: etiology and specific treatments.
Rev. Prat. 55: 1539-1548 (2005).
-
Fattorossi A, Battaglia A, Buzzonetti A, Ciaraffa F, Scambia G, Evoli A. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.
Immunology 116: 134-141 (2005).
*
-
Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.
Gastroenterology 121: 255-260 (2001).
*
-
Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.
Drugs 45: 953-1040 (1993).
-
Fauroux B, Clement A. Paediatric sarcoidosis.
Paediatr. Respir. Rev. 6: 128-133 (2005).
-
Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.
Eur. J. Haematol. 66: 408-411 (2001).
*
-
Faust D, Menge F, Armbruster FP, Lembcke B, Stein J. Increased serum bone sialoprotein concentrations in patients with Crohn's disease.
Z. Gastroenterol. 41: 243-247 (2003).
-
Fautrel B, Flipo RM, Saraux A. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
Rheumatology (Oxford) 47: 1698-1703 (2008).
*
-
Feagan BG, Sandborn WJ. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Rev. Gastroenterol. Disord. 2 Suppl. 2: S9-S15 (2002).
*
-
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Aliment. Pharmacol. Ther. 21: 373-384 (2005).
*
-
Fedorak RN. Conservative approach to severe ulcerative colitis.
Dig. Liver Dis. 36: 4-6 (2004).
*
-
Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide.
Adv. Drug Deliv. Rev. 57: 303-316 (2005).
*
-
Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
Gastroenterology 119: 1473-1482 (2000).
*
-
Fefferman DS, Lodhavia PJ, Alsahli M, Falchuk KR, Peppercorn MA, Shah SA, Farrell RJ. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease.
Inflamm. Bowel Dis. 10: 346-351 (2004).
*
-
Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade.
J. Clin. Rheumatol. 11: 219-222 (2005).
-
Feld J, Heathcote E. Epidemiology of autoimmune liver disease.
J. Gastroenterol. Hepatol. 18: 1118-1128 (2003).
*
-
Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.
Hepatology 42: 53-62 (2005).
*
-
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.
Lancet 371: 2201-2212 (2008).
*
-
Feldman SR, Brown KL, Heald P. 'Coral reef' psoriasis: a marker of resistance to topical treatment.
J. Dermatolog. Treat. 19: 257-258 (2008).
-
Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
Osteoporos. Int. 16: 2168-2174 (2005).
*
-
Felekis T, Katsanos K, Kitsanou M, Trakos N, Theopistos V, Christodoulou D, Asproudis I, Tsianos EV. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: A prospective single-center study.
Inflamm. Bowel Dis. 15: 29-34 (2009).
*
-
Felizardo M, Gomes A, Sousa M, Teixeira A, Freitas J, Tavares A, Vaz Patto J, Gomes M. Immunosuppression and tuberculosis.
Rev. Port. Pneumol. 13: S23-S24 (2007).
-
Fenoglio D, Ferrera F, Fravega M, Balestra P, Battaglia F, Proietti M, Andrei C, Olive D, Antonio LC, Indiveri F, Filaci G. Advancements on phenotypic and functional characterization of non-antigen-specific CD8+CD28- regulatory T cells.
Hum. Immunol. 69: 745-750 (2008).
-
Fenton C, Plosker GL. Calcipotriol/Betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris.
Am. J. Clin. Dermatol. 5: 463-478 (2004).
-
Ference JD, Last AR. Choosing topical corticosteroids.
Am. Fam. Physician 79: 135-140 (2009).
-
Fernandes NF, Martin RR, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity.
Am. J. Gastroenterol. 95: 532-535 (2000).
*
-
Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis.
Am. J. Gastroenterol. 94: 241-248 (1999).
*
-
Fernandez Perez FJ, Rodriguez F, De Sola C, Fernandez Moreno N, Vera F, Rivera R, Sanchez Cantos A. Granulocytapheresis in inflammatory bowel disease. Efficacy of an induction plus maintenance sessions protocol at 32 weeks.
Rev. Esp. Enferm. Dig. 99: 628-635 (2007).
*
-
Fernandez-Banares F, Cabre E, Gonzalez-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn's disease.
Gut 35: S55-S59 (1994).
*
-
Fernandez-Castro M, Mellor-Pita S, Jesus Citores M, Munoz P, Tutor-Ureta P, Silva L, Antonio Vargas J, Yebra-Bango M, Luis Andreu J. Common variable immunodeficiency in systemic lupus erythematosus.
Semin. Arthritis Rheum. 36: 238-245 (2007).
*
-
Fernandez-Nebro A, Irigoyen MV, Urena I, Belmonte-Lopez MA, Coret V, Jimenez-Nunez FG, Diaz-Cordoves G, Lopez-Lasanta MA, Ponce A, Rodriguez-Perez M, Calero E, Gonzalez-Santos P. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
J. Rheumatol. 34: 2334-2342 (2007).
-
Ferrandiz-Pulido C, Bartralot R, Fuente MJ, Heras C, Bassas P, Aparicio G, Bodet D, Mollet J, Tortola MT, Garcia-Patos V. Postoperative pyoderma gangrenosum: diagnostic value of 16s ribosomal RNA sequencing and review of the literature.
Clin. Exp. Dermatol. Dec 15 [Epub ahead of print] (2008).
*
-
Ferrante M, D'Hoore A, Vermeire S, Declerck S, Noman M, Van Assche G, Hoffman I, Rutgeerts P, Penninckx F. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis.
Inflamm. Bowel Dis. 15: 1062-1070 (2009).
-
Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes K, Rutgeerts P. Predictors of early response to infliximab in patients with ulcerative colitis.
Inflamm. Bowel Dis. 13: 123-128 (2007).
*
-
Ferreira AR, Roquete ML, Penna FJ, Toppa NH. Autoimmune hepatitis in children and adolescents: clinical study, diagnosis and therapeutic response.
J. Pediatr. (Rio. J.) 78: 309-314 (2002).
*
-
Ferri C. Mixed cryoglobulinemia.
Orphanet J. Rare Dis. 3: 25 (2008).
*
-
Ferri S, Muratori L, Quarneti C, Muratori P, Menichella R, Pappas G, Granito A, Ballardini G, Bianchi FB, Lenzi M. Clinical features and effect of antiviral therapy on anti-liver/kindey microsomal antibody type 1 positive chronic hepatitis C.
J. Hepatol. 50: 1093-1101 (2009).
-
Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment.
Clin. J. Am. Soc. Nephrol. 3: 905-919 (2008).
*
-
Fiedorczyk M, Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis.
Przegl. Lek. 62: 1321-1324 (2005).
-
Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, Schiano TD. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.
Liver Transpl. 14: 861-871 (2008).
*
-
Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia.
J. Clin. Rheumatol. 13: 94-95 (2007).
-
Firouzi F, Rashidi M, Hashemi S, Kangavari M, Bahari A, Daryani NE, Emam MM, Naderi N, Shalmani HM, Farnood A, Zali M. A decision tree-based approach for determining low bone mineral density in inflammatory bowel disease using WEKA software.
Eur. J. Gastroenterol. Hepatol. 19: 1075-1081 (2007).
-
Fishman SJ, Feins NR, D' Amato RJ, Folkman J. Long-term remission of Crohn's disease treated with thalidomide: a seminal case report.
Angiogenesis 3: 201-204 (1999).
*
-
Flamant M, Bourreille A. Biologic therapies in inflammatory bowel disease.
Rev. Med. Interne. 28: 852-861 (2007).
-
Fleischmann RM, Tesser J, Schiff M, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
Ann. Rheum. Dis. 65: 1006-1012 (2006).
*
-
Flieger D, Varvenne M, Kleinschmidt R, Schmidt-Wolf IG. Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody 17-1A and interleukin-2.
Cell. Immunol. 246: 26-33 (2007).
*
-
Flood L, Lofberg R, Stierna P, Wikstrom AC. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy.
Inflamm. Bowel Dis. 7: 202-209 (2001).
*
-
Focosi D, Maggi F, Ceccherini-Nelli L, Marchi S, Petrine M. Progressive multifocal leukoencephalopathy in autoimmune disorders.
Gut 58: 605 (2009).
-
Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, Horneff G, Kuis W, Sorg C, Roth J. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations.
Arthritis Rheum. 50: 1286-1295 (2004).
*
-
Fogarty PF, Seggewiss R, McCloskey DJ, Boss CA, Dunbar CE, Rick ME. Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura.
Haematologica 91: 277-278 (2006).
*
-
Foocharoen C, Nanagara R, Salang L, Suwannaroj S, Mahakkanukrauh A. Pregnancy and disease outcome in patients with systemic lupus erythematosus (SLE): a study at Srinagarind Hospital.
J. Med. Assoc. Thai. 92: 167-174 (2009).
-
Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis.
Curr. Opin. Ophthalmol. 14: 395-398 (2003).
-
Foteinou PT, Calvano SE, Lowry SF, Androulakis IP. In silico simulation of corticosteroids effect on an NFkB- dependent physicochemical model of systemic inflammation.
PLoS ONE 4: e4706 (2009).
*
-
Foucaud P, de Truchis A, Tassin E, Allouch P, Pangon B. Pseudomonas aeruginosa and cystic fibrosis: non-antibiotic strategy.
Arch. Pediatr. 13 Suppl. 1: S44-S47 (2006).
-
Fouillard L, Gorin NC, Laporte JP, Leon A, Brantus JF, Miossec P. Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood.
Lupus 8: 320-323 (1999).
-
Franchimont D. Mechanisms of steroid refractory disease.
Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 72-73. May 7-8 (2004). *
-
Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis.
Curr. Gastroenterol. Rep. 1: 95-101 (1999).
-
Frederiksen SL, Chen W. D-penicillamine for primary sclerosing cholangitis.
Cochrane Database Syst. Rev. 2: CD004182 (2004). *
-
Fredin MF, Ulfhammer E, Rhedin M, Melgar S, Mellgard B, Peterson A. Anti-inflammatory effects of budesonide in intestinal epithelial cells.
Pharmacol. Res. 52: 422-428 (2005).
*
-
Freeman HJ. Long-term clinical behavior of jejunoileal involvement in Crohn's disease.
Can. J. Gastroenterol. 19: 575-578 (2005).
-
Freeman HJ. Natural history and long-term clinical behavior of segmental colitis associated with diverticulosis (SCAD syndrome).
Dig. Dis. Sci. 53: 2452-2457 (2008).
*
-
Freeman HJ, Berean K, Nimmo M. Evolution of collagenous colitis into severe and extensive ulcerative colitis.
Can. J. Gastroenterol. 21: 315-318 (2007).
-
Freeman HJ, Freeman KJ. Prevalence rates and an evaluation of reported risk factors for osteonecrosis (avascular necrosis) in Crohn's disease.
Can. J. Gastroenterol. 14: 138-143 (2000).
-
Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.
Orphanet J. Rare Dis. 3: 16 (2008).
*
-
French MA. Immune reconstitution inflammatory syndrome: a reappraisal.
Clin. Infect. Dis. 48: 101-107 (2009).
*
-
Frigerio E, Ramoni S, Franchi C, Garutti C, Garavaglia M, Spinelli M, Capsoni F, Altomare GF. Successful cyclosporine treatment in a case of amicrobial pustulosis associated with immunological abnormalities.
Int. J. Immunopathol. Pharmacol. 22: 243-246 (2009).
-
Froehlich F, Fried M, Gonvers JJ, Saraga E, Thorens J, Pecoud A. Association of Crohn's disease and Cogan's syndrome.
Dig. Dis. Sci. 39: 1134-1137 (1994).
-
Froehlich F, Juillerat P, Felley C, Mottet C, Vader JP, Burnand B, Michetti P, Gonvers JJ. Treatment of postoperative Crohn's disease.
Digestion 71: 49-53 (2005).
-
Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ. Maintenance of surgically induced remission of Crohn's disease.
Digestion 76: 130-135 (2007).
*
-
Fuchtenbusch M, Vogel A, Achenbach P, Gummer M, Ziegler AG, Albert E, Standl E, Manns MP. Lupus-like panniculitis in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
Exp. Clin. Endocrinol. Diabetes 111: 288-293 (2003).
-
Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum.
Br. J. Dermatol. 151: 1090-1092 (2004).
*
-
Fujimoto T, Kato J, Nasu J, Kuriyama M, Okada H, Yamamoto H, Mizuno M, Shiratori Y; for the Japan West Ulcerative Colitis (JWUC) Study Group. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000.
Eur. J. Gastroenterol. Hepatol. 19: 229-235 (2007).
-
Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis.
J. Gastroenterol. 43: 951-958 (2008).
*
-
Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, Atsumi T, Koike T. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases.
Rheumatology (Oxford) 47: 1686-1691 (2008).
*
-
Fuller SJ, Kumar P, Weltman M, Wiley JS. Autoimmune hemolysis associated with primary biliary cirrhosis responding to ursodeoxycholic acid as sole treatment.
Am. J. Hematol. 72: 31-33 (2003).
*
-
Funayama Y, Fukushima K, Shibata C, Koyama K, Miura K, Takahashi K, Hashimoto A, Sasaki I, Kinouchi Y, Hiwatashi N, Takeda K, Matsuno S. Acute pancreatitis complicating ulcerative colitis under administration of corticosteroid in surgical cases.
J. Gastroenterol. 39: 592-594 (2004).
*
-
Funayama Y, Kumagai E, Takahashi KI, Fukushima K, Sasaki I. Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease.
Dis. Colon Rectum 52: 311-314 (2009).
-
Furst A, Schmidbauer C, Swol-Ben J, Iesalnieks I, Schwandner O, Agha A. Gracilis transposition for repair of recurrent anovaginal and rectovaginal fistulas in Crohn's disease.
Int. J. Colorectal Dis. 23: 349-353 (2008).
*
-
Furst DE. Serum immunoglobulins and risk of infection: how low can you go?
Semin. Arthritis Rheum. Jul 10 [Epub ahead of print] (2008).
*
-
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
J. Rheumatol. 30: 2563-2571 (2003).
-
Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME; Members of the First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment sponsored by the American Gastroenterological Association (AGA) Institute and North American Society of Pediatric Gastroenterol.
Gastroenterology 133: 1342-1363 (2007).
*
-
Furuta R, Ando T, Watanabe O, Maeda O, Ishiguro K, Ina K, Kusugami K, Goto H. Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis.
J. Gastroenterol. Hepatol. 22: 261-267 (2007).
*
-
Futami S, Aoyama N, Honsako Y, Tamura T, Morimoto S, Nakashima T, Ohmoto A, Okano H, Miyamoto M, Inaba H. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression.
Dig. Dis. Sci. 40: 814-818 (1995).
-
Gadowska-Cicha A, Latos W, Niepsuj KJ, Sieron A. The therapy of Lesniowski-Crohn disease of the upper part of the gastrointestinal tract.
Wiad. Lek. 58: 307-312 (2005).
-
Gaia E, Pais P, Salacone P, Morello C. Preliminary results obtained with cefoperazone plus corticosteroids in the treatment of active Crohn's disease.
Inflamm. Bowel Dis. Oct 22 [Epub ahead of print] (2008).
-
Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis.
Cochrane Database Syst. Rev. 1: CD002277 (2008).
*
-
Gajic-Veljic M, Nikolic M, Medenica L. Juvenile bullous pemphigoid: the presentation and follow-up of six cases.
J. Eur. Acad. Dermatol. Venereol. Apr 23 [Epub ahead of print] (2009).
*
-
Gajinov Z, Vuckovic N, Duran V, Matic M, Ivkov-Simic M, Rajic N. Viral form of hemophagocytic syndrome with erythrodermal clinical picture - case report.
Med. Pregl. 61: 405-408 (2008).
-
Gal I, Toth L, Szegedi L, Kiss GG. Gastric bleeding in a patient with rheumatoid arthritis complicated by immune thrombocytopenic purpura.
Joint Bone Spine 75: 350-352 (2008).
*
-
Galandi D, Allgaier HP. Diet therapy in chronic inflammatory bowel disease: results from meta-analysis and randomized controlled trials.
Schweiz. Rundsch. Med. Prax. 91: 2041-2049 (2002).
-
Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C, Caporali R, Sebastiani GD. Treatment of rheumatic diseases in patients with HCV and HIV infection.
Autoimmun. Rev. 8: 100-103 (2008).
-
Gallerani I, Innocenti DD, Coronella G, Berti S, Amato L, Moretti S, Fabbri P. Cutaneous sarcoid-like granulomas in a patient with X-linked hyper-IgM syndrome.
Pediatr. Dermatol. 21: 39-43 (2004).
*
-
Gambichler T, Reich S, Banasch M, Altmeyer P. Complex extra-intestinal complications of ulcerative colitis in a patient with alpha1-antitrypsin deficiency.
Eur. J. Med. Res. 11: 135-138 (2006).
-
Garcia Planella E. Inflammatory bowel disease. Should bone densitometry always be performed when corticosteroids are prescribed in a flare of inflammatory bowel disease?
Gastroenterol. Hepatol. 31: 618-619 (2008).
-
Garcia RF, Garcia CE, McMaster P. Chronic rejection of the liver: the role of immunosuppression.
BioDrugs 14: 283-297 (2000).
-
Garcia Romero R, Martin de Carpi J, Bernal Cuartas C, Pinillos Pison S, Varea Calderon V. Autoimmune hepatitis in pediatric patients.
Rev. Esp. Enferm. Dig. 99: 255-258 (2007).
-
Gardinal I, Ammoury A, Paul C. Moderate to severe psoriasis: from topical to biological treatment.
J. Eur. Acad. Dermatol. Venereol. Mar 11 [Epub ahead of print] (2009).
*
-
Gardner TB, Chari ST. Autoimmune pancreatitis.
Gastroenterol. Clin. North Am. 37: 439-460 (2008).
-
Garnett WR, Yunker N. Treatment of Crohn's disease with infliximab.
Am. J. Health Syst. Pharm. 58: 307-316 (2001).
-
Garrity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab.
Am. J. Ophthalmol. 138: 925-930 (2004).
-
Gary A, Modeste AB, Richard C, Jubert C, Majour F, Nouvet G, Remond B, Joly P. Methotrexate for the treatment of patients with chronic cutaneous sarcoidosis: 4 cases.
Ann. Dermatol. Venereol. 132: 659-662 (2005).
-
Gaspar C, Leyral C, Orlandini V, Begueret H, Pellegrin JL, Doutre MS, Beylot-Barry M. Lethal pulmonary involvement of neutrophilic dermatosis following erythropoietin therapy.
Ann. Dermatol. Venereol. 135: 384-388 (2008).
-
Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis.
Dig. Dis. Sci. 52: 2433-2437 (2007).
*
-
Gavalas E, Kountouras J, Stergiopoulos C, Zavos C, Gisakis D, Nikolaidis N, Giouleme O, Chatzopoulos D, Kapetanakis N. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients.
Hepatogastroenterology 54: 1074-1079 (2007).
-
Geier DL, Miner PB Jr. New therapeutic agents in the treatment of inflammatory bowel disease.
Am. J. Med. 93: 199-208 (1992).
-
Gelbmann CM. Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease - do we have reliable markers?
Inflamm. Bowel Dis. 6: 123-131 (2000).
*
-
Georgescu SO, Dubei L, Cardeiu C, Anton R. Primary hyperslenism due by accessory spleens after splenectomy.
Chirurgia (Bucur.) 103: 233-237 (2008).
-
Georgii A, Przybilla B, Schmoeckel C. Olmstedt syndrome-associated with primary sclerosing cholangitis and immune deficiency of uncertain origin.
Hautarzt. 40: 708-712 (1989).
-
Gerber NL, Steinberg AD. Clinical use of immunosuppressive drugs: part II.
Drugs 11: 90-112 (1976).
-
Gerdes S, Mrowietz U. Classical topical therapy of psoriasis.
Hautarzt. 57: 666-671 (2006).
-
Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy.
Lupus 15: 148-155 (2006).
-
Geubel AP, Keller RH, Summerskill WH, Dickson ER, Tomasi TB, Shorter RG. Lymphocyte cytotoxicity and inhibition studied with autologous liver cells: observations in chronic active liver disease and the primary biliary cirrhosis syndrome.
Gastroenterology 71: 450-456 (1976).
-
Geubel AP, Sempoux C, Rahier J. Bile duct disorders.
Clin. Liver Dis. 7: 295-309 (2003).
-
Ghazale A, Chari ST. Optimising corticosteroid treatment for autoimmune pancreatitis.
Gut 56: 1650-1652 (2007).
*
-
Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.
Dermatol. Online J. 8: 5 (2002).
-
Ghosh S, Chaudhary R, Carpani M, Playford RJ. Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?
Gut 55: 6-8 (2006).
*
-
Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, Aul C. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.
Eur. J. Haematol. 69: 95-100 (2002).
*
-
Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion.
Acta Haematol. 113: 146-149 (2005).
-
Giannattasio A, D'Ambrosi M, Volpicelli M, Iorio R. Steroid therapy for a case of severe drug-induced cholestasis.
Ann. Pharmacother. 40: 1196-1199 (2006).
-
Giavina-Bianchi P, Silva Fde S, Toledo-Barros M, Birolini D, Kalil J, Rizzo LV. A rare intestinal manifestation in a patient with common variable immunodeficiency and strongyloidiasis.
Int. Arch. Allergy Immunol. 140: 199-204 (2006).
-
Gibelli NE, Tannuri U, Mello ES, Cancado ER, Santos MM, Ayoub AA, Maksoud-Filho JG, Velhote MC, Silva MM, Pinho-Apezzato ML, Maksoud JG. Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation.
Pediatr. Transplant. 10: 371-376 (2006).
-
Gibson PR, Anderson RP. Inflammatory bowel disease.
Med. J. Aust. 169: 387-394 (1998).
-
Gilissen LP, Derijks LJ, Bos LP, Bus PJ, Hooymans PM, Engels LG. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy.
Clin. Drug Investig. 24: 479-486 (2004).
-
Gionchetti P, D'arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A, Varoli G, Campieri M; and the Italian BDP Study Group. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial.
J. Clin. Gastroenterol. 39: 291-297 (2005).
-
Gionchetti P, Rizzello F. CBP-1011 (InKine Pharmaceutical Co).
IDrugs 4: 935-938 (2001).
-
Gionchetti P, Rizzello F, Habal F, Morselli C, Amadini C, Romagnoli R, Campieri M. Standard treatment of ulcerative colitis.
Dig. Dis. 21: 157-167 (2003).
-
Gipson IK, Hori Y, Argueso P. Character of ocular surface mucins and their alteration in dry eye disease.
Ocul. Surf. 2: 131-148 (2004).
-
Girardin M, Waschke KA, Seidman EG. A case of acute loss of vision as the presenting symptom of Crohn's disease.
Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 695-698 (2007).
*
-
Gire J, Guigou S, Darrason G, Carpentier S, Denis D. Orbital pseudotumors and Riedel's thyroiditis: case report.
J. Fr. Ophtalmol. 31: e15 (2008).
-
Girelli CM, Serio G, Rocca E, Rocca F. Refractory ulcerative colitis and iatrogenic colorectal Kaposi's sarcoma.
Dig. Liver Dis. 41: 170-174 (2009).
-
Giron RM, Maiz L, Barrio I, Martinez MT, Salcedo A, Prados C. Nontuberculous mycobacterial infection in patients with cystic fibrosis: a multicenter prevalence study.
Arch. Bronconeumol. 44: 679-684 (2008).
-
Giron RM, Sanchez Molini P, Almonacid C, Jimenez I, Rodriguez Salvanes F, Garcia Vadillo A, Quintana ML, Hurtado J, Ancochea J. A study of bone mineral density in adult patients with cystic fibrosis.
Med. Clin. (Barc.) 123: 81-84 (2004).
-
Girschick HJ, Zimmer C, Klaus G, Darge K, Dick A, Morbach H. Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated?
Nat. Clin. Pract. Rheumatol. 3: 733-738 (2007).
*
-
Girszyn N, Leport J, Arnaud L, Kahn JE, Piette AM, Bletry O. Crohn's disease affecting only vulvoperineal area.
Presse. Med. 36: 1762-1765 (2007).
-
Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond.
Int. J. Clin. Pract. 59: 969-974 (2005).
*
-
Glass-Marmor L, Paperna T, Ben-Yosef Y, Miller A. Chronotherapy using corticosteroids for multiple sclerosis relapses.
J. Neurol. Neurosurg. Psychiatry 78: 886-888 (2007).
*
-
Gluck T, Kiefmann B, Grohmann M, Falk W, Straub RH, Scholmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy.
J. Rheumatol. 32: 1473-1480 (2005).
-
Goerres MS, Meijer JWR, Wahab PJ, Kerckhaert JAM, Groenen PJTA, Van Krieken JHJM, Mulder CJJ. Azathioprine and prednisone combination therapy in refractory Coeliac disease.
Aliment. Pharmacol. Ther. 18: 487-494 (2003).
*
-
Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy.
Inflamm. Bowel Dis. 13: 1365-1368 (2007).
*
-
Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease.
Aliment. Pharmacol. Ther. 17: 307-320 (2003).
*
-
Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis.
Neurotherapeutics 5: 535-541 (2008).
-
Goldstein ES, Marion JF, Present DH. 6-Mercaptopurine is effective in Crohn's disease without concomitant steroids.
Inflamm. Bowel Dis. 10: 79-84 (2004).
*
-
Goldstein ES, Rubin PH. Endoscopic therapy for inflammatory bowel disease.
Curr. Treat. Options Gastroenterol. 6: 237-243 (2003).
-
Goncalves DU, de Castro MM, Galvao CP, Brandao AZ, de Castro MC, Lambertucci JR. Cheilitis granulomatosa associated with Melkersson-Rosenthal syndrome.
Rev. Bras. Otorrinolaringol. (Engl. Ed.) 73: 132-133 (2007).
*
-
Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F. Maintenance of remission in Crohn's disease.
Digestion 71: 41-48 (2005).
-
Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F. Maintenance of medically induced remission of Crohn's disease.
Digestion 76: 116-129 (2007).
*
-
Gonzalez ID, Saeza RS, Rodilla EM, Yges y EL, Toledano FL. Hypersensitivity reactions to chemotherapy drugs.
Alergol. Inmunol. Clin. 15: 161-181 (2000). *
-
Gonzalez MG, Madrazo CP, Rodriguez AB, Gutierrez MG, Herrero JI, Pallardo JM, Ortiz de Urbina J, Paricio PP. An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: a comparison of dual vs. triple drug therapy.
Liver Transpl. 11: 515-524 (2005).
*
-
Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, Rosen CB, Wiesner RH. Recurrent autoimmune hepatitis after orthotopic liver transplantation.
Liver Transpl. 7: 302-310 (2001).
*
-
Gooding IR, Springall R, Talbot IC, Silk DB. Idiopathic small-intestinal inflammation after colectomy for ulcerative colitis.
Clin. Gastroenterol. Hepatol. 6: 707-709 (2008).
-
Gorard DA, Hunt JB, Payne-James JJ, Palmer KR, Rees RG, Clark ML, Farthing MJ, Misiewicz JJ, Silk DB. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone.
Gut 34: 1198-1202 (1993).
*
-
Gorgievska Sukarovska B, Lipozencic J. Topical management of psoriasis - corticosteroids and sparing corticosteroid therapy.
Acta Dermatovenerol. Croat. 14: 188-196 (2006).
-
Gorman MP, Golomb MR, Walsh LE, Hobson GM, Garbern JY, Kinkel RP, Darras BT, Urion DK, Eksioglu YZ. Steroid-responsive neurologic relapses in a child with a proteolipid protein-1 mutation.
Neurology 68: 1305-1307 (2007).
-
Gorson KC. Therapy for vasculitic neuropathies.
Curr. Treat. Options Neurol. 8: 105-117 (2006).
-
Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Anaya JM, Sibilia J, Mariette X. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Ann. Rheum. Dis. 64: 913-920 (2005).
*
-
Gotua M, Lomidze N, Dolidze N, Gotua T. IgE-mediated food hypersensitivity disorders.
Georgian Med. News 157: 39-44 (2008).
-
Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome.
BMJ 312: 169-172 (1996).
*
-
Goyal S, Gupta P, Ryan CM, Kazlas M, Noviski N, Sheridan RL. Toxic epidermal necrolysis in children: medical, surgical, and ophthalmologic considerations.
J. Burn Care Res. 30: 437-449 (2009).
-
Graf J, Webb A, Davis J. The use of topical tacrolimus (FK506/protopic) in cutaneous manifestations of autoimmune diseases.
J. Clin. Rheumatol. 9: 310-315 (2003).
-
Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management.
Inflamm. Bowel Dis. 15: 1105-1118 (2009).
-
Gram JT, Gundersen T. Allopurinol hypersensitivity syndrome.
Tidsskr. Nor. Laegeforen. 109: 3102-3104 (1989).
-
Grando SA. New approaches to the treatment of pemphigus.
J. Investig. Dermatol. Symp. Proc. 9: 84-91 (2004).
*
-
Granito A, Muratori P, Ferri S, Pappas G, Quarneti C, Lenzi M, Bianchi FB, Muratori L. Diagnosis and therapy of autoimmune hepatitis.
Mini Rev. Med. Chem. 9: 847-860 (2009).
-
Gras M, van Kemenade FJ, van Maarsseveen AC, Alberts C. Sarcoidosis: immunopathogenesis and the potential of immunotherapy.
Ned. Tijdschr. Geneeskd. 147: 150-155 (2003).
-
Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease.
Am. J. Gastroenterol. 83: 703-709 (1988).
-
Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis.
Lupus 12: 409-412 (2003).
-
Green D. The management of acquired haemophilia.
Haemophilia 12 Suppl. 5: 32-36 (2006).
-
Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
Gastroenterology 110: 45-51 (1996).
*
-
Greenberg SA. Inflammatory myopathies: evaluation and management.
Semin. Neurol. 28: 241-249 (2008).
-
Greenberger PA, Yucha CB, Janson S, Huss K. Using rare diseases as models for biobehavioral research: allergic bronchopulmonary aspergillosis.
Allergy Asthma Proc. 28: 489-496 (2007).
-
Greene MT, Whitington PF. Outcomes in pediatric autoimmune hepatitis.
Curr. Gastroenterol. Rep. 11: 248-251 (2009).
-
Greenough A. Emerging drugs for the prevention of bronchopulmonary dysplasia.
Expert Opin. Emerg. Drugs 13: 537-546 (2008).
-
Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 3: gastrointestinal system.
Br. Dent. J. 194: 659-663 (2003).
-
Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis.
Expert Opin. Pharmacother. 7: 1907-1918 (2006).
-
Griffiths AM. Enteral feeding in inflammatory bowel disease.
Curr. Opin. Clin. Nutr. Metab. Care 9: 314-318 (2006).
-
Griffiths AM. Enteral nutrition in the management of Crohn's disease.
JPEN J. Parenter. Enteral Nutr. 29: S108-S117 (2005).
*
-
Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease.
Gut 34: 939-943 (1993).
*
-
Griga T, Wilkens C, Schmiegel W, Folwaczny C, Hagedorn M, Duerig N, Epplen J, Klein W. Association between the promoter polymorphism T/C at position -159 of the CD14 gene and anti-inflammatory therapy in patients with inflammatory bowel disease.
Eur. J. Med. Res. 10: 183-186 (2005).
-
Griga T, Wilkens C, Wirkus N, Epplen J, Schmiegel W, Klein W. A polymorphism in the macrophage migration inhibitory factor gene is involved in the genetic predisposition of Crohn's disease and associated with cumulative steroid doses.
Hepatogastroenterology 54: 784-786 (2007).
-
Grijm R, Huibregtse K, Bartelsman J, Mathus-Vliegen EM, Dekker W, Tytgat GN. Therapeutic investigations in primary sclerosing cholangitis.
Dig. Dis. Sci. 31: 792-798 (1986).
-
Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa.
J. Gastroenterol. Hepatol. 10: 387-395 (1995).
-
Grogan PM, Katz JS. Inflammatory myopathies.
Curr. Treat. Options Neurol. 6: 155-161 (2004).
-
Grommes C, Griffin C, Downes KA, Lerner AJ. Steroid-responsive encephalopathy associated with autoimmune thyroiditis presenting with diffusion MR imaging changes.
AJNR Am. J. Neuroradiol. 29: 1550-1551 (2008).
-
Gronbek H, Thogersen T, Frystyk J, Vilstrup H, Flyvbjerg A, Dahlerup JF. Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment.
Am. J. Gastroenterol. 97: 673-678 (2002).
*
-
Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
Kidney Int. 70: 732-742 (2006).
*
-
Gros C, Delesalle F, Gautier S, Delaporte E. Leflunomide-induced skin necrosis.
Ann. Dermatol. Venereol. 135: 205-208 (2008).
-
Grossman AB, Mamula P. What is the optimal management approach for pediatric patients with severe ulcerative colitis?
Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 542-543 (2008).
-
Grossman AB, Noble AJ, Mamula P, Baldassano RN. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.
Inflamm. Bowel Dis. 14: 750-755 (2008).
*
-
Grubic Z, Zunec R, Peros-Golubicic T, Tekavec-Trkanjec J, Martinez N, Alilovic M, Smojver-Jezek S, Kerhin-Brkljacic V. HLA class I and class II frequencies in patients with sarcoidosis from Croatia: role of HLA-B8, -DRB1*0301, and -DQB1*0201 haplotype in clinical variations of the disease.
Tissue Antigens 70: 301-306 (2007).
*
-
Gualco G, van den Berg A, Koopmans S, Bacchi LM, Carneiro SS, Ruiz E Jr, Vecchi AP, Chan JK. Autoimmune lymphoproliferative syndrome in a patient with a new minimal deletion in the death domain of the FAS gene.
Hum. Pathol. 39: 137-141 (2008).
-
Guerre-Schmidt AR, Pelletier F, Carbonnel F, Humbert P, Aubin F. Dermatosis-arthritis syndrome associated with Crohn's disease in a teenager.
Rev. Med. Interne. 27: 874-877 (2006).
-
Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis.
Clin. Exp. Rheumatol. 26: S23-S29 (2008).
-
Guilhon de Araujo Sant'anna AM, Dubois J, Miron MC, Seidman EG. Wireless capsule endoscopy for obscure small-bowel disorders: final results of the first pediatric controlled trial.
Clin. Gastroenterol. Hepatol. 3: 264-270 (2005).
*
-
Guillevin L, Pagnoux C. Treatment of systemic vasculitides.
Rev. Prat. 58: 541-544 (2008).
-
Guilpain P, Viallard JF, Lagarde P, Cohen P, Kambouchner M, Pellegrin JL, Guillevin L. Churg-Strauss syndrome in two patients receiving montelukast.
Rheumatology (Oxford) 41: 535-539 (2002).
*
-
Gundling F, Rohrbach H, Schepp W. Cholestatic hepatitis in situs inversus abdominalis.
Schweiz. Rundsch. Med. Prax. 96: 1029-1033 (2007).
-
Guo ZY, He XS, Wu LW, Zhu XF, Ju WQ, Wang DP, You S, Ma Y, Wang GD, Huang JF. Graft-verse-host disease after liver transplantation: a report of two cases and review of literature.
World J. Gastroenterol. 14: 974-979 (2008).
*
-
Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease.
Clin. Gastroenterol. Hepatol. 4: 1483-1490 (2006).
-
Gupta N, Bostrom AG, Kirschner BS, Cohen SA, Abramson O, Ferry GD, Gold BD, Winter HS, Baldassano RN, Smith T, Heyman MB. Presentation and disease course in early- compared to later-onset pediatric Crohn's disease.
Am. J. Gastroenterol. 103: 2092-2098 (2008).
-
Gupta SK, Peters-Golden M, Fitzgerald JF, Croffie JM, Pfefferkorn MD, Molleston JP, Corkins MR, Lim JR. Cysteinyl leukotriene levels in esophageal mucosal biopsies of children with eosinophilic inflammation: are they all the same?
Am. J. Gastroenterol. 101: 1125-1128 (2006).
*
-
Gupte AR, Draganov PV. Eosinophilic esophagitis.
World J. Gastroenterol. 15: 17-24 (2009).
*
-
Gur C, Lalazar G, Doviner V, Fridlender ZG, Molcho V, Abu-Much S, Shalit M, Elinav E. Late-onset sarcoidosis after liver transplantation for primary biliary cirrhosis.
J. Clin. Gastroenterol. 41: 329-332 (2007).
-
Gurudu S, Fiocchi C, Katz JA. Inflammatory bowel disease.
Best Pract. Res. Clin. Gastroenterol. 16: 77-90 (2002).
-
Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzen H, Tysk C, Jarnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era.
Am. J. Gastroenterol. 102: 2513-2519 (2007).
*
-
Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Deviere J, Franchimont D. Profile of soluble cytokine receptors in Crohn's disease.
Gut 54: 488-495 (2005).
*
-
Gutierrez Gutierrez HI, Carrillo Iniguez MJ, Pestana Mendoza S, Santamaria Ferreira M. Ofuji's diseases and pregnancy. A report of a case.
Ginecol. Obstet. Mex. 74: 158-163 (2006).
-
Gutkowski K, Bilkiewicz T. Experimental methods in the treatment of Lesniowski-Crohn disease.
Pol. Merkuriusz. Lek. 20: 457-461 (2006).
-
Guyonnet-Duperat V, Geverink N, Plastow GS, Evans G, Ousova O, Croisetiere C, Foury A, Richard E, Mormede P, Moisan MP. Functional implication of an Arg307Gly substitution in corticosteroid binding globulin, a candidate gene for a QTL associated with cortisol variability and obesity.
Genetics 173: 2143-2149 (2006).
*
-
Gvozdjakova A, Kucharska J, Bartkovjakova M, Gazdikova K, Gazdik FE. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma.
Biofactors 25: 235-240 (2005).
-
Haas SL, Lohse P, Schmitt WH, Hildenbrand R, Karaorman M, Singer MV, Bocker U. Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution.
Gastroenterology 130: 172-178 (2006).
*
-
Habal FM, Greenberg GR. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
Am. J. Gastroenterol. 83: 15-19 (1988).
-
Haber BA, Erlichman J, Thayu M, Flake AW, Rand EB. Successful revision of portoenterostomy in an infant with biliary atresia.
J. Pediatr. Surg. 41: e1-e3 (2006).
-
Hafer A, Kramer S, Duncker S, Kruger M, Manns MP, Bischoff SC. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study.
BMC Gastroenterol. 7: 36 (2007).
*
-
Hagymasi K, Tulassay Z. Pharmacogenetics of inflammatory bowel disease.
Orv. Hetil. 146: 1143-1150 (2005).
-
Haider D, Dhawahir-Scala FE, Strouthidis NG, Davies N. Acute panuveitis with hypopyon in Crohn's disease secondary to medical therapy; a case report.
J. Med. Case Reports. 1: 42 (2007).
*
-
Hakem D, Berrah A, Berkane S, Asselah H, Ait-Younes S, Asselah F, Salah S, Merriche S, Abbadi MC. Autoimmune chronic active hepatitis: anatomoclinic's study of 50 patients.
Rev. Med. Interne. 26: 858-865 (2005).
-
Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis.
Cytokine 33: 231-237 (2006).
-
Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio).
Br. J. Dermatol. 150: 146-149 (2004).
*
-
Hamano H, Kawa S, Uehara T, Ochi Y, Takayama M, Komatsu K, Muraki T, Umino J, Kiyosawa K, Miyagawa S. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis?
Gastrointest. Endosc. 62: 152-157 (2005).
*
-
Hamilton C, Seidner DL. Metabolic bone disease and parenteral nutrition.
Curr. Gastroenterol. Rep. 6: 335-341 (2004).
-
Hamnik SE, Hacein-Bey L, Biller J, Gruener G, Jay W. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations.
Semin. Ophthalmol. 23: 191-200 (2008).
-
Hamon MA, Nicolas G, Deviere F, Letournel F, Dubas F. Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature.
Rev. Neurol. (Paris) 163: 1232-1235 (2007).
-
Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Drugs 64: 1767-1777 (2004).
-
Hanada H, Okita K. Primary biliary cirrhosis: therapy and prognosis.
Nippon Rinsho 52: 256-261 (1994).
-
Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Nagata S, Takai K. Adsorptive depletion of elevated proinflammatory CD14(+)CD16(+)DR(++) monocytes in patients with inflammatory bowel disease.
Am. J. Gastroenterol. 103: 1210-1216 (2008).
*
-
Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study.
Clin. Gastroenterol. Hepatol. 1: 28-35 (2003).
*
-
Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Kikuch K, Saniabadi AR. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis.
Digestion 70: 36-44 (2004).
-
Hanauer SB. Medical therapy for ulcerative colitis 2004.
Gastroenterology 126: 1582-1592 (2004).
*
-
Hanauer SB. Update on medical management of inflammatory bowel disease: ulcerative colitis.
Rev. Gastroenterol. Disord. 1: 169-176 (2001).
*
-
Hanauer SB. Factoring in growth factors for treatment of inflammatory bowel disease.
Curr. Gastroenterol. Rep. 5: 485 (2003).
-
Hanauer SB. Aminosalicylates in inflammatory bowel disease.
Aliment. Pharmacol. Ther. 20 Suppl. 4: 60-65 (2004).
*
-
Hanauer SB. New biologicals for inflammatory bowel disease.
Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 67-71 (2006). *
-
Hanauer SB. A BALANCING VIEW: lifetime channeling of infliximab for Crohn's disease.
Am. J. Gastroenterol. 100: 1438-1439 (2005).
*
-
Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
Aliment. Pharmacol. Ther. 27 Suppl. 1: 15-21 (2008).
-
Hanauer SB. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down".
Rev. Gastroenterol. Disord. 7 Suppl. 2: S17-S22 (2007).
-
Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease.
Inflamm. Bowel Dis. Mar 23 [Epub ahead of print] (2009).
-
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Lancet 359: 1541-1549 (2002).
*
-
Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease.
Rev. Gastroenterol. Disord. 3: 81-92 (2003).
*
-
Handa R. Spondylo-arthropathies.
J. Indian Med. Assoc. 101: 514, 516, 518 (2003).
-
Haque S, Bruce IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease.
Nat. Clin. Pract. Cardiovasc. Med. 2: 423-430 (2005).
-
Harada M, Hashimoto O, Kumemura H, Taniguchi E, Shiratsuchi M, Harada R, Sakamoto M, Yoshida H, Fukuda T, Sakisaka S, Sata M. Bronchiolitis obliterans organizing pneumonia in a patient with primary biliary cirrhosis and rheumatoid arthritis treated with prednisolone.
Hepatol. Res. 23: 301 (2002).
-
Haram K, Gjelland K. Foetal growth restriction.
Tidsskr. Nor. Laegeforen. 127: 2665-2669 (2007).
-
Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis.
Expert Rev. Gastroenterol. Hepatol. 2: 357-370 (2008).
-
Harmon WA, Helman CA. Eosinophilic gastroenteritis and ascites.
J. Clin. Gastroenterol. 3: 371-373 (1981).
-
Harpavat M, Greenspan SL, O'Brien C, Chang CC, Bowen A, Keljo DJ. Altered bone mass in children at diagnosis of Crohn disease: a pilot study.
J. Pediatr. Gastroenterol. Nutr. 40: 295-300 (2005).
*
-
Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease.
J. Clin. Gastroenterol. 38: 218-224 (2004).
-
Harris CL, Raisch DW, Abhyankar U, Marfatia S, Campbell HM, Sather MR. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs.
Ann. Pharmacother. 40: 1924-1931 (2006).
-
Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ, Griese M, Krauss-Etschmann S. Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma.
J. Allergy Clin. Immunol. 119: 1258-1266 (2007).
*
-
Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases.
World J. Gastroenterol. 15: 2570-2578 (2009).
*
-
Hasanbegovic E. Autoimmune hemolitic anemia in sensitive to corticosteroids and high dosage immunoglobulins therapy.
Med. Arh. 62: 56-57 (2008).
-
Hashimoto N, Iwasaki T, Sekiguchi M, Takatsuka H, Okamoto T, Hashimoto T, Sano H. Autologous hematopoietic stem cell transplantation for refractory antiphospholipid syndrome causing myocardial necrosis.
Bone Marrow Transplant. 33: 863-866 (2004).
*
-
Hashkes PJ, Laxer RM. Update on the medical treatment of juvenile idiopathic arthritis.
Curr. Rheumatol. Rep. 8: 450-458 (2006).
-
Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis.
JAMA 294: 1671-1684 (2005).
*
-
Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy.
Clin. Exp. Rheumatol. 21: 645-646 (2003).
-
Hassan AS, Simon D, Simon HU, Braathen LR, Yawalkar N. Efalizumab-associated papular psoriasis.
Arch. Dermatol. 143: 900-906 (2007).
*
-
Hasselmann DO, Bens G, Tilgen W, Reichrath J. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature.
J. Dtsch. Dermatol. Ges. 5: 560-564 (2007).
-
Havrdova E, Horakova D, Kovarova I, Krasulova E. Future possibilities of the multiple sclerosis treatment.
Cas. Lek. Cesk. 144: 663-665 (2005).
-
Havrdova E, Zivadinov R, Krasensky J, Dwyer M, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox J, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Mult. Scler. May 22 [Epub ahead of print] (2009).
-
Haworth CS, Selby PL, Webb AK, Martin L, Elborn JS, Sharples LD, Adams JE. Inflammatory related changes in bone mineral content in adults with cystic fibrosis.
Thorax 59: 613-617 (2004).
*
-
Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, Malkinson C, Shaheen MZ, Willars JE. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial.
Gut 33: 922-928 (1992).
*
-
Hawthorne AB, Record CO, Holdsworth CD, Giaffer MH, Burke DA, Keech ML, Hawkey CJ. Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis.
Gut 34: 125-128 (1993).
*
-
Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, Kahn MF, Meyer O. SAPHO syndrome: a long-term follow-up study of 120 cases.
Semin. Arthritis Rheum. 29: 159-171 (1999).
*
-
Healy E, Newell L, Howarth P, Friedmann PS. Control of salicylate intolerance with fish oils.
Br. J. Dermatol. 159: 1368-1369 (2008).
*
-
Heathcote J. Overlap syndromes - outlier syndromes and changing diagnoses.
Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 39-41. October 15-16 (2003). *
-
Heazell AE, Sinha A, Bhatti NR. A case of gestational diabetes arising following treatment with glucocorticosteroids for pemphigoid gestationis.
J. Matern. Fetal Neonatal Med. 18: 353-355 (2005).
-
Hefti MM, Chessin DB, Harpaz NH, Steinhagen RM, Ullman TA. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis.
Dis. Colon Rectum 52: 193-197 (2009).
-
Hegarty AM, Barrett AW, Scully C. Pyostomatitis vegetans.
Clin. Exp. Dermatol. 29: 1-7 (2004).
*
-
Hegyi J, Frey T, Arenberger P. Unilesional mycosis fungoides treated with photodynamic therapy. A case report.
Acta Dermatovenerol. Alp. Panonica Adriat. 17: 75-78 (2008).
-
Heiligenhaus A, Horneff G, Greiner K, Mackensen F, Zierhut M, Foeldvari I, Michels H. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood.
Klin. Monatsbl. Augenheilkd. 224: 526-531 (2007).
-
Heilman RL, Chakkera HA, Reddy KS, Colby TV, Moss AA, Williams JW, Mazur MJ, Petrides S, Mulligan DC. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression.
Clin. Transplant. 22: 309-315 (2008).
*
-
Heim MH. Autoimmune hepatitis.
Ther. Umsch. 61: 499-504 (2004).
-
Heine RG. Pathophysiology, diagnosis and treatment of food protein-induced gastrointestinal diseases.
Curr. Opin. Allergy Clin. Immunol. 4: 221-229 (2004).
-
Hellinger WC, Bonatti H, Yao JD, Alvarez S, Brumble LM, Keating MR, Mendez JC, Kramer DJ, Dickson RC, Harnois DM, Spivey JR, Hughes CB, Nguyen JH, Steers JL. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation.
Liver Transpl. 11: 656-662 (2005).
*
-
Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review.
J. Rheumatol. 33: 1439-1441 (2006).
-
Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions.
J. Rheumatol. 35: 472-476 (2008).
-
Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
Am. J. Gastroenterol. 101: 119-123 (2006).
*
-
Hendrickx AG, Makori N, Peterson P. Nonhuman primates: their role in assessing developmental effects of immunomodulatory agents.
Hum. Exp. Toxicol. 19: 219-225 (2000).
-
Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis.
Hepatology 35: 7-13 (2002).
*
-
Hengge UR, Krause W, Hofmann H, Stadler R, Gross G, Meurer M, Brinkmeier T, Frosch P, Moll I, Fritsch P, Muller K, Meykadeh N, Marini A, Ruzicka T, Gollnick H. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus.
Br. J. Dermatol. 155: 1021-1028 (2006).
*
-
Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B, Group TI. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study).
Scand. J. Gastroenterol. 42: 602-610 (2007).
*
-
Hentgen V, Granel B, Dode C, Cuisset L, Delpech M, Grateau G. Tumor necrosis factor receptor superfamily 1A-associated periodic syndrome (TRAPS).
Rev. Med. Interne. 24: 781-785 (2003).
-
Hentgen V, Reinert P. TNF receptor-associated periodic syndrome (TRAPS): clinical aspects and physiopathology of a rare familial disease.
Arch. Pediatr. 10: 45-53 (2003).
-
Herfarth H. Therapy of IBD: bottom-up or top-down?
Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 56-57 (2006). *
-
Herrlinger KR, Jewell DP. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.
Aliment. Pharmacol. Ther. 24: 1403-1412 (2006).
*
-
Herrmann DN, Blaivas M, Wald JJ, Feldman EL. Granulomatous myositis, primary biliary cirrhosis, pancytopenia, and thymoma.
Muscle Nerve 23: 1133-1136 (2000).
*
-
Hervier B, Bordure P, Masseau A, Calais C, Agard C, Hamidou M. Auto-immune sensorineural deafness: physiopathology and therapeutic approach.
Rev. Med. Interne. Feb 20 [Epub ahead of print] (2009).
-
Hester KL, Powell T, Downey DG, Elborn JS, Jarad NA. Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: a UK survey.
J. Cyst. Fibros. 6: 311-313 (2007).
-
Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease.
Inflamm. Bowel Dis. 14: 839-849 (2008).
*
-
Hibi T, Inoue N, Ogata H, Naganuma M. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
J. Gastroenterol. 38 Suppl. 15: 36-42 (2003).
-
Higa F, Fujita J, Koide M, Haranaga S, Tateyama M. Clinical features of two cases of Legionnaires' disease with persistence of Legionella urinary antigen excretion.
Intern. Med. 47: 173-178 (2008).
*
-
Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment.
Proc. Am. Thorac. Soc. 2: 12-19 (2005).
*
-
Hirakata M. Autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions.
Nihon Rinsho Meneki Gakkai Kaishi 30: 444-454 (2007).
-
Hirano K, Komatsu Y, Yamamoto N, Nakai Y, Sasahira N, Toda N, Isayama H, Tada M, Kawabe T, Omata M. Pancreatic mass lesions associated with raised concentration of IgG4.
Am. J. Gastroenterol. 99: 2038-2040 (2004).
*
-
Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, Sasahira N, Tsujino T, Yoshida H, Kawabe T, Omata M. Long-term prognosis of autoimmune pancreatitis without and with corticosteroid treatment.
Gut 56: 1719-1724 (2007).
*
-
Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal.
Semin. Liver Dis. 26: 201-210 (2006).
-
Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort.
Aliment. Pharmacol. Ther. 24: 319-330 (2006).
*
-
Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG, Arnott ID, Satsangi J. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.
Am. J. Gastroenterol. 104: 673-678 (2009).
-
Ho GT, Mowat A, Potts L, Cahill A, Mowat C, Lees CW, Hare NC, Wilson JA, Boulton-Jones R, Priest M, Watts DA, Shand AG, Arnott ID, Russell RK, Wilson DC, Morris AJ, Satsangi J. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008).
Aliment. Pharmacol. Ther. 29: 527-534 (2009).
*
-
Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, Satsangi J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery.
Aliment. Pharmacol. Ther. 19: 1079-1087 (2004).
*
-
Ho GT, Seddon AJ, Therapondos G, Satsangi J, Hayes PC. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation.
Eur. J. Gastroenterol. Hepatol. 17: 1379-1385 (2005).
-
Ho GT, Smith L, Aitken S, Lee HM, Ting T, Fennell J, Lees CW, Palmer KR, Penman ID, Shand AG, Arnott ID, Satsangi J. The use of adalimumab in the management of refractory Crohn's disease.
Aliment. Pharmacol. Ther. 27: 308-315 (2008).
*
-
Hodgson HJ. New therapeutic approaches in inflammatory bowel disease.
Neth. J. Med. 50: S15-S18 (1997).
-
Hoefnagels MA, van Leusen R, de Vries RA. Three patients with weight loss as a result of sarcoidosis presenting as liver disease.
Ned. Tijdschr. Geneeskd. 147: 2453-2457 (2003).
-
Hoffmann JC, Zeitz M. Treatment of Crohn's disease.
Hepatogastroenterology 47: 90-100 (2000).
-
Hogenmiller MS, Lozada CJ. An update on osteoarthritis therapeutics.
Curr. Opin. Rheumatol. 18: 256-260 (2006).
-
Hojaili B, Keiser HD. Relapsing polychondritis presenting with complete heart block.
J. Clin. Rheumatol. 14: 24-26 (2008).
-
Hollanders D. Sensorineural deafness - a new complication of ulcerative colitis?
Postgrad. Med. J. 62: 753-755 (1986).
*
-
Holt PJ, Davies MG, Saunders KC, Nuki G. Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis.
Medicine (Baltimore) 59: 114-133 (1980).
-
Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease.
J. Clin. Gastroenterol. 20: 123-126 (1995).
-
Holtmann MH, Galle PR, Neurath MF. Immunotherapeutic approaches to inflammatory bowel diseases.
Expert Opin. Biol. Ther. 1: 455-466 (2001).
-
Homan M, Baldassano RN, Mamula P. Managing complicated Crohn's disease in children and adolescents.
Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 572-579 (2005).
*
-
Homar V, Grosek S, Battelino T. High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.
Neonatology 94: 306-309 (2008).
-
Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy VG, Grippon P, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis.
Hepatology 7: 1333-1339 (1987).
-
Homeff G, Burgos-Vargas R. TNF-alpha antagonists for the treatment of juvenile-onset spondyloarthritides.
Clin. Exp. Rheumatol. 20: S137-S142 (2002).
-
Hon KL, Leung AK, Ng PC. Unusual loss of body hair in childhood: trichotillomania or alopecia.
Adv. Ther. 25: 380-387 (2008).
-
Hong S, Lee J, Chi H, Lee C, Nah S, Kim Y, Oh J, Moon H, Yoo B. Systemic lupus erythematosus complicated by acquired von Willebrand's syndrome.
Lupus 17: 846-848 (2008).
-
Hong SP, Park SW, Chung JP, Chung JB, Kang JK, Kim J, Kim MJ, Park YN, Song SY. Autoimmune pancreatitis with effective steroid therapy.
Yonsei Med. J. 44: 534-538 (2003).
*
-
Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, Park KS, Park KJ, Sung JJ, Sohn EH, Lee YB, Jeong D, Joo IS, Choi BO, Choi YC; for the Korean Research Group for Neuromuscular Diseases. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients.
J. Neurol. Sci. 273: 10-14 (2008).
-
Honma T, Sugimura K, Asakura H, Matsuzawa J, Suzuki K, Kobayashi M, Aoyagi Y. Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis.
J. Clin. Gastroenterol. 39: 886-890 (2005).
-
Hordinsky M, Ericson M. Autoimmunity: alopecia areata.
J. Investig. Dermatol. Symp. Proc. 9: 73-78 (2004).
*
-
Horiuchi A, Kawa S, Hamano H, Hayama M, Ota H, Kiyosawa K. ERCP features in 27 patients with autoimmune pancreatitis.
Gastrointest. Endosc. 55: 494-499 (2002).
*
-
Horiuchi A, Kawa S, Hamano H, Ochi Y, Kiyosawa K. Sclerosing pancreato-cholangitis responsive to corticosteroid therapy: report of 2 case reports and review.
Gastrointest. Endosc. 53: 518-522 (2001).
*
-
Horiuchi H, Hashikura Y, Hisa K, Saito N, Ikegami T, Nakazawa Y, Karakida O, Kobayashi S, Nawata M, Kawasaki S, Takaoka K. Osteonecrosis of the femoral head in Japanese adults after liver transplantation: a preliminary report.
J. Orthop. Sci. 9: 119-121 (2004).
*
-
Horslen SP, McCowan TC, Goertzen TC, Warkentin PI, Cai HB, Strom SC, Fox IJ. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder.
Pediatrics 111: 1262-1267 (2003).
*
-
Hoshina D, Sawamura D, Nomura T, Tanimura S, Abe M, Onozuka T, Kodama K, Akiyama M, Shimizu H. Epidermolysis bullosa acquisita associated with psoriasis vulgaris.
Clin. Exp. Dermatol. 32: 516-518 (2007).
*
-
Hoskison TK, Wortmann RL. Advances in the management of gout and hyperuricaemia.
Scand. J. Rheumatol. 35: 251-260 (2006).
*
-
Howarth LJ, Wiskin AE, Griffiths DM, Afzal NA, Beattie RM. Outcome of childhood ulcerative colitis at 2 years.
Acta Paediatr. 96: 1790-1793 (2007).
*
-
Howarth PH, Babu KS, Arshad HS, Lau LC, Buckley MG, McConnell W, Beckett P, Ali MA, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma.
Thorax 60: 1012-1018 (2005).
*
-
Hu S, Cohen D, Murphy G, Mody E, Qureshi AA. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept.
Cutis 81: 336-338 (2008).
-
Huang PY, Chu CY, Hsiao CH. Multiple eruptive dermatofibromas in a patient with dermatomyositis taking prednisolone and methotrexate.
J. Am. Acad. Dermatol. 57: S81-S84 (2007).
-
Huang X, Hua J, Shen N, Chen S. Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients.
Mod. Rheumatol. 17: 220-223 (2007).
-
Huang XL, Chen J, Ma M, Wang PX, Li ZY. Diagnosis and treatment of Crohn's disease in children: 10 years' clinical experience.
Zhonghua Er Ke Za Zhi 45: 248-251 (2007).
-
Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom.
Arch. Intern. Med. 167: 935-943 (2007).
*
-
Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, Rick ME, Kimball J, Greene A, Hansmann K, Gratwohl A, Young N, Barrett AJ, Dunbar CE. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia.
Blood 101: 71-77 (2003).
*
-
Hulten K, Almashhrawi A, El-Zaatari FA, Graham DY. Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria.
Dig. Dis. Sci. 45: 445-456 (2000).
*
-
Hung JJ, Ou LS, Lee WI, Huang JL. Central nervous system infections in patients with systemic lupus erythematosus.
J. Rheumatol. 32: 40-43 (2005).
-
Hunninghake GM, Soto-Quiros ME, Avila L, Su J, Murphy A, Demeo DL, Ly NP, Liang C, Sylvia JS, Klanderman BJ, Lange C, Raby BA, Silverman EK, Celedon JC. Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood.
J. Allergy Clin. Immunol. 120: 84-90 (2007).
*
-
Hurd LB, Lichtenstein GR. Therapeutic potential of infliximab in inflammatory bowel disease.
Gastroenterol. Nurs. 22: 199-208 (1999).
-
Hussain I, Kline JN. DNA, the immune system, and atopic disease.
J. Investig. Dermatol. Symp. Proc. 9: 23-28 (2004).
*
-
Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease.
Aliment. Pharmacol. Ther. 28: 598-605 (2008).
*
-
Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003.
Gastroenterology 133: 1779-1786 (2007).
*
-
Huugen D, Cohen Tervaert JW, Heeringa P. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations.
Clin. J. Am. Soc. Nephrol. 1: 1100-1107 (2006).
*
-
Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, Otley A, Evans J, Pfefferkorn M, Rosh J, Rothbaum R, Kugathasan S, Mezoff A, Wyllie R, Tolia V, Delrosario JF, Moyer MS, Oliva-Hemker M, Leleiko N. The natural history of corticosteroid therapy for ulcerative colitis in children.
Clin. Gastroenterol. Hepatol. 4: 1118-1123 (2006).
-
Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Mamula P, Kay M, Crandall W, Oliva-Hemker M, Keljo D, Leleiko N, Markowitz J. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease.
Inflamm. Bowel Dis. 15: 816-822 (2009).
*
-
Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
J. Pediatr. 137: 192-196 (2000).
*
-
Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children?
J. Pediatr. Gastroenterol. Nutr. 40: 262-272 (2005).
*
-
Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumor necrosis factor-alpha is not elevated in children with inflammatory bowel disease.
J. Pediatr. Gastroenterol. Nutr. 12: 233-236 (1991).
-
Hytonen J, Hartiala P, Oksi J, Viljanen MK. Borreliosis: recent research, diagnosis, and management.
Scand. J. Rheumatol. 37: 161-172 (2008).
-
Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.
Liver Transpl. 13: 996-1003 (2007).
*
-
Iino S, Hino K, Yasuda K. Synthetic glucocorticoid therapy in liver diseases.
Nippon Rinsho 52: 719-727 (1994).
-
Ikeda Y, Yagi S, Yamaguchi H, Fujimura M, Hashizume S, Aihara K, Akaike M, Azuma H, Matsumoto T. Intra-vascular ultrasound findings of diffuse coronary atherosclerotic change in systemic lupus erythematosus with secondary antiphospholipid syndrome.
Circ. J. 70: 1082-1085 (2006).
*
-
Ikegawa S, Urano F, Suzuki S, Fujisawa N, Nishii Y. Three cases of pustulotic arthro-osteitis associated with episcleritis.
J. Am. Acad. Dermatol. 41: 845-846 (1999).
-
Imazio M, Trinchero R. Treatment of acute and recurrent pericarditis. What the clinical cardiologist should know.
G. Ital. Cardiol. (Rome) 9: 826-834 (2008).
-
Imazio M, Trinchero R, Shabetai R. Pathogenesis, management, and prevention of recurrent pericarditis.
J. Cardiovasc. Med. (Hagerstown) 8: 404-410 (2007).
-
Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients.
World J. Surg. 33: 1049-1052 (2009).
*
-
Ingen-Housz S, Venutolo E, Pinquier L, Cavelier-Balloy B, Dubertret L, Flageul B. Erythema annulare centrifugum and relapsing polychondritis.
Ann. Dermatol. Venereol. 127: 735-739 (2000).
-
Ingram JR, Rhodes J, Evans BK, Newcombe RG, Thomas GA. Comparative study of enema retention and preference in ulcerative colitis.
Postgrad. Med. J. 81: 594-598 (2005).
*
-
Inui N, Matsui T, Suda T, Chida K. Anti-endothelial cell antibodies in patients with sarcoidosis.
Chest 133: 955-960 (2008).
*
-
Ioannides D, Lazaridou E, Rigopoulos D. Pemphigus.
J. Eur. Acad. Dermatol. Venereol. 22: 1478-1496 (2008).
-
Ip WK, Wong CK, Leung TF, Lam CW. Plasma concentrations of soluble CTLA-4, CD28, CD80 and CD86 costimulatory molecules reflect disease severity of acute asthma in children.
Pediatr. Pulmonol. 41: 674-682 (2006).
-
Iranzo P, Alsina M, Martinez-De Pablo I, Segura S, Mascaro J, Herrero C. Gold: an old drug still working in refractory pemphigus.
J. Eur. Acad. Dermatol. Venereol. 21: 902-907 (2007).
*
-
Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk.
Gastroenterology 119: 1740-1744 (2000).
*
-
Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn's disease.
Aliment. Pharmacol. Ther. 26: 313-329 (2007).
*
-
Irving PM, Macey MG, Shah U, Webb L, Langmead L, Rampton DS. Formation of platelet-leukocyte aggregates in inflammatory bowel disease.
Inflamm. Bowel Dis. 10: 361-372 (2004).
-
Isaia G, Di Stefano M, Roggia C, Ardissone P, Rosina F. Bone disorders in cholestatic liver diseases.
Forum (Genova) 8: 28-38 (1998).
-
Isenberg D, Rahman A. Systemic lupus erythematosus - 2005 annus mirabilis?
Nat. Clin. Pract. Rheumatol. 2: 145-152 (2006).
*
-
Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease.
Semin. Liver Dis. 27: 214-226 (2007).
-
Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis.
J. Gastroenterol. 34: 66-74 (1999).
-
Islam S, Riordan JW, McDonald JA. Case report: a rare association of primary biliary cirrhosis and systemic lupus erythematosus and review of the literature.
J. Gastroenterol. Hepatol. 14: 431-435 (1999).
*
-
Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation.
J. Oral Sci. 49: 89-106 (2007).
*
-
Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease.
Inflamm. Bowel Dis. 14: 1432-1442 (2008).
*
-
Issenman RM. Bone mineral metabolism in pediatric inflammatory bowel disease.
Inflamm. Bowel Dis. 5: 192-199 (1999).
-
Itaba S, Iwasa T, Sadamoto Y, Nasu T, Misawa T, Inoue K, Shimokawa H, Nakamura K, Takayanagi R. Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease.
Dig. Dis. Sci. 52: 1438-1441 (2007).
*
-
Ito H, Kaizaki Y, Noda Y, Fujii S, Yamamoto S. IgG4-related inflammatory abdominal aortic aneurysm associated with autoimmune pancreatitis.
Pathol. Int. 58: 421-426 (2008).
*
-
Ito S, Oyake T, Uchiyama T, Sugawara T, Murai K, Ishida Y. Successful treatment with cyclosporine and high-dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia.
Int. J. Hematol. 80: 250-253 (2004).
-
Ito T, Aoshima M, Ito N, Uchiyama I, Sakamoto K, Kawamura T, Yagi H, Hashizume H, Takigawa M. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata.
Arch. Dermatol. Res. 301: 373-380 (2009).
*
-
Iwata T, Yamamoto T, Umegae S, Matsumoto K. Pouchitis and pre-pouch ileitis developed after restorative proctocolectomy for ulcerative colitis: a case report.
World J. Gastroenterol. 13: 643-646 (2007).
*
-
Izzedine H, Brocheriou I, Valantin MA, Camous L, Bourry E, Baumelou A, Deray G, Katlama C. A case of acute renal failure associated with diffuse infiltrative lymphocytosis syndrome.
Nat. Clin. Pract. Nephrol. 4: 110-114 (2008).
*
-
Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis.
Gut 36: 459-461 (1995).
*
-
Jacob DA, Neumann UP, Bahra M, Klupp J, Puhl G, Neuhaus R, Langrehr JM. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients.
Clin. Transplant. 20: 211-220 (2006).
-
Jacobstein DA, Markowitz JE, Kirschner BS, Ferry G, Cohen SA, Gold BD, Winter HS, Heyman MB, Baldassano RN. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
Inflamm. Bowel Dis. 11: 442-446 (2005).
*
-
Jaffer AN, Brodell RT. Exfoliative dermatitis. Erythroderma can be a sign of a significant underlying disorder.
Postgrad. Med. 117: 49-51 (2005).
-
Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.
Gut 40: 313-319 (1997).
*
-
Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study.
Scand. J. Gastroenterol. 39: 145-153 (2004).
*
-
Jain S, Markham R, Thomas HC, Sherlock S. Double-stranded DNA-binding capacity of serum in acute and chronic liver disease.
Clin. Exp. Immunol. 26: 35-41 (1976).
*
-
Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis.
Int. J. Technol. Assess. Health Care 20: 274-279 (2004).
-
Jakab SS, West AB, Meighan DM, Brown RS Jr, Hale WB. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome.
World J. Gastroenterol. 13: 6087-6089 (2007).
*
-
Jakobovits SL, Travis SP. Management of acute severe colitis.
Br. Med. Bull. 75-76: 131-144 (2006).
*
-
James SL, Irving PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: frequently asked questions analysis.
Intern. Med. J. 38: 114-119 (2008).
*
-
James SP, Hoofnagle JH, Strober W, Jones EA. NIH conference: Primary biliary cirrhosis: a model autoimmune disease.
Ann. Intern. Med. 99: 500-512 (1983).
-
Janczewska I, Mejhert M, Hast R, Runarsson G, Sandstedt B. Primary AL-amyloidosis, ulcerative colitis and collagenous colitis in a 57-year-old woman: a case study.
Scand. J. Gastroenterol. 39: 1306-1309 (2004).
*
-
Jani N, Regueiro MD. Medical therapy for ulcerative colitis.
Gastroenterol. Clin. North Am. 31: 147-166 (2002).
-
Janisson-Dargaud D, Reguiai Z, Perceau G, Eschard C, Bernard P. Juvenile pemphigus vulgaris.
Ann. Dermatol. Venereol. 135: 843-847 (2008).
-
Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.
Gastroenterology 128: 1805-1811 (2005).
*
-
Jaspers GJ, Verkade HJ, Escher JC, de Ridder L, Taminiau JA, Rings EH. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease.
Inflamm. Bowel Dis. 12: 831-836 (2006).
*
-
Jatwa R, Parmar HS, Panda S, Kar A. Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice.
Basic Clin. Pharmacol. Toxicol. 101: 177-180 (2007).
-
Jayne D. Stem cell transplantation in systemic lupus erythematosus.
Best Pract. Res. Clin. Haematol. 17: 291-304 (2004).
-
Jesse NM, McCartney JC, Feng X, Richards EM, Wood CE, Keller-Wood M. Expression of ENaC subunits, chloride channels and aquaporins in ovine fetal lung: ontogeny of expression and effects of altered fetal cortisol concentrations.
Am. J. Physiol. Regul. Integr. Comp. Physiol. Jun 10 [Epub ahead of print] (2009).
-
Jessop S, Khumalo NP. Pemphigus: a treatment update.
Am. J. Clin. Dermatol. 9: 147-154 (2008).
-
Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China.
World J. Gastroenterol. 8: 158-161 (2002).
*
-
Jimenez-Saenz M, Villar-Rodriguez JL, Torres Y, Carmona I, Salas-Herrero E, Gonzalez-Vilches J, Herrerias-Gutierrez JM. Biliary tract disease: a rare manifestation of eosinophilic gastroenteritis.
Dig. Dis. Sci. 48: 624-627 (2003).
*
-
Jinno Y, Ohtani H, Nakamura S, Oki M, Maeda K, Fukushima K, Nagura H, Oshitani N, Matsumoto T, Arakawa T. Infiltration of CD19(+) plasma cells with frequent labeling of Ki-67 in corticosteroid-resistant active ulcerative colitis.
Virchows Arch. 448: 412-421 (2006).
*
-
Jirapongsananuruk O, Melamed I, Leung DY. Additive immunosuppressive effects of 1,25-dihydroxyvitamin D3 and corticosteroids on TH1, but not TH2, responses.
J. Allergy Clin. Immunol. 106: 981-985 (2000).
-
Johansson M, Jonsson M, Norrgard O, Forsgren S. New aspects concerning ulcerative colitis and colonic carcinoma: analysis of levels of neuropeptides, neurotrophins, and TNFalpha/TNFreceptor in plasma and mucosa in parallel with histological evaluation of the intestine.
Inflamm. Bowel Dis. 14: 1331-1340 (2008).
-
Johansson M, Norrgard O, Forsgren S. Study of expression patterns and levels of neurotrophins and neurotrophin receptors in ulcerative colitis.
Inflamm. Bowel Dis. 13: 398-409 (2007).
*
-
Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
Dig. Dis. Sci. Dec 23 [Epub ahead of print] (2008).
*
-
Jojic N. Pharmacotherapy of inflammatory bowel disease.
Acta Chir. Iugosl. 47: 51-55 (2000).
-
Jones JH, Lennard-Jones JE. Corticosteroids and corticotrophin in the treatment of Crohn's disease.
Gut 7: 181-187 (1966).
*
-
Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, van den Berg WB. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Arthritis Res. 1: 81-91 (1999).
*
-
Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
Hepatology 35: 409-413 (2002).
*
-
Josse G, Rouvrais C, Mas A, Haftek M, Delalleau A, Ferraq Y, Ossant F, George J, Lagarde JM, Schmitt AM. A multitechnique evaluation of topical corticosteroid treatment.
Skin Res. Technol. 15: 35-39 (2009).
-
Josselin L, Mahr A, Cohen P, Pagnoux C, Guaydier-Souquieres G, Hayem G, Job-Deslandre C, Liferman F, Pourrat J, Guillevin L. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.
Ann. Rheum. Dis. 67: 1343-1346 (2008).
-
Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.
Sarcoidosis Vasc. Diffuse Lung Dis. 23: 51-57 (2006).
-
Juel VC, Massey JM. Myasthenia gravis.
Orphanet J. Rare Dis. 2: 44 (2007).
*
-
Juillerat P, Mottet C, Froehlich F, Felley C, Vader JP, Burnand B, Gonvers JJ, Michetti P. Extraintestinal manifestations of Crohn's disease.
Digestion 71: 31-36 (2005).
-
Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P. Extraintestinal manifestations of Crohn's disease.
Digestion 76: 141-148 (2007).
*
-
Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy.
Digestion 76: 161-168 (2007).
*
-
Kaaroud H, Beji S, Jebali A, Ben Hamida F, Ben Moussa F, Ben Abdallah T, Abderrahim E, Bardi R, Ayed K, Kheder A. Pustular psoriasis after renal transplantation.
Transplant. Proc. 39: 1130-1131 (2007).
*
-
Kadunce DP, Krueger GG. Pathogenesis of psoriasis.
Dermatol. Clin. 13: 723-737 (1995).
-
Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
Melanoma Res. Jun 8 [Epub ahead of print] (2009).
-
Kahn KL, Maclean CH, Liu H, Rubenstein LZ, Wong AL, Harker JO, Chen WP, Fitzpatrick DM, Bulpitt KJ, Traina SB, Mittman BS, Hahn BH, Paulus HE. Application of explicit process of care measurement to rheumatoid arthritis: moving from evidence to practice.
Arthritis Rheum. 55: 884-891 (2006).
*
-
Kakinoki Y, Nagase M, Okada K, Chiba K, Fukuhara T, Miyake T. Evans syndrome associated with idiopathic mixed-type autoimmune hemolytic anemia.
Rinsho Ketsueki 49: 516-520 (2008).
-
Kallinowski B, Noldge G, Stiehl A. Crohn's disease with Behcet's syndrome like appearance: a case report.
Z. Gastroenterol. 32: 642-644 (1994).
-
Kamal MA, Jusko WJ. Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.
J. Clin. Pharmacol. 44: 1034-1045 (2004).
*
-
Kamata N, Oshitani N, Sogawa M, Yamagami H, Watanabe K, Fujiwara Y, Arakawa T. Usefulness of magnetic resonance imaging for detection of asymptomatic osteonecrosis of the femoral head in patients with inflammatory bowel disease on long-term corticosteroid treatment.
Scand. J. Gastroenterol. 43: 308-313 (2008).
*
-
Kamikozuru K, Fukunaga K, Hirota S, Hida N, Ohda Y, Yoshida K, Yokoyama Y, Tozawa K, Kawa K, Iimuro M, Nagase K, Saniabadi AR, Nakamura S, Miwa H, Matsumoto T. The expression profile of functional regulatory T cells, CD4(+)CD25(high+)/forkhead box protein P3(+), in patients with ulcerative colitis during active and quiescent disease.
Clin. Exp. Immunol. 156: 320-327 (2009).
*
-
Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Morphological changes after steroid therapy in autoimmune pancreatitis.
Scand. J. Gastroenterol. 39: 1154-1158 (2004).
*
-
Kamisawa T, Okamoto A, Wakabayashi T, Watanabe H, Sawabu N. Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome.
Scand. J. Gastroenterol. 43: 609-613 (2008).
*
-
Kamisawa T, Satake K. Therapeutic strategy for autoimmune pancreatitis.
Adv. Med. Sci. 53: 145-148 (2008).
-
Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease.
Aliment. Pharmacol. Ther. 16: 1509-1517 (2002).
*
-
Kang MJ, Namgung KY, Kim MS, Ko BS, Han CS, Ahn HT, Shin HM. A case of Kaposi's sarcoma associated with ulcerative colitis.
Korean J. Gastroenterol. 43: 316-319 (2004).
-
Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis.
Dig. Liver Dis. 36: 811-817 (2004).
-
Kanmura S, Uto H, Numata M, Hashimoto S, Moriuchi A, Fujita H, Oketani M, Ido A, Kodama M, Ohi H, Tsubouchi H. Human neutrophil peptides 1-3 are useful biomarkers in patients with active ulcerative colitis.
Inflamm. Bowel Dis. 15: 909-917 (2009).
*
-
Kanski JJ. Care of children with anterior uveitis.
Trans. Ophthalmol. Soc. U.K. 101: 387-390 (1981).
-
Kansu A, Kalayci AG, Altuntas B, Doganci T, Girgin N. Autoimmune hepatitis in children: a report of ten cases.
Turk. J. Med. Sci. 30: 55-61 (2000). *
-
Kaposi Novak P, Schmidt Z. Polymyalgia rheumatica.
Orv. Hetil. 147: 1791-1802 (2006).
-
Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis.
Cochrane Database Syst. Rev. 1: CD000996 (2009).
-
Karagiannidis A, Karavalaki M, Koulaouzidis A. Hepatic sarcoidosis.
Ann. Hepatol. 5: 251-256 (2006).
*
-
Karnsakul W, Sawathiparnich P, Nimkarn S, Likitmaskul S, Santiprabhob J, Aanpreung P. Anterior pituitary hormone effects on hepatic functions in infants with congenital hypopituitarism.
Ann. Hepatol. 6: 97-103 (2007).
*
-
Karoui S, Djebbi S, Belkhodja A, Boubaker J, Filali A. Maintenance therapy by azathioprine after successful treatment by intravenous corticosteroid in acute severe colitis. An open prospective study.
Tunis. Med. 86: 322-327 (2008).
-
Karoui S, Serghini M, Chaieb M, Jomni T, Kallel L, Fekih M, Matri S, Boubaker J, Filali A. Frequency and predictive factors of colectomy and coloproctectomy in ulcerative colitis.
Tunis. Med. 87: 115-119 (2009).
-
Kasai S, Tokuda H, Yoshikawa M, Nishine H, Nishiyama H. A case of salazosulfapyridine-induced pneumonitis presenting with multiple pulmonary nodules and lymphadenopathy.
Nihon Kokyuki Gakkai Zasshi 44: 928-932 (2006).
-
Kasperkiewicz M, Zillikens D. Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases.
Hautarzt. 58: 115-121 (2007).
-
Kasperlik-Zaluska AA, Czarnocka B, Czech W, Walecki J, Makowska AM, Brzezinski J, Aniszewski J. Secondary adrenal insufficiency associated with autoimmune disorders: a report of twenty-five cases.
Clin. Endocrinol. (Oxf.) 49: 779-783 (1998).
*
-
Katayama Y, Kohriyama K, Kirizuka K, Nishizaki H, Fujii H, Tanji Y. Sjogren's syndrome complicated with autoimmune hepatitis and antiphospholipid antibody syndrome.
Intern. Med. 39: 73-76 (2000).
*
-
Kato A, Chustz RT, Ogasawara T, Kulka M, Saito H, Schleimer RP, Matsumoto K. Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells.
J. Immunol. 182: 7233-7243 (2009).
-
Kato Y, Epstein O, Dick R, Sherlock S. Radiological patterns of cortical bone modelling in women with chronic liver disease.
Clin. Radiol. 33: 313-317 (1982).
-
Katsenos S, Psathakis K, Kokkonouzis I, Panagou P, Tsintiris K, Bouros D. Drug-induced pulmonary toxicity in a patient treated with mesalazine and azathioprine for ulcerative colitis.
Acta Gastroenterol. Belg. 70: 290-292 (2007).
-
Katz JA. Management of inflammatory bowel disease in adults.
J. Dig. Dis. 8: 65-71 (2007).
-
Katz JA. Treatment of inflammatory bowel disease with corticosteroids.
Gastroenterol. Clin. North Am. 33: 171-189 (2004).
-
Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
Am. J. Gastroenterol. 99: 2385-2392 (2004).
*
-
Kaufmann J, Hunzelmann N, Genth E, Krieg T. The clinical spectrum of dermatomyositis.
J. Dtsch. Dermatol. Ges. 3: 181-194 (2005).
-
Kawa S, Hamano H. Clinical features of autoimmune pancreatitis.
J. Gastroenterol. 42 Suppl. 18: 9-14 (2007).
*
-
Kawa S, Hamano H, Umemura T, Kiyosawa K, Uehara T. Sclerosing cholangitis associated with autoimmune pancreatitis.
Hepatol. Res. 37 Suppl. 3: S487-S495 (2007).
*
-
Kawaguchi N, Kuwabara S, Nemoto Y, Fukutake T, Satomura Y, Arimura K, Osame M, Hattori T; The Study Group for Myasthenia Gravis in Japan. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000.
J. Neurol. Sci. 224: 43-47 (2004).
-
Kayacetin E, Koklu S, Temucin T. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis with unusual initial presentation as fulminant hepatic failure.
Dig. Liver Dis. 36: 419-422 (2004).
-
Kazumori H, Hashimoto T, Akagi S, Adachi K, Watanabe M, Kinoshita Y. Sclerosing cholangitis and systemic lymphadenopathy.
J. Gastroenterol. 36: 429-432 (2001).
*
-
Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases.
Clin. Evid. (Online) pii: 2406 (2009).
-
Keely S, Ryan SM, Haddleton DM, Limer A, Mantovani G, Murphy EP, Colgan SP, Brayden DJ. Dexamethasone-pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers.
J. Control Release 135: 35-43 (2009).
*
-
Kefalides PT, Hanauer SB. Ulcerative colitis: diagnosis and management. Case study and commentary.
Hospital Physician June: 53-63 (2002). *
-
Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, Reding R. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial.
Lancet 364: 1054-1061 (2004).
*
-
Kennedy HJ, Compston J, Heynen G, Kanis JA, Merrett AL, Truelove SC, Warner GT. Calcium metabolism in subjects living with a permanent ileostomy.
Digestion 26: 131-136 (1983).
-
Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis.
Dig. Dis. Sci. 31: 705-711 (1986).
-
Kesisoglou F, Zimmermann EM. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
Expert Opin. Drug Deliv. 2: 451-463 (2005).
-
Khalifa M, Slim I, Ghannouchi N, Kaabia N, Sriha B, Letaief A, Bahri F. Eosinophilic fasciitis and toxic thyroid adenoma - a novel association.
Acta Clin. Belg. 63: 197-199 (2008).
-
Khalil F, Mir MA, Venuto RC. Mycophenolate mofetil in the treatment of retroperitoneal fibrosis.
Clin. Rheumatol. 27: 679-681 (2008).
*
-
Khamashta MA. Systemic lupus erythematosus and pregnancy.
Best Pract. Res. Clin. Rheumatol. 20: 685-694 (2006).
-
Khan AM, Elahi F, Hashmi SR, Mahida KH, Ingrams DR. Wegener's granulomatosis: a rare, chronic and multisystem disease.
Surgeon 4: 45-52 (2006).
-
Khan DA. Chronic urticaria: diagnosis and management.
Allergy Asthma Proc. 29: 439-446 (2008).
-
Khan S. Eosinophilic gastroenteritis.
Best Pract. Res. Clin. Gastroenterol. 19: 177-198 (2005).
-
Khan S, Orenstein SR. Eosinophilic gastroenteritis: epidemiology, diagnosis and management.
Paediatr. Drugs 4: 563-570 (2002).
-
Kharchafi A, Morlat P, Bernard PH, Bernard N, Balabaud C, Beylot J. Hepatitis C-autoimmune hepatitis overlap syndrome: a five new cases study.
Rev. Med. Interne. 27: 916-923 (2006).
-
Khemiri M, Ouederni M, Khaldi F, Barsaoui S. Screening for celiac disease in idiopathic pulmonary hemosiderosis.
Gastroenterol. Clin. Biol. 32: 745-748 (2008).
*
-
Kho YH, Pool MO, Jansman FG, Harting JW. Pharmacotherapeutic options in inflammatory bowel disease: an update.
Pharm. World Sci. 23: 17-21 (2001).
*
-
Khosravi AR, Mansouri P, Naraghi Z, Shokri H, Ziglari T. Unusual presentation of tinea cruris due to Trichophyton mentagrophytes var. mentagrophytes.
J. Dermatol. 35: 541-545 (2008).
-
Khurrum Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD. Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases.
Colorectal Dis. 6: 250-253 (2004).
-
Kikuchi H, Nagamine H, Setoyama M. A case of cytomegalovirus colitis following immunosuppressive treatment for pyoderma gangrenosum.
J. Dermatol. 32: 299-302 (2005).
-
Kilby AE, Krawitt EL, Albertini RJ, Chastenay BF, John A. Suppressor T-cell deficiency in primary sclerosing cholangitis. Case and family study.
Dig. Dis. Sci. 36: 1213-1216 (1991).
*
-
Kim BJ, Kazim M. Prominent premalar and cheek swelling: a sign of thyroid-associated orbitopathy.
Ophthal. Plast. Reconstr. Surg. 22: 457-460 (2006).
-
Kim BS, Jang HS, Jwa SW, Jang BS, Kim MB, Oh CK, Kwon YW, Kwon KS. Generalized pustular psoriasis and hepatic dysfunction associated with oral terbinafine therapy.
J. Korean Med. Sci. 22: 167-169 (2007).
*
-
Kim HA, Chung JW, Park HJ, Joe DY, Yim HE, Park HS, Suh CH. An antinuclear antibody-negative patient with lupus nephritis.
Korean J. Intern. Med. 24: 76-79 (2009).
*
-
Kim KH, Lichtenstein GR. Refractory inflammatory bowel disease.
Curr. Treat. Options Gastroenterol. 7: 201-211 (2004).
-
Kim SH, Ye YM, Hur GY, Lee HY, Jee YK, Lee SH, Holloway JW, Park HS. Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment.
Yonsei Med. J. 50: 182-188 (2009).
*
-
Kim SW, Lee ST, Lee SO, Choi SC. Clinical improvement of severe ulcerative colitis after incidental appendectomy: a case report.
Korean J. Gastroenterol. 47: 463-466 (2006).
-
Kimura Y, Walco GA. Treatment of chronic pain in pediatric rheumatic disease.
Nat. Clin. Pract. Rheumatol. 3: 210-218 (2007).
*
-
King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?
Drugs 67: 965-974 (2007).
-
King SJ, Topliss DJ, Kotsimbos T, Nyulasi IB, Bailey M, Ebeling PR, Wilson JW. Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor.
Eur. Respir. J. 25: 54-61 (2005).
*
-
Kinyoun JL. Treatment of Candida endophthalmitis.
Retina 2: 215-222 (1982).
-
Kiran RP, O'Brien-Ermlich B, Achkar JP, Fazio VW, Delaney CP. Management of peristomal pyoderma gangrenosum.
Dis. Colon Rectum 48: 1397-1403 (2005).
*
-
Kirk AP, Dooley JS, Hunt RH. Peptic ulceration in patients with chronic liver disease.
Dig. Dis. Sci. 25: 756-760 (1980).
-
Kirou KA, Salmon JE, Crow MK. Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system.
Rheum. Dis. Clin. North Am. 32: 103-119 (2006).
-
Kis K, Bodai L, Polyanka H, Eder K, Pivarcsi A, Duda E, Soos G, Bata-Csorgo Z, Kemeny L. Budesonide, but not tacrolimus, affects the immune functions of normal human keratinocytes.
Int. Immunopharmacol. 6: 358-368 (2006).
-
Kitamura M, Ishizaki T. Sarcoidosis of the liver and spleen in Japan.
Nippon Rinsho 52: 1595-1598 (1994).
-
Kittaka K, Dobashi H, Baba N, Iseki K, Kameda T, Susaki K, Kitanaka A, Kubota Y, Ishida T. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab.
Scand. J. Rheumatol. 37: 390-393 (2008).
-
Kitumnuaypong T, Scalzi LV, Nalbant S, Von Feldt JM, Schumacher HR Jr. Is there a role for Chlamydia pneumoniae infection in systemic lupus erythematosus and in the associated atherosclerotic cardiovascular disease?
Clin. Exp. Rheumatol. 22: 339-342 (2004).
-
Klaus J, Reinshagen M, Adler G, Boehm B, von Tirpitz C. Bones and Crohn's: estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density.
BMC Gastroenterol. 8: 48 (2008).
*
-
Kleerekoper M, Nelson DA. Is BMD testing appropriate for all menopausal women?
Int. J. Fertil. Womens Med. 50: 61-66 (2005).
-
Klein A, Szeimies RM, Landthaler M, Karrer S. Exacerbation of pityriasis rubra pilaris under efalizumab therapy.
Dermatology 215: 72-75 (2007).
-
Klicek R, Sever M, Radic B, Drmic D, Kocman I, Zoricic I, Vuksic T, Ivica M, Barisic I, Ilic S, Berkopic L, Vrcic H, Brcic L, Blagaic AB, Coric M, Brcic I, Rokotov DS, Anic T, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.
J. Pharmacol. Sci. 108: 7-17 (2008).
*
-
Klingenstein G, Levy RN, Kornbluth A, Shah AK, Present DH. Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature.
Aliment. Pharmacol. Ther. 21: 243-249 (2005).
*
-
Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
Adv. Drug Deliv. Rev. 57: 267-279 (2005).
*
-
Kmiec Z, Sokolowska I. Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis - new therapeutical opportunities.
Pol. Merkur. Lekarski. 22: 300-304 (2007).
-
Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis.
Int. J. Cancer 100: 82-85 (2002).
*
-
Knox DL. Psoriasis and intraocular inflammation.
Trans. Am. Ophthalmol. Soc. 77: 210-224 (1979).
*
-
Knyazhitskiy A, Masson RG, Corkey R, Joiner J. Beneficial response to macrolide antibiotic in a patient with desquamative interstitial pneumonia refractory to corticosteroid therapy.
Chest 134: 185-187 (2008).
*
-
Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.
J. Dermatolog. Treat. 20: 100-108 (2009).
-
Koene HR. New approaches to the treatment of idiopathic thrombocytopenia.
Ned. Tijdschr. Geneeskd. 151: 2609-2614 (2007).
-
Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Infliximab in the treatment of severe ulcerative colitis: a follow-up study.
Eur. Rev. Med. Pharmacol. Sci. 8: 235-237 (2004).
-
Kojima E, Kimura K, Noda Y, Kobayashi G, Itoh K, Fujita N. Autoimmune pancreatitis and multiple bile duct strictures treated effectively with steroid.
J. Gastroenterol. 38: 603-607 (2003).
-
Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients.
Clin. Rheumatol. 23: 45-49 (2004).
*
-
Kokubo Y, Kuzuhara S, Isoda K, Sato K, Kawada N, Narita Y. Neuro-Sweet disease: report of the first autopsy case.
J. Neurol. Neurosurg. Psychiatry 78: 997-1000 (2007).
-
Kolkman JJ, Mollmann HW, Mollmann AC, Pena AS, Greinwald R, Tauschel HD, Hochhaus G. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.
Drugs Today (Barc.) 40: 589-601 (2004).
-
Kommareddi PK, Nair TS, Vallurupalli M, Telian SA, Alexander Arts H, El-Kashlan HK, Sataloff RT, Carey TE. Autoantibodies to recombinant human CTL2 in autoimmune hearing loss.
Laryngoscope 119: 924-932 (2009).
-
Kong H, Lee Y, Hong S, Han J, Choi B, Jung Y, Kim YM. Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis.
J. Drug Target 17: 450-458 (2009).
-
Kontzias A, Efthimiou P. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.
Drugs 68: 319-337 (2008).
-
Koo JY. Relevance of the COBRA trial in current psoriasis practice.
Cutis 80: S4-S11 (2007).
-
Korelitz BI. Inflammatory bowel disease and pregnancy.
Gastroenterol. Clin. North Am. 27: 213-224 (1998).
-
Kosari P, Feldman SR. Case report: fluocinonide-induced perioral dermatitis in a patient with psoriasis.
Dermatol. Online J. 15: 15 (2009).
*
-
Kotilainen E, Hohenthal U, Karhu J, Kotilainen P. Spinal epidural lipomatosis caused by corticosteroid treatment in ulcerative colitis.
Eur. J. Intern. Med. 17: 138-140 (2006).
-
Kotter I, Daikeler T, Amberger C, Tyndall A, Kanz L. Autologous stem cell transplantation of treatment-resistant systemic vasculitis - a single center experience and review of the literature.
Clin. Nephrol. 64: 485-489 (2005).
-
Kotter I, Wacker A, Koch S, Henes J, Richter C, Engel A, Gunaydin I, Kanz L. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
Semin. Arthritis Rheum. 37: 189-197 (2007).
*
-
Kouklakis G, Efremidou EI, Papageorgiou MS, Pavlidou E, Manolas KJ, Liratzopoulos N. Complicated Crohn's-like colitis, associated with Hermansky-Pudlak syndrome, treated with infliximab: a case report and brief review of the literature.
J. Med. Case Reports 1: 176 (2007).
*
-
Kraemer A, Lewin M, Balladur P, Mourra N, Tiret E, Paye F. Autoimmune pancreatitis mimicking an intra-ductal papillary mucinous neoplasm of the pancreas: an original case.
Gastroenterol. Clin. Biol. 32: 635-639 (2008).
-
Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkila H, Jolliffe D, Peyri J, Svensson A, Toole J, Wozel G. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.
Br. J. Dermatol. 154: 1155-1160 (2006).
*
-
Kragballe K, Corvari L. An innovation in topical therapy: insights from international dermatologists.
Cutis 79: S39-S45 (2007).
-
Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions.
Epilepsy Curr. 6: 33-37 (2006).
-
Krawitt EL. Can you recognize autoimmune hepatitis?
Postgrad. Med. 104: 145-149, 152 (1998).
-
Kreth F, Neumann S, Hegenbart U, Mossner J, Caca K. A 26-year-old patient with colitis ulcerosa and anemia.
Internist (Berl.) 45: 217-220 (2004).
-
Kristan SS, Malovrh MM, Silar M, Kern I, Flezar M, Kosnik M, Suskovic S, Korosec P. Airway angiogenesis in patients with rhinitis and controlled asthma.
Clin. Exp. Allergy 39: 354-360 (2009).
-
Krom RA, Wiesner RH, Rettke SR, Ludwig J, Southorn PA, Hermans PE, Taswell HF. The first 100 liver transplantations at the Mayo Clinic.
Mayo Clin. Proc. 64: 84-94 (1989).
-
Kruis W. Crohn's disease - standards of treatment 2004.
Schweiz. Rundsch. Med. Prax. 94: 1595-1598 (2005).
-
Kryczka W, Walewska-Zielecka B, Dutkiewicz E. Acute seronegative hepatitis C manifesting itself as adult giant cell hepatitis - a case report and review of literature.
Med. Sci. Monit. 9 Suppl. 3: 29-31 (2003).
-
Kubota D, Kanai T, Yui F, Matsumoto T, Kawamura T, Itsui Y, Okada E, Chin S, Ooka S, Nagahori M, Tsuchiya K, Araki A, Sakamoto N, Miyata T, Watanabe M. A case of severe ulcerative colitis successfully withintravenous cyclosporine without high dose corticosteroid.
Nippon Shokakibyo Gakkai Zasshi 104: 42-46 (2007).
-
Kubota K, Iida H, Fujisawa T, Ogawa M, Inamori M, Saito S, Kakuta Y, Oshiro H, Nakajima A. Clinical significance of swollen duodenal papilla in autoimmune pancreatitis.
Pancreas 35: e51-e60 (2007).
-
Kubota Y, Hosogi S, Iwasaki Y. A case of Crohn's disease with broncho-bronchiolitis.
Nihon Kokyuki Gakkai Zasshi 42: 655-659 (2004).
-
Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, Wachs ME, Bak T, Kam I, Everson GT. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation.
Liver Transpl. 9: 727-732 (2003).
*
-
Kuhbacher T, Schreiber S, Folsch UR. Ulcerative colitis: conservative management and long-term effects.
Langenbecks Arch. Surg. 389: 350-353 (2004).
*
-
Kulkarni AS, Balkrishnan R, Richmond D, Pearce DJ, Feldman SR. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States.
J. Am. Acad. Dermatol. 52: 27-31 (2005).
-
Kumagai M, Yamato Y, Maeda K, Nakashima E, Ushijima K, Kimura A. Extracorporeal leukocyte removal therapy for patients with ulcerative colitis.
Pediatr. Int. 49: 431-436 (2007).
*
-
Kumar A, Teuber SS, Naguwa S, Prindiville T, Gershwin ME. Eosinophilic gastroenteritis and citrus-induced urticaria.
Clin. Rev. Allergy Immunol. 30: 61-70 (2006).
-
Kumar NB, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening.
Cancer Control 12: 149-157 (2005).
*
-
Kummer W, Wiegand S, Akinci S, Schinkel AH, Wess J, Koepsell H, Haberberger RV, Lips KS. Role of acetylcholine and muscarinic receptors in serotonin-induced bronchoconstriction in the mouse.
J. Mol. Neurosci. 30: 67-68 (2006).
-
Kunitomi A, Konaka Y, Yagita M, Nishimoto N, Kishimoto T, Takatsuki K. Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia.
Int. J. Hematol. 80: 246-249 (2004).
-
Kuriyama M, Kato J, Fujimoto T, Nasu J, Miyaike J, Morita T, Okada H, Suzuki S, Shiode J, Yamamoto H, Shiratori Y; Japan West Ulcerative Colitis (JWUC) Study Group. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background.
Dis. Colon Rectum 49: 1307-1315 (2006).
*
-
Kuriyama M, Kato J, Kuwaki K, Morimoto N, Nawa T, Fujimoto T, Kono H, Okano N, Miyaike J, Morita T, Okada H, Suzuki S, Yoshioka T, Shiode J, Suwaki K, Sakaguchi K, Shiratori Y; for the Japan West Ulcerative Colitis Study Group. Clinical factors that impair health-related quality of life in ulcerative colitis patients vary with the disease duration.
Eur. J. Gastroenterol. Hepatol. 20: 634-641 (2008).
-
Kuriyan AE, Phipps RP, Feldon SE. The eye and thyroid disease.
Curr. Opin. Ophthalmol. 19: 499-506 (2008).
-
Kurokohchi K, Arima K, Masaki T, Deguchi A, Nakai S, Morishita A, Yoneyama H, Ohgi T, Ono M, Yoshitake A, Maeta T, Mori Y, Kohi F, Nishioka M, Kuriyama S. Analysis of CD28 and bcl-2 expression on peripheral blood and liver-infiltrating mononuclear cells in patients with autoimmune hepatitis.
J. Clin. Immunol. 26: 323-330 (2006).
*
-
Kurokohchi K, Masaki T, Himoto T, Deguchi A, Nakai S, Morishita A, Yoneyama H, Kimura Y, Watanabe S, Kuriyama S. Usefulness of liver infiltrating CD86-positive mononuclear cells for diagnosis of autoimmune hepatitis.
World J. Gastroenterol. 12: 2523-2529 (2006).
*
-
Kusugami K, Ina K, Ando T, Hibi K, Nishio Y, Goto H. Immunomodulatory therapy for inflammatory bowel disease.
J. Gastroenterol. 39: 1129-1137 (2004).
*
-
Kuwabara S. Guillain-Barre syndrome: epidemiology, pathophysiology and management.
Drugs 64: 597-610 (2004).
-
Kuwabara S, Kuwabara S. Guillain-Barre syndrome.
Curr. Neurol. Neurosci. Rep. 7: 57-62 (2007).
-
Kuwahara R, Saitsu H, Abe M, Takata A, Tanaka K, Hino T, Ide T, Kuromatsu R, Tanikawa K, Kage M, Kumashiro R, Sata M. Successful treatment with corticosteroid and lamivudine for autoimmune hepatitis in a patient with asymptomatic HBV infection.
Dig. Dis. Sci. 52: 908-913 (2007).
*
-
Kyokane K, Ichihara T, Horisawa M, Suzuki N, Ichihara S, Suga S, Nakao A, Morise K. Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid.
Hepatogastroenterology 41: 449-452 (1994).
-
Kyttaris VC, Wang Y, Juang YT, Weinstein A, Tsokos GC. cAMP response element modulator a expression in patients with systemic lupus erythematosus.
Lupus 15: 840-844 (2006).
-
Laban-Guceva N, Bogoev M, Antova M. Serum concentrations of interleukin (IL-)1alpha, 1beta, 6 and tumor necrosis factor (TNF) alpha in patients with thyroid eye disease (TED).
Med. Arh. 61: 203-206 (2007).
-
Labeur M, Paez-Pereda M, Arzt E, Stalla GK. Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas.
Rev. Endocr. Metab. Disord. 10: 103-109 (2009).
-
Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ. The role of PPARs in lung fibrosis.
PPAR Res. 2007: 71323 (2007).
*
-
Lakatos L, Lakatos PL. Management of inflammatory bowel diseases in Eastern Europe.
Postgrad. Med. J. 82: 270-273 (2006).
*
-
Lakatos PL, Lakatos L. Ulcerative proctitis: a review of pharmacotherapy and management.
Expert Opin. Pharmacother. 9: 741-749 (2008).
-
Lalive PH, Truffert A, Magistris MR, Landis T, Dosso A. Peripheral autoimmune neuropathy assessed using corneal in vivo confocal microscopy.
Arch. Neurol. 66: 403-405 (2009).
-
Lam A, Toma W, Schlesinger N. Mycobacterium marinum arthritis mimicking rheumatoid arthritis.
J. Rheumatol. 33: 817-819 (2006).
-
Lamazza L, Guerra F, Pezza M, Messina A, Galluccio A, Spink M, De Biase A. The use of etanercept as a non-surgical treatment for temporomandibular joint psoriatric arthritis: a case report.
Aust. Dent. J. 54: 161-165 (2009).
-
Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, Muller AF. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease.
Aliment. Pharmacol. Ther. 16: 1895-1902 (2002).
*
-
Lambert GM. Does intestinal resection affect the absorption of essential vitamins, minerals, and bile salts? An overview of the literature.
Ostomy Wound Manage. 54: 36-47 (2008).
-
Lamireau T, Cezard JP, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies JL, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
Inflamm. Bowel Dis. 10: 745-750 (2004).
*
-
Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy.
Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).
-
Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment.
Am. Fam. Physician 76: 1323-1330 (2007).
*
-
Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Rheumatology (Oxford) 44: 1546-1548 (2005).
*
-
Langer-Gould A, Atlas SW, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
N. Engl. J. Med. 353: 375-381 (2005).
*
-
Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis.
J. Hepatol. 37: 441-447 (2002).
*
-
Lapcevic M. Autoimmune thyroid disease and associated diseases.
Srp. Arh. Celok. Lek. 133 Suppl. 1: 84-87 (2005).
-
Larsen FS. Treatment of patients with severe autoimmune hepatitis.
Minerva Gastroenterol. Dietol. 54: 57-63 (2008).
-
Lashner BA. Ulcerative colitis and colorectal cancer chemoprevention.
Medscape (http://www.medscape.com/viewarticle/566843) (2008). *
-
Lau CF, Wong AM, Yee KS, Loo CK, Hui PK, Lam KM. A case of colonic tuberculosis mimicking Crohn's disease.
Hong Kong Med. J. 4: 63-66 (1998).
-
Lawson M, Thomas A, Akobeng A. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 3: CD005112 (2006).
*
-
Lazaridis KN, Lindor KD. Primary biliary cirrhosis.
Curr. Treat. Options Gastroenterol. 2: 473-480 (1999).
-
Le Gars L, Grandpierre C, Chazouilleres O, Berenbaum F, Poupon R. Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease.
Joint Bone Spine 69: 195-200 (2002).
-
Le Guern V, Pannier E, Goffinet F. Systemic lupus erythematosus and pregnancy.
Presse. Med. 37: 1627-1635 (2008).
-
Le K, Wong LC, Fischer G. Vulval and perianal inflammatory linear verrucous epidermal naevus.
Australas. J. Dermatol. 50: 115-117 (2009).
-
Lebreton G, Fatome A. Management of severe acute colitis.
J. Chir. (Paris) 140: 201-210 (2003).
-
Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab.
Eur. J. Neurol. 16: 246-250 (2009).
-
Lebwohl M, Colon LE. The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis.
Cutis 80: S29-S40 (2007).
-
Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: traditional therapy.
Ann. Rheum. Dis. 64 Suppl. 2: ii83-ii86 (2005).
*
-
Lee CK, Kim HJ. Pathogenesis and treatment of intestinal Behcet's disease.
Korean J. Gastroenterol. 50: 3-8 (2007).
-
Lee LA. The clinical spectrum of neonatal lupus.
Arch. Dermatol. Res. 301: 107-110 (2009).
*
-
Lee M, Hodges WG, Huggins TL, Lee EL. Eosinophilic gastroenteritis.
South. Med. J. 89: 189-194 (1996).
-
Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn's disease: exercise as a potential countermeasure.
Inflamm. Bowel Dis. 11: 1108-1118 (2005).
*
-
Lee SH, Kim HJ, Yang SK, Kim WH, Joo YS, Dong SH, Kim BH, Lee JI, Chang YW, Chang R. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea.
J. Gastroenterol. Hepatol. 15: 512-518 (2000).
*
-
Lee SS, Lin HY, Wang SR, Tsai YY. Allopurinol hypersensitivity syndrome.
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 27: 140-147 (1994).
-
Lee YM, Kaplan MM. Primary sclerosing cholangitis.
N. Engl. J. Med. 332: 924-933 (1995).
*
-
Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Boulton-Jones R, Williams A, Church N, Satsangi J, Arnott ID; ON BEHALF OF THE SCOTTISH SOCIETY OF GASTROENTEROLOGY INFLIXIMAB GROUP. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.
Aliment. Pharmacol. Ther. 26: 411-419 (2007).
*
-
Lega JC, Cottin V, Schuller A, Lazor R, Jullien D, Cordier JF. Unusual pulmonary presentation of systemic Langerhans cell histiocytosis.
Rev. Med. Interne. 29: 669-672 (2008).
-
Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease.
Aliment. Pharmacol. Ther. 14: 801-806 (2000).
*
-
Lelubre C, Lheureux PE. Epigastric pain as presentation of an Addisonian crisis in a patient with Schmidt syndrome.
Am. J. Emerg. Med. 26: 251.e3-e4 (2008).
-
Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.
Am. J. Transplant. 4: 1514-1522 (2004).
-
Lemann M. Review article: can post-operative recurrence in Crohn's disease be prevented?
Aliment. Pharmacol. Ther. 24 Suppl. 3: 22-28 (2006).
*
-
Lemann M, Allez M. Strategies for treatment of inflammatory bowel disease.
Rev. Prat. 55: 984-992 (2005).
-
Lemann M, Chamiot-Prieur C, Mesnard B, Halphen M, Messing B, Rambaud JC, Gendre JP, Colombel JF, Modigliani R. Methotrexate for the treatment of refractory Crohn's disease.
Aliment. Pharmacol. Ther. 10: 309-314 (1996).
*
-
Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma.
Injury 38: 1336-1345 (2007).
-
Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis.
Dig. Dis. Sci. 53: 1455-1461 (2008).
*
-
Levine A, Kori M, Dinari G, Broide E, Shaoul R, Yerushalmi B, On A, Bujanover Y, Prols M, Greinwald R; Israeli Pediatric Budesonide Study Group. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.
Inflamm. Bowel Dis. 15: 1055-1061 (2009).
-
Levine DS, Fischer SH, Christie DL, Haggitt RC, Ochs HD. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis.
Am. J. Gastroenterol. 87: 91-100 (1992).
-
Levinson JR, Gordon SC. Liver diseases in the elderly.
Clin. Geriatr. Med. 7: 371-385 (1991).
-
Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation.
Liver Transpl. 9: 733-736 (2003).
*
-
Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease.
Semin. Liver Dis. 24: 233-247 (2004).
-
Levy C, Lindor KD. Management of primary biliary cirrhosis.
Curr. Treat. Options Gastroenterol. 6: 493-498 (2003).
-
Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis.
Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).
-
Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis.
J. Hepatol. 38: S24-S37 (2003).
*
-
Levy P, Hammel P, Ruszniewski P. Autoimmune pancreatitis.
Presse. Med. 36: 1925-1934 (2007).
-
Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, Ziol M, Arrive L, Beaugrand M, Poupon R, Valla D, Chazouilleres O, Corpechot C. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective MRI and histological study.
Hepatology [In Press] (2009).
-
Lewis EC, Mizrahi M, Toledano M, Defelice N, Wright JL, Churg A, Shapiro L, Dinarello CA. alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice.
Proc. Natl. Acad. Sci. U.S.A. 105: 16236-16241 (2008).
*
-
Lewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL. Seasonal variation in flares of inflammatory bowel disease.
Gastroenterology 126: 665-673 (2004).
*
-
Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL. Immunosuppressant medications and mortality in inflammatory bowel disease.
Am. J. Gastroenterol. 103: 1428-1435 (2008).
*
-
Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.
Am. J. Gastroenterol. 96: 3323-3328 (2001).
*
-
Li L, Chen M, Huang DY, Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type I.
J. Gastroenterol. Hepatol. 15: 1176-1182 (2000).
*
-
Li YC, Lu JR, Li SY. Levels of interleukin-23 in asthmatic children before and after glucocorticosteroid treatment.
Zhonghua Er Ke Za Zhi 45: 218-219 (2007).
-
Li ZG, Mu R, Dai ZP, Gao XM. T cell vaccination in systemic lupus erythematosus with autologous activated T cells.
Lupus 14: 884-889 (2005).
-
Liacouras CA, Markowitz JE. Eosinophilic esophagitis: a subset of eosinophilic gastroenteritis.
Curr. Gastroenterol. Rep. 1: 253-258 (1999).
-
Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.
World J. Gastroenterol. 14: 114-119 (2008).
*
-
Liang HL, Ouyang Q. A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis.
Zhonghua Nei Ke Za Zhi 45: 548-551 (2006).
-
Liberman AC, Druker J, Refojo D, Arzt E. Molecular mechanisms of action of some immunosuppressive drugs.
Medicina (B. Aires) 68: 455-464 (2008).
-
Lichte V, Ghoreschi K, Metzler G, Möhrle M, Geyer A, Röcken M, Schaller M. Pagetoid reticulosis (Woringer-Kolopp disease).
J. Dtsch. Dermatol. Ges. Nov 26 [Epub ahead of print] (2008).
-
Lichtenstein GR. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
Inflamm. Bowel Dis. 7 Suppl. 1: S23-S29 (2001).
*
-
Lichtenstein GR. Management of bone loss in inflammatory bowel disease.
Semin. Gastrointest. Dis. 12: 275-283 (2001).
-
Lichtenstein GR. PRO: Maintenance therapy is superior to episodic therapy.
Am. J. Gastroenterol. 100: 1433-1435 (2005).
*
-
Lichtenstein GR. Treatment of fistulizing Crohn's disease.
Gastroenterology 119: 1132-1147 (2000).
*
-
Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
Gastroenterology 130: 940-987 (2006).
*
-
Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
Gastroenterology 130: 935-939 (2006).
*
-
Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease.
Inflamm. Bowel Dis. 8: 237-243 (2002).
*
-
Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
Aliment. Pharmacol. Ther. 29: 643-653 (2009).
*
-
Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Am. J. Gastroenterol. 101: 1030-1038 (2006).
*
-
Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
Rev. Gastroenterol. Mex. 71: 351-401 (2006).
-
Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments.
Curr. Gastroenterol. Rep. 6: 60-65 (2004).
-
Liebman HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders.
Semin. Hematol. 46: S33-S36 (2009).
-
Lienert C, Sturzenegger M. Cerebral vasculitis.
Ther. Umsch. 65: 259-263 (2008).
-
Likic R, Kuzmanic D. Severe thrombocytopenia as a complication of acute Epstein-Barr virus infection.
Wien. Klin. Wochenschr. 116: 47-50 (2004).
-
Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma.
Curr. Opin. Pulm. Med. 15: 57-62 (2009).
-
Lind-Ayres MR, Abramowsky C, Mahle WT. Pediatric giant cell myocarditis and orbital myositis.
Pediatr. Cardiol. 30: 510-512 (2009).
-
Lindor KD, Fleming CR, Burnes JU, Nelson JK, Ilstrup DM. A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease.
Mayo Clin. Proc. 67: 328-333 (1992).
-
Lindsay J, Punekar Y, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulising disease in adults.
Aliment. Pharmacol. Ther. 28: 76-87 (2008).
*
-
Lindzen E, Jewells V, Bouldin T, Speer D, Royal W 3rd, Markovic-Plese S. Progressive tumefactive inflammatory central nervous system demyelinating disease in an acquired immunodeficiency syndrome patient treated with highly active antiretroviral therapy.
J. Neurovirol. Nov 19 [Epub ahead of print] (2008).
-
Linehan JD, Kolios G, Valatas V, Robertson DA, Westwick J. The effect of corticosteroids on nitric oxide production in inflammatory bowel disease: are leukocytes the site of action?
Am. J. Physiol. Gastrointest. Liver Physiol. 288: G261-G267 (2005).
*
-
Linker RA, Weller C, Luhder F, Mohr A, Schmidt J, Knauth M, Metselaar JM, Gold R. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations.
Exp. Neurol. 211: 397-406 (2008).
-
Lipozencic J. Keynote from Japan 5th Georg Rajka International Symposium on Atopic Dermatitis, Kyoto, May 11-13, 2008.
Acta Dermatovenerol. Croat. 16: 168-169 (2008).
-
Listrom C, Holt K. Inflammatory bowel disease.
Emerg. Med. 36: 24-28 (2004).
-
Lisukov IA, Sizikova SA, Kulagin AD, Kruchkova IV, Gilevich AV, Konenkova LP, Zonova EV, Chernykh ER, Leplina OY, Sentyakova TN, Demin AA, Kozlov VA. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus.
Lupus 13: 89-94 (2004).
-
Littal S. Skin lesions mimicking septic arthritis.
J. Fam. Pract. 55: 881-884 (2006).
*
-
Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
Liver Transpl. 10: 728-733 (2004).
*
-
Liu X, Yang P, Lin X, Ren X, Zhou H, Huang X, Chi W, Kijlstra A, Chen L. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome.
Clin. Immunol. 131: 333-342 (2009).
*
-
Ljubojevic S, Milavec-Puretic V, Sredoja-Tisma V, Rados J, Kalauz M, Hrstic I. Pyoderma gangrenosum associated with ulcerative colitis.
Acta Dermatovenerol. Croat. 14: 35-39 (2006).
-
Ljung T, Thomsen OO, Vatn M, Karlen P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Lofberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia.
Scand. J. Gastroenterol. 42: 221-227 (2007).
*
-
Lobo D, Trinidad A, Garcia-Berrocal JR, Verdaguer JM, Ramirez-Camacho R. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.
Eur. Arch. Otorhinolaryngol. 263: 622-626 (2006).
-
Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schutz T, van Gemert W, van Gossum A, Valentini L. ESPEN guidelines on enteral nutrition: gastroenterology.
Clin. Nutr. 25: 260-274 (2006).
-
Lofberg R. Review article: medical treatment of mild to moderately active Crohn's disease.
Aliment. Pharmacol. Ther. 17 Suppl. 2: 18-22 (2003).
-
Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G, Jewell D, Ostergaard Thomsen O, Lorenz-Meyer H, Goebell H, Hodgson H, Persson T, Seidegard C. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.
Gut 39: 82-86 (1996).
*
-
Loftus EV. Management of extraintestinal manifestations and other complications of inflammatory bowel disease.
Curr. Gastroenterol. Rep. 6: 506-513 (2004).
-
Loftus EV. CON: "Lifetime use" is an awfully long time.
Am. J. Gastroenterol. 100: 1435-1438 (2005).
*
-
Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted county, Minnesota.
Clin. Gastroenterol. Hepatol. 1: 465-473 (2003).
*
-
Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ 3rd. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota.
Gastroenterology 123: 468-475 (2002).
*
-
Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review.
Aliment. Pharmacol. Ther. 16: 51-60 (2002).
*
-
Lohse AW. Standard treatment of autoimmune hepatitis.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 65-66 (2004). *
-
Lomer MC, Grainger SL, Ede R, Catterall AP, Greenfield SM, Cowan RE, Vicary FR, Jenkins AP, Fidler H, Harvey RS, Ellis R, McNair A, Ainley CC, Thompson RP, Powell JJ. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease.
Eur. J. Gastroenterol. Hepatol. 17: 377-384 (2005).
-
Long RG, Meinhard E, Skinner RK, Varghese Z, Wills MR, Sherlock S. Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease.
Gut 19: 85-90 (1978).
*
-
Lopes LH, Sdepanian VL, Szejnfeld VL, de Morais MB, Fagundes-Neto U. Risk factors for low bone mineral density in children and adolescents with inflammatory bowel disease.
Dig. Dis. Sci. 53: 2746-2753 (2008).
*
-
Lopez P, Gomez J, Mozo L, Gutierrez C, Suarez A. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.
Arthritis Res. Ther. 8: R42 (2006).
*
-
Lopez-Hoyos M, Rodrigo E, Fernandez-Fresnedo G, Martinez-Taboada VM, Valero R, Arias M. Lack of effect of rapamycin in anti-CCP antibody production in a rheumatoid arthritis kidney allograft recipient.
Clin. Exp. Rheumatol. 23: 529-531 (2005).
-
Lorenzi AR, Morgan TA, Anderson AE, Catterall JB, Patterson AM, Foster HE, Isaacs JD. Thymic function in juvenile idiopathic arthritis.
Ann. Rheum. Dis. 68: 983-990 (2009).
*
-
Louis E, Boverie J, Dewit O, Baert F, De Vos M, D'Haens G; Belgian IBD Research Group. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study.
Acta Gastroenterol. Belg. 70: 15-19 (2007).
-
Louthrenoo W, Aramsareewong T, Sukitawut W. Adult onset Still's disease: clinical features and outcome in 16 Thai patients.
J. Clin. Rheumatol. 7: 301-307 (2001).
-
Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.
Gastroenterology May 12 [Epub ahead of print] (2009).
*
-
Louzir B, Othmani S, Ben Abdelhafidh N; Groupe d'Etude du Lupus Erythematuex Systemique en Tunisie. Systemic lupus erythematosus in Tunisia. A multicentric study. About 295 cases.
Rev. Med. Interne. 24: 768-774 (2003).
-
Lovell DJ, Glass D, Ranz J, Kramer S, Huang B, Sierra RI, Henderson CJ, Passo M, Graham B, Bowyer S, Higgins G, Rennebohm R, Schikler KN, Giannini E. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis.
Arthritis Rheum. 54: 2235-2242 (2006).
*
-
Lowenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how?
Drugs 66: 1431-1439 (2006).
-
Lu W, Sun G. Clinical characteristics of primary biliary cirrhosis with Sjogren's syndrome of 20 cases.
Zhonghua Nei Ke Za Zhi 40: 747-749 (2001).
-
Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease.
Am. J. Gastroenterol. 104: 444-453 (2009).
-
Lucarelli S, Borrelli O, Paganelli M, Capocaccia P, Frediani T, Ferri F, Cucchiara S. Vertebral fractures and increased sensitivity to corticosteroids in a child with ulcerative colitis: successful use of pamidronate.
J. Pediatr. Gastroenterol. Nutr. 43: 533-535 (2006).
*
-
Lucha PA Jr, Fticsar JE, Francis MJ. The strictured anastomosis: successful treatment by corticosteroid injections - report of three cases and review of the literature.
Dis. Colon Rectum 48: 862-865 (2005).
*
-
Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base.
Curr. Opin. Neurol. 21: 8-15 (2008).
-
Luckschander N, Allenspach K, Hall J, Seibold F, Grone A, Doherr MG, Gaschen F. Perinuclear antineutrophilic cytoplasmic antibody and response to treatment in diarrheic dogs with food responsive disease or inflammatory bowel disease.
J. Vet. Intern. Med. 20: 221-227 (2006).
-
Ludwig D, Stange EF. Treatment of ulcerative colitis.
Hepatogastroenterology 47: 83-89 (2000).
-
Luger T, Paul C. Potential new indications of topical calcineurin inhibitors.
Dermatology 215 Suppl. 1: S45-S54 (2007).
-
Luger TA, Cambazard F, Larsen FG, Bourcier M, Gupta G, Clonier F, Kidson P, Shear NH. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.
Dermatology 217: 321-328 (2008).
-
Lugovic L, Buljan M, Situm M, Poduje S, Bulat V, Vucic M, Budimir J. Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report.
Acta Dermatovenerol. Croat. 15: 236-242 (2007).
-
Lukas K. The large intestine - literature review of recent years.
Cas. Lek. Cesk. 143: 149-153 (2004).
-
Luketic VA, Gomez DA, Sanyal AJ, Shiffman ML. An atypical presentation for primary sclerosing cholangitis.
Dig. Dis. Sci. 42: 2009-2016 (1997).
*
-
Lukjanowicz M, Ostanek L, Bohatyrewicz A, Bielicki D, Brzosko M. Fungal spondylodiscitis in a patient with ulcerative colitis - case report.
Ortop. Traumatol. Rehabil. 8: 708-713 (2006).
-
Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study.
Dis. Colon Rectum 40: 451-456 (1997).
-
Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome.
J. Am. Acad. Dermatol. 1: 365-374 (1979).
-
Lurati-Ruiz F, Spertini F. Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis.
J. Rheumatol. 32: 2167-2172 (2005).
-
Lustig MJ, Cunningham ET Jr. Use of immunosuppressive agents in uveitis.
Curr. Opin. Ophthalmol. 14: 399-412 (2003).
-
Luth S, Weiler-Normann C, Schramm C, Lohse AW. Autoimmune liver diseases.
Internist (Berl.) 50: 310-317 (2009).
-
Luxon BA. Autoimmune hepatitis. Making sense of all those antibodies.
Postgrad. Med. 114: 79-82, 85-88 (2003).
-
Lv J, Zhang H, Cui Z, Su T, Zhang Y, Wang H. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy.
Nephrol. Dial. Transplant. 23: 2868-2872 (2008).
-
Lyckegaard E, Hakansson K, Bengtsson B. Budesonide in Crohn's disease: findings of a compassionate-use program.
Hepatogastroenterology 54: 2024-2027 (2007).
-
Lynch JP 3rd, White E, Tazelaar H, Langford CA. Wegener's granulomatosis: evolving concepts in treatment.
Semin. Respir. Crit. Care Med. 25: 491-521 (2004).
-
Mack DR. Ongoing advances in inflammatory bowel diseases, including maintenance therapies, biologic agents, and biology of disease.
Curr. Opin. Pediatr. 10: 499-506 (1998).
-
Mackay IR. Treatment of chronic active hepatitis and other liver diseases with corticosteroid agents.
Med. J. Aust. 146: 370-374 (1987).
-
MacLean CH, Mojica WA, Newberry SJ, Pencharz J, Garland RH, Tu W, Hilton LG, Gralnek IM, Rhodes S, Khanna P, Morton SC. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease.
Am. J. Clin. Nutr. 82: 611-619 (2005).
*
-
Maconi G, Colombo E, Zerbi P, Sampietro GM, Fociani P, Bosani M, Cassinotti A, Casini V, Russo A, Ardizzone S, Porta M, Bianchi Porro G. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection.
Dig. Liver Dis. 37: 418-423 (2005).
-
Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology.
Dermatol. Ther. 20: 239-250 (2007).
-
Madsen JR, Laursen LS, Lauritsen K. Chronic inflammatory bowel disease - current status.
Ugeskr. Laeger. 154: 2243-2250 (1992).
-
Maekawa S, Yoshikawa I, Yamasaki M, Kume K, Kanda K, Kihara Y, Tashiro M, Otsuki M. Episcleritis and erythema nodosum in a patient with ulcerative colitis.
Nippon Shokakibyo Gakkai Zasshi 105: 686-691 (2008).
-
Maggiore G, Sciveres M. Autoimmune hepatitis: a childhood disease.
Current Pediatric Reviews 1: 73-90 (2005). *
-
Magnant J, Lhommet C, Machet L, Machet MC, Guilmot JL, Diot E. Cutaneous polyarteritis nodosa and Crohn's disease: an association not to be ignored.
Rev. Med. Interne. 30: 345-348 (2009).
-
Magrini L, Rotiroti G, Conti F, Viganego F, Alessandri C, Picardo V, Valesini G. Orbital myositis in a patient with primary biliary cirrhosis: successful treatment with methotrexate and corticosteroids.
Isr. Med. Assoc. J. 5: 825-826 (2003).
*
-
Mahadevan U. TNF-alpha antagonists: benefits beyond remission.
Rev. Gastroenterol. Disord. 7 Suppl. 1: S13-S19 (2007).
-
Mahadevan U, Loftus EV Jr, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications.
Inflamm. Bowel Dis. 8: 311-316 (2002).
*
-
Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease.
Inflamm. Bowel Dis. 7: 38-42 (2001).
*
-
Mahmud N, Weir DG. The urban diet and Crohn's disease: is there a relationship?
Eur. J. Gastroenterol. Hepatol. 13: 93-95 (2001).
*
-
Maier K, Fischer C, Klotz U, Heinkel K. 5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl.).
Dtsch. Med. Wochenschr. 107: 1131-1134 (1982).
-
Majdan M, Stepniak C, Piotrowicz S, Broniek K, Blajer B, Bednarek-Skublewska A. The analysis of the clinical course of disease and subsequent dialysotherapy in a group of patients with rheumatoid arthritis and end-stage renal disease.
Pol. Arch. Med. Wewn. 113: 334-340 (2005).
-
Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy.
Rheumatology (Oxford) 44: 386-389 (2005).
*
-
Makhlof A, Tozuka Y, Takeuchi H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model.
Eur. J. Pharm. Biopharm. 72: 1-8 (2009).
-
Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction.
Curr. Pharm. Des. 15: 290-303 (2009).
-
Makrygiannakis D, Af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Arthritis Rheum. 54: 1463-1472 (2006).
*
-
Malaguarnera M, Guccione N, Musumeci S, Brogna A, Motta M, Di Fazio I. Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C.
BioDrugs 18: 63-70 (2004).
-
Maleki M, Faghihi M, Golshan M. Primary sclerosing cholangitis.
South. Med. J. 71: 855-857 (1978).
-
Malemud CJ. Cytokines as therapeutic targets for osteoarthritis.
BioDrugs 18: 23-35 (2004).
-
Malerba G, Pignatti PF. A review of asthma genetics: gene expression studies and recent candidates.
J. Appl. Genet. 46: 93-104 (2005).
*
-
Malhotra S, Bhasin D, Shafiq N, Pandhi P. Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond.
Expert Opin. Pharmacother. 5: 329-334 (2004).
-
Malik M, Gurcan HM, Ahmed AR. Coexistence of mucous membrane pemphigoid and connective-tissue disease.
Clin. Exp. Dermatol. May 5 [Epub ahead of print] (2009).
*
-
Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 4: CD005573 (2007).
*
-
Malphettes M, Oksenhendler E, Galicier L, Fieschi C. Granulomatous disease in common variable immunodeficiency.
Rev. Med. Interne. 29: 28-32 (2008).
-
Mamula P, Markowitz JE, Cohen LJ, Von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up.
J. Pediatr. Gastroenterol. Nutr. 38: 298-301 (2004).
*
-
Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.
Clin. Gastroenterol. Hepatol. 5: 851-856 (2007).
-
Manns M, Meyer zum Buschenfelde KH, Arnold W. The diagnostic value of immunologic findings in the differentiation of chronic liver diseases.
Leber. Magen. Darm. 18: 290-292, 295, 298 (1988).
-
Manns MP, Wiegand J. Novel approaches to the treatment of autoimmune hepatitis.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 67-70 (2004). *
-
Mansfield JC, Giaffer MH, Holdsworth CD. Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease.
Gut 36: 60-66 (1995).
*
-
Manson JJ, Rahman A. Systemic lupus erythematosus.
Orphanet J. Rare Dis. 1: 6 (2006).
*
-
Mansueto P, Montalto G, Pacor ML, Esposito-Pellitteri M, Ditta V, Lo Bianco C, Leto-Barone SM, Di Lorenzo G. Food allergy in gastroenterologic diseases: review of literature.
World J. Gastroenterol. 12: 7744-7752 (2006).
*
-
Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno De Mesquita M, D'Hoore A, Penninckx F, Rutgeerts P. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
Aliment. Pharmacol. Ther. 19: 749-754 (2004).
*
-
Marchand-Adam S, El Khatib A, Guillon F, Brauner MW, Lamberto C, Lepage V, Naccache JM, Valeyre D. Short- and long-term response to corticosteroid therapy in chronic beryllium disease.
Eur. Respir. J. 32: 687-693 (2008).
-
Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management.
Liver Transpl. 11: 612-620 (2005).
*
-
Marcinkiewicz M, Gryc E, Kreczko S. The role of selected serologic markers in the diagnosis of autoimmune hepatitis.
Przegl. Lek. 55: 614-618 (1998).
-
Marin-Jimenez I, Pena AS. Budesonide for ulcerative colitis.
Rev. Esp. Enferm. Dig. 98: 362-373 (2006).
*
-
Marion JF. Crohn's disease and ulcerative colitis: when is a diagnostic procedure necessary?
Minerva Gastroenterol. Dietol. 47: 9-16 (2001).
-
Mark EJ, Ruangchira-Urai R. Bronchiolitis interstitial pneumonitis: a pathologic study of 31 lung biopsies with features intermediate between bronchiolitis obliterans organizing pneumonia and usual interstitial pneumonitis, with clinical correlation.
Ann. Diagn. Pathol. 12: 171-180 (2008).
-
Markel G, Imazio M, Brucato A, Adler Y. Colchicine for the prevention of recurrent pericarditis.
Isr. Med. Assoc. J. 10: 69-72 (2008).
*
-
Markowitz J, Hyams J, Mack D, Leleiko N, Evans J, Kugathasan S, Pfefferkorn M, Mezoff A, Rosh J, Tolia V, Otley A, Griffiths A, Moyer MS, Oliva-Hemker M, Wyllie R, Rothbaum R, Bousvaros A, Del Rosario JF, Hale S, Lerer T. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.
Clin. Gastroenterol. Hepatol. 4: 1124-1129 (2006).
-
Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
Arthritis Rheum. 52: 3168-3174 (2005).
*
-
Marks SD, Tullus K. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
Paediatr. Drugs 9: 371-378 (2007).
-
Marmont AM. Stem cell transplantation for severe autoimmune diseases: progress and problems.
Haematologica 83: 733-743 (1998).
*
-
Marques PP, Da Fonseca J, Goncalves P, Leal FC. Primary biliary cirrhosis associated arthritis.
Acta Med. Port. 15: 447-450 (2002).
-
Marrache F, Hammel P, O'Toole D, Cazals-Hatem D, Vullierme MP, Sibert A, Ponsot P, Maire F, Hentic O, Sauvanet A, Levy P, Ruszniewski P. Severe cholangitis following pancreaticoduodenectomy for pseudotumoral form of lymphoplasmacytic sclerosing pancreatitis.
Am. J. Gastroenterol. 100: 2808-2813 (2005).
*
-
Marshall JK, Irvine EJ, Steinhart AH, Thabane M. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 2: CD004115 (2004). *
-
Marshall JK, Irvine EJ, Steinhart AH, Thabane M. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 2: CD004118 (2004). *
-
Marten K, Fend F, Hautmann H, Kremer M, Rummeny EJ, Engelke C. Fatal acute exacerbation of usual interstitial pneumonia in ulcerative colitis.
Br. J. Radiol. 78: 762-766 (2005).
-
Martin L, Rubin A, Tran K, Pas H, Marr P, Edmonds J, Murrell D. A complicated blistering disease case demonstrating the usefulness of immunoblotting and ELISA for the diagnosis of immunobullous diseases.
Australas. J. Dermatol. 47: A57 (2006).
-
Martin WJ 2nd, Iannuzzi MC, Gail DB, Peavy HH. Future directions in sarcoidosis research: summary of an NHLBI working group.
Am. J. Respir. Crit. Care Med. 170: 567-571 (2004).
*
-
Martinez Albaladejo M, Alguacil Garcia G, Gonzalez Pina B, de Paco Moya M, Herranz Marin T, Moreno-Requena J. Eosinophilic gastroenteritis, apropos a new case.
An. Med. Interna 14: 187-189 (1997).
-
Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
Arch. Dermatol. Res. 299: 461-465 (2007).
*
-
Marx J. Biomedicine. Puzzling out the pains in the gut.
Science 315: 33-35 (2007).
*
-
Marzano A, Ramoni S, Del Papa N, Barbareschi M, Alessi E. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions.
Lupus 17: 329-331 (2008).
-
Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid.
J. Dermatolog. Treat. 17: 370-376 (2006).
-
Marzano AV, Ramoni S, Caputo R. Amicrobial pustulosis of the folds. Report of 6 cases and a literature review.
Dermatology 216: 305-311 (2008).
-
Marzano AV, Ramoni S, Spinelli D, Alessi E, Berti E. Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium.
J. Dermatolog. Treat. 19: 364-367 (2008).
-
Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.
Clin. Gastroenterol. Hepatol. 6: 1112-1116 (2008).
-
Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis.
Cochrane Database Syst. Rev. 2: CD005028 (2009).
*
-
Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy?
Drugs 65: 2069-2083 (2005).
-
Masuda J, Omagari K, Matsuo I, Kinoshita H, Sakimura K, Hazama H, Ohba K, Isomoto H, Murase K, Murata I, Kohno S. Changes in titers of antimitochondrial and antinuclear antibodies during the course of primary biliary cirrhosis.
J. Gastroenterol. Hepatol. 16: 239-243 (2001).
*
-
Mathurin P. Corticosteroids for alcoholic hepatitis - what's next?
J. Hepatol. 43: 526-533 (2005).
*
-
Matsumoto Y. New approach to immunotherapy against organ-specific autoimmune diseases with T cell receptor and chemokine receptor DNA vaccines.
Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 73-77 (2005).
-
Matsuo T, Masuda I, Ota K, Yamadori I, Sunami R, Nose S. Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin a nephropathy.
Acta Med. Okayama 61: 305-309 (2007).
*
-
Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, Horikawa M, Kondo M, Orito H, Kaji K, Saito Y, Matsushita Y, Kawara S, Yasui M, Seishima M, Ozaki S, Kuwana M, Ogawa F, Sato S, Takehara K. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis.
J. Rheumatol. 34: 1012-1018 (2007).
-
Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases - performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay.
Ann. Rheum. Dis. 67: 84-90 (2008).
-
Maunder RG, Greenberg GR, Nolan RP, Lancee WJ, Steinhart AH, Hunter JJ. Autonomic response to standardized stress predicts subsequent disease activity in ulcerative colitis.
Eur. J. Gastroenterol. Hepatol. 18: 413-420 (2006).
-
Mauras N. Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects.
Horm. Res. 56 Suppl. 1: 13-18 (2001).
-
Mauras N, George D, Evans J, Milov D, Abrams S, Rini A, Welch S, Haymond MW. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study.
Metabolism 51: 127-135 (2002).
*
-
Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjogren's syndrome.
Clin. Rev. Allergy Immunol. 32: 284-291 (2007).
*
-
Mazariegos GV, Salzedas AA, Zavatsky J, Sindhi R, Parizhskaya M, McGhee W, Jain A, Reyes J. Long term management of liver transplant rejection in children.
BioDrugs 14: 31-48 (2000).
-
Mazzella G, Fusaroli P, Pezzoli A, Azzaroli F, Mazzeo C, Zambonin L, Simoni P, Festi D, Roda E. Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile.
Dig. Dis. Sci. 44: 2478-2483 (1999).
*
-
McDonald J, Feagan B, Jewell D, Brynskov J, Stange E, Macdonald J. Cyclosporine for induction of remission in Crohn's disease.
Cochrane Database Syst. Rev. 2: CD000297 (2005).
*
-
McEwan IJ, Lavery D, Fischer K, Watt K. Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors.
Nucl. Recept. Signal. 5: e001 (2007).
*
-
McGovern DP, Jewell DP. Risks and benefits of azathioprine therapy.
Gut 54: 1055-1059 (2005).
*
-
McGovern DP, Travis SP. Smoking status in therapeutic trials in Crohn's disease.
Gut 54: 1047-1048 (2005).
*
-
McGowan JW 4th, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept.
J. Drugs Dermatol. 3: 441-444 (2004).
-
McGrath J, McDonald J, Macdonald J. Transdermal nicotine for induction of remission in ulcerative colitis.
Cochrane Database Syst. Rev. 4: CD004722 (2004).
*
-
McKaig B, Stack W. Novel approaches to inflammatory bowel disease.
Expert Opin. Investig. Drugs 7: 1099-1113 (1998).
-
McKaig BC, Stack WA. Current pharmacotherapy for inflammatory bowel disease.
Expert Opin. Pharmacother. 1: 3-14 (1999).
-
Medlicott SA, Coderre S, Horne G, Panaccione R. Multimodal immunosuppressant therapy in steroid-refractory common variable immunodeficiency sprue: a case report complicating cytomegalovirus infection.
Int. J. Surg. Pathol. 14: 101-106 (2006).
-
Meeuwissen J, Maertens J, Verbeken E, Blockmans D. Case reports: testicular pain as a manifestation of polyarteritis nodosa.
Clin. Rheumatol. 27: 1463-1466 (2008).
-
Meijssen MA. Cyclosporine and inflammatory bowel disease: buying time.
Mediators Inflamm. 7: 145-147 (1998).
*
-
Melillo N, Corrado A, Quarta L, Cantatore FP. Corticosteroids, a review.
Panminerva Med. 49: 29-33 (2007).
-
Menchen LM, Ripoll C, Breton I, Moreno C, de la Cuerda C, Camblor M, Garcia-Peris P, Gonzalez-Lara V, Cos E. Osteoporosis and inflammatory bowel disease.
Nutr. Hosp. 20: 26-37 (2005).
-
Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O, Valente J. Behcet's disease - a contemporary review.
J. Autoimmun. 32: 178-188 (2009).
-
Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis.
Am. J. Gastroenterol. 101: 2070-2075 (2006).
*
-
Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Escarcega RO, Jimenez-Hernandez M, Etchegaray-Morales I, Soto-Vega E, Munoz-Guarneros M, Lopez-Colombo A, Deleze-Hinojosa M, Cervera R. Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.
Clin. Rheumatol. 28: 65-70 (2009).
-
Menon KVN, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, Shah V. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis.
Am. J. Gastroenterol. 99: 255-260 (2004).
*
-
Menon RT, Feferman T, Aricha R, Souroujon MC, Fuchs S. Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent.
J. Neuroimmunol. 201-202: 128-135 (2008).
-
Menozzi A, Pozzoli C, Poli E, Lazzaretti M, Cantoni A, Grandi D, Giovannini E, Coruzzi G. Effect of the macrolide antibacterial drug, tylosin, on TNBS-induced colitis in the rat.
Pharmacology 74: 128-135 (2005).
-
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
J. Am. Acad. Dermatol. 60: 643-659 (2009).
-
Merrill JT. Emergence of targeted immune therapies for systemic lupus.
Expert Opin. Emerg. Drugs 10: 53-65 (2005).
-
Meur YL, Djebli N, Szelag JC, Hoizey G, Toupance O, Rerolle JP, Marquet P. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.
Clin. Pharmacol. Ther. 80: 51-60 (2006).
*
-
Meuwissen SG, Schellekens PT, Huismans L, Tytgat GN. Impaired anamnestic cellular immune response in patients with Crohn's disease.
Gut 16: 854-860 (1975).
*
-
Meyer T, Lauschke J, Ruppert V, Richter A, Pankuweit S, Maisch B. Isolated cardiac sarcoidosis associated with the expression of a splice variant coding for a truncated BTNL2 protein.
Cardiology 109: 117-121 (2007).
-
Mezquita Raya P, Munoz Torres M, Lopez Rodriguez F, Martinez Martin N, Conde Valero A, Ortego Centeno N, Gonzalez Calvin J, Raya Alvarez E, Luna Jd Jde D, Escobar Jimenez F. Prevalence of vitamin D deficiency in populations at risk for osteoporosis: impact on bone integrity.
Med. Clin. (Barc.) 119: 85-89 (2002).
-
Michaels A, Levy C. The medical management of primary sclerosing cholangitis.
Medscape J. Med. 10: 61 (2008).
*
-
Michalska Z, Radowska D, Staike P, Sikorska K, Lakomy A, Witczak-Malinowska K, Bakowska A, Stolarczyk J, Trocha H, Pawiak A, Kowalik M. Autoimmune hepatitis in the material of Department and Regional Hospital of Infectious Diseases in Gdansk.
Med. Sci. Monit. 9 Suppl. 3: 49-54 (2003).
-
Michel M. Characteristics of warm autoimmune hemolytic anemia and Evans syndrome in adults.
Presse. Med. 37: 1309-1318 (2008).
-
Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease.
Digestion 71: 19-25 (2005).
-
Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader JP, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease.
Digestion 76: 99-108 (2007).
*
-
Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, Budde U, van Vliet HH. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Semin. Thromb. Hemost. 32: 577-588 (2006).
-
Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children.
Clin. Liver Dis. 6: 335-346 (2002).
-
Migita K, Abiru S, Maeda Y, Nakamura M, Komori A, Ito M, Fujiwara S, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H. Elevated serum BAFF levels in patients with autoimmune hepatitis.
Hum. Immunol. 68: 586-591 (2007).
-
Mignogna MD, Leuci S, Fedele S, Ruoppo E, Adamo D, Russo G, Pagliuca R. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study.
Am. J. Clin. Dermatol. 9: 323-331 (2008).
-
Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.
Arch. Intern. Med. 158: 2200-2211 (1998).
*
-
Miller V, Whorwell PJ. Treatment of inflammatory bowel disease: a role for hypnotherapy?
Int. J. Clin. Exp. Hypn. 56: 306-317 (2008).
-
Min JK, Han NI, Kim JA, Lee YS, Cho CS, Kim HY. A case of cholestatic autoimmune hepatitis and acute liver failure: an unusual hepatic manifestation of mixed connective tissue disease and Sjogren's syndrome.
J. Korean Med. Sci. 16: 512-515 (2001).
*
-
Minami M, Hasegawa T, Ando T, Maeda O, Ohkura T, Ohta M, Goto H. Post-colonoscopic Listeria septicemia in ulcerative colitis during immunosuppressive therapy.
Intern. Med. 46: 2023-2028 (2007).
*
-
Miner J, Gillan MM, Alex P, Centola M. Steroid-refractory ulcerative colitis treated with corticosteroids, metronidazole and vancomycin: a case report.
BMC Gastroenterol. 5: 3 (2005).
*
-
Mir A, Minguez M, Tatay J, Pascual I, Pena A, Sanchiz V, Almela P, Mora F, Benages A. Elevated serum eotaxin levels in patients with inflammatory bowel disease.
Am. J. Gastroenterol. 97: 1452-1477 (2002).
*
-
Mirowska-Guzel DM, Kurowska K, Skierski J, Koronkiewicz M, Wicha W, Kruszewska J, Czlonkowski A, Czlonkowska A. High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse.
J. Neuroimmunol. 176: 134-140 (2006).
-
Mirza M, Zamilpa I, Wilson JM. Localized penile bullous pemphigoid of childhood.
J. Pediatr. Urol. 4: 395-397 (2008).
-
Mishima Y, Ishihara S, Amano Y, Oshima N, Kadota C, Otani A, Moriyama I, Li YY, Aziz M, Kinoshita Y. Alterations of peripheral blood CD5(+) B cells in inflammatory bowel disease.
Scand. J. Gastroenterol. 44: 172-179 (2009).
*
-
Mitchell KD, Kruth SA, Wood RD, Jefferson B. Serum acute phase protein concentrations in dogs with autoimmune hemolytic anemia.
J. Vet. Intern. Med. Mar 9 [Epub ahead of print] (2009).
-
Mitchell SA, Chapman RW. Review article: the management of primary sclerosing cholangitis.
Aliment. Pharmacol. Ther. 11: 33-43 (1997).
-
Mitchell SA, Chapman RW. The management of primary sclerosing cholangitis.
Clin. Liver Dis. 2: 353-372, x (1998).
-
Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Ando M, Sakaguchi K, Yamamoto K. Clinical features of antinuclear antibodies-negative type 1 autoimmune hepatitis.
Hepatol. Res. 39: 241-246 (2009).
*
-
Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Sakaguchi K, Ando M, Yamamoto K. Clinical features of type 1 autoimmune hepatitis in adolescence and early adulthood.
Hepatol. Res. Apr 3 [Epub ahead of print] (2009).
*
-
Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis.
Aliment. Pharmacol. Ther. 24: 519-523 (2006).
*
-
Miyake Y, Iwasaki Y, Takaki A, Onishi T, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Kobashi H, Sakaguchi K, Shiratori Y. Human leukocyte antigen DR status and clinical features in Japanese patients with type 1 autoimmune hepatitis.
Hepatol. Res. 38: 96-102 (2008).
*
-
Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis.
Aliment. Pharmacol. Ther. 24: 1197-1205 (2006).
*
-
Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Kobashi H, Sakaguchi K, Shiratori Y. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis.
Hepatol. Res. 37: 801-805 (2007).
*
-
Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamaoto R, Ikeda H, Sakai N, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis.
J. Hepatol. 43: 951-957 (2005).
*
-
Miyake Y, Sakaguchi K, Tanaka H, Nakamura S, Kobayashi Y, Fujioka S, Iwasaki Y, Shiratori Y. Development of hepatocellular carcinoma in a woman with HBV- and HCV-negative autoimmune hepatitis with unsatisfactory response to corticosteroid.
Intern. Med. 44: 949-953 (2005).
*
-
Miyata M, Kasugai K, Ishikawa T, Kakumu S, Onishi M, Mori T. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.
Dig. Dis. Sci. 50 Suppl. 1: S119-S123 (2005).
*
-
Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis.
J. Gastroenterol. Hepatol. 20: 366-370 (2005).
*
-
Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome.
Gastroenterology 80: 72-76 (1981).
-
Moisan J, Camateros P, Thuraisingam T, Marion D, Koohsari H, Martin P, Boghdady ML, Ding A, Gaestel M, Guiot MC, Martin JG, Radzioch D. TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway.
Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L987-L995 (2006).
*
-
Mok CC. Therapeutic options for resistant lupus nephritis.
Semin. Arthritis Rheum. 36: 71-81 (2006).
*
-
Mok CC, To CH, Mak A, Poon WL. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica.
J. Rheumatol. 35: 172-174 (2008).
-
Mok MY, Wong SY, Chan TM, Tang WM, Wong WS, Lau CS. Necrotizing fasciitis in rheumatic diseases.
Lupus 15: 380-383 (2006).
-
Molero Richard X. Chronic pancreatitis.
Gastroenterol. Hepatol. 29 Suppl. 3: 85-90 (2006).
-
Molitch ME, Gillam MP. Lymphocytic hypophysitis.
Horm. Res. 68 Suppl. 5: S145-S150 (2007).
-
Monnet D, Moachon L, Dougados M, Brezin AP. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis.
Nat. Clin. Pract. Rheumatol. 2: 393-397 (2006).
*
-
Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis.
Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 202-214 (2007).
*
-
Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
Am. J. Gastroenterol. 102: 1005-1012 (2007).
*
-
Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis.
Am. J. Gastroenterol. 103: 1944-1951 (2008).
*
-
Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.
Hepatology 46: 1138-1145 (2007).
*
-
Montejo M, Valdivielso A, Suarez MJ, Testillano M, Bustamante J, Gastaca M, Campo M, Errazti G, Perdigo K, Aguirrebengoa K, Gonzalez de Zarate P, Ortiz de Urbina J. Infection after orthotopic liver transplantation: analysis of the first 120 consecutive cases.
Rev. Clin. Esp. 200: 245-251 (2000).
-
Mor E, Yussim A, Chodoff L, Schwartz ME. New immunosuppressive agents for maintenance therapy in organ transplantation.
BioDrugs 8: 469-488 (1997).
-
Mor F. Treatment of autoimmune disease: time for a paradigm shift?
Arch. Immunol. Ther. Exp. (Warsz.) 55: 13-18 (2007).
-
Mor F, Cohen IR. Vaccines to prevent and treat autoimmune diseases.
Int. Arch. Allergy Immunol. 108: 345-349 (1995).
-
Moradinejad MH. Treatment of intractable pulmonary hemorrhage in two patients with childhood systemic lupus erythematosus.
Rheumatol. Int. 29: 1113-1115 (2009).
*
-
Moraes-Fontes MF, Rebelo M, Iris Caramalho, Zelenay S, Bergman ML, Coutinho A, Demengeot J. Steroid treatments in mice do not alter the number and function of regulatory T cells, but amplify cyclophosphamide-induced autoimmune disease.
J. Autoimmun. Apr 10 [Epub ahead of print] (2009).
-
Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
J. Rheumatol. 33: 854-861 (2006).
-
Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis.
Immunol. Lett. 100: 7-13 (2005).
-
Morichika S, Arima T, Nagashima H. Clinical evaluation of autoantibodies to liver cell membrane specific antigen, liver specific lipoprotein, and Tamm-Horsfall glycoprotein in autoimmune chronic active hepatitis.
Gastroenterol. Jpn. 22: 24-33 (1987).
-
Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis.
Nephrol. Dial. Transplant. 22: 2531-2539 (2007).
-
Mosca M, Baldini C, Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus.
Expert Opin. Pharmacother. 8: 873-879 (2007).
-
Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.
Clin. Gastroenterol. Hepatol. 4: 760-765 (2006).
-
Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options?
Drugs 68: 1157-1167 (2008).
-
Mossop H, Davies P, Murphy MS. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
J. Pediatr. Gastroenterol. Nutr. 47: 123-129 (2008).
-
Mottet C, Juillerat P, Gonvers JJ, Froehlich F, Burnand B, Vader JP, Michetti P, Felley C. Pregnancy and Crohn's disease.
Digestion 71: 54-61 (2005).
-
Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, Michetti P, Felley C. Pregnancy and breastfeeding in patients with Crohn's disease.
Digestion 76: 149-160 (2007).
*
-
Moussata D, Nancey S, Flourie B, Bonvoisin SC, Cenni JC, Descos L. Chronic active ulcerative colitis.
Presse. Med. 33: 590-594 (2004).
-
Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.
Clin. Gastroenterol. Hepatol. 2: 309-313 (2004).
*
-
Mrukwa-Kominek E, Rogowska-Godela A, Gierek-Ciaciura S. The influence of anti-inflammatory therapy on the treatment of dry eye syndrome.
Klin. Oczna. 109: 79-84 (2007).
-
Mueller S, Boehme MW, Hofmann WJ, Stremmel W. Extrapulmonary sarcoidosis primarily diagnosed in the liver.
Scand. J. Gastroenterol. 35: 1003-1008 (2000).
*
-
Mueller S, Dubal DB, Josephson SA. A case of paraneoplastic myelopathy associated with the neuromyelitis optica antibody.
Nat. Clin. Pract. Neurol. 4: 284-288 (2008).
-
Mulder CJ, Tytgat GN. Review article: topical corticosteroids in inflammatory bowel disease.
Aliment. Pharmacol. Ther. 7: 125-130 (1993).
-
Muller BA. Urticaria and angioedema: a practical approach.
Am. Fam. Physician 69: 1123-1128 (2004).
*
-
Muller W, Fiebich BL, Stratz T. New treatment options using 5-HT(3) receptor antagonists in rheumatic diseases.
Curr. Top. Med. Chem. 6: 2035-2042 (2006).
-
Muller-Berghaus J, Kemper MJ, Hoppe B, Querfeld U, Muller-Wiefel DE, Morahan G, Schadendorf D, Tenbrock K. The clinical course of steroid-sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism.
Nephrol. Dial. Transplant. 23: 3841-3844 (2008).
-
Mundo J, Peris P, Monegal A, Navasa M, Cervera R, Guaniabens N. Multifocal avascular necrosis after liver transplantation: an unusual presentation of the antiphospholipid syndrome.
Lupus 15: 304-307 (2006).
-
Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, Ihata A, Ueda A, Ohno S, Watanuki Y, Kaneko T, Ishigatsubo Y. Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis.
Tuberculosis (Edinb.) 89: 136-141 (2009).
-
Muraki T, Hamano H, Ochi Y, Arakura N, Takayama M, Komatsu K, Komiyama Y, Kawa S, Uehara T, Kiyosawa K. Corticosteroid-responsive pancreatic cyst found in autoimmune pancreatitis.
J. Gastroenterol. 40: 761-766 (2005).
*
-
Muraki T, Hamano H, Ochi Y, Komatsu K, Komiyama Y, Arakura N, Yoshizawa K, Ota M, Kawa S, Kiyosawa K. Autoimmune pancreatitis and complement activation system.
Pancreas 32: 16-21 (2006).
-
Murakoshi K, Momohara S, Ikari K, Iwamoto T, Kawamura K, Tomatsu T, Iikuni N, Okamoto H. Neglected spontaneous rupture of the Achilles' tendon in patients with systemic lupus erythematosus.
Mod. Rheumatol. 16: 324-326 (2006).
*
-
Muratov V, Ulfgren AK, Engstrom M, Elvin K, Winqvist O, Lofberg R, Lundahl J. Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis.
J. Gastroenterol. 43: 277-282 (2008).
*
-
Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases.
J. Appl. Toxicol. 28: 93-103 (2008).
*
-
Musch E, Andus T, Malek M, Chrissafidou A, Schulz M. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta - an open long-term trial.
Z. Gastroenterol. 45: 1235-1240 (2007).
-
Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, Scalone R. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell reinfusion for severe autoimmune disease.
Am. J. Hematol. 66: 75-79 (2001).
-
Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool.
Eur. J. Gastroenterol. Hepatol. 16: 775-778 (2004).
-
Myrelid P, Svarm S, Andersson P, Almer S, Bodemar G, Olaison G. Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease.
Scand. J. Gastroenterol. 41: 1190-1195 (2006).
*
-
Mysliwiec J, Kretowski A, Stepien A, Oklota M, Kinalska I. Serum Fas in patients with Graves' ophthalmopathy as a marker of activity of the ocular inflammatory infiltration.
Pol. Merkuriusz. Lek. 17: 368-370 (2004).
-
Mysliwiec J, Waligorski D, Nikolajuk A, Gorska M. Soluble CD40 and its ligand CD154 in patients with Graves' ophthalmopathy during combined therapy with corticosteroids and teleradiotherapy.
Adv. Med. Sci. 52: 104-108 (2007).
-
Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis.
Inflamm. Bowel Dis. 10: 251-257 (2004).
*
-
Nagy F, Molnar T, Szepes Z, Farkas K, Nyari T, Lonovics J. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease.
World J. Gastroenterol. 14: 4342-4346 (2008).
*
-
Nakamura T, Nagahori M, Kanai T, Watanabe M. Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis.
Digestion 77 Suppl. 1: S36-S41 (2008).
*
-
Nakase H, Mikami S, Matsuura M, Ueno S, Uza N, Inoue S, Kitamura H, Kasahara K, Yoshino T, Takeda Y, Chiba T. Rescue therapy with tacrolimus for a patient with severe ulcerative colitis refractory to combination leukocytapheresis and high-dose corticosteroid therapy.
Intern. Med. 46: 717-720 (2007).
*
-
Nakayama S, Mukae H, Morisaki T, Sakamoto N, Ohba K, Abe K, Takeshima F, Mizuta Y, Ida H, Ozono Y, Kohno S. Sarcoidosis accompanied by systemic lupus erythematosus and autoimmune hepatitis.
Intern. Med. 46: 1657-1661 (2007).
*
-
Nakazawa T, Ohara H, Sano H, Aoki S, Kobayashi S, Okamoto T, Imai H, Nomura T, Joh T, Itoh M. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis.
Gastrointest. Endosc. 60: 937-944 (2004).
*
-
Naldi L, Rzany B. Psoriasis (chronic plaque).
Clin. Evid. (Online) pii: 1706 (2009).
-
Narain S, Richards HB, Satoh M, Sarmiento M, Davidson R, Shuster J, Sobel E, Hahn P, Reeves WH. Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting.
Arch. Intern. Med. 164: 2435-2441 (2004).
*
-
Narang VS, Fraga C, Kumar N, Shen J, Throm S, Stewart CF, Waters CM. Dexamethasone increases expression and activity of multi-drug resistance transporters at the rat blood-brain barrier.
Am. J. Physiol. Cell Physiol. 295: C440-C450 (2008).
*
-
Nast A, Reytan N, Rosumeck S, Erdmann R, Rzany B. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry.
J. Eur. Acad. Dermatol. Venereol. 22: 1337-1342 (2008).
-
Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration.
J. Gastroenterol. Hepatol. 23: 954-958 (2008).
*
-
Natsuga K, Sawamura D, Homma E, Nomura T, Abe M, Muramatsu R, Mochizuki T, Koike T, Shimizu H. Amicrobial pustulosis associated with IgA nephropathy and Sjogren's syndrome.
J. Am. Acad. Dermatol. 57: 523-526 (2007).
-
Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues.
Am. J. Gastroenterol. 98: S18-S23 (2003).
*
-
Nayar M, Rhodes JM. Management of inflammatory bowel disease.
Postgrad. Med. J. 80: 206-213 (2004).
*
-
Neau D, Bonnet F, Michaud M, Perel Y, Longy-Boursier M, Ragnaud JM, Guillard JM. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases.
Scand. J. Infect. Dis. 30: 115-118 (1998).
-
Neff AG, Turner M, Mutasim DF. Treatment strategies in mucous membrane pemphigoid.
Ther. Clin. Risk. Manag. 4: 617-626 (2008).
-
Nemoto T, Kubota K, Kita J, Shimoda M, Rokkaku K, Tagaya N, Fujiwara T, Sunakawa M. Unusual onset of chronic graft-versus-host disease after adult living-related liver transplantation from a homozygous donor.
Transplantation 75: 733-736 (2003).
-
Nesher G, Breuer GS, Temprano K, Moore TL, Dahan D, Baer A, Alberton J, Izbicki G, Hersch M. Lupus-associated pancreatitis.
Semin. Arthritis Rheum. 35: 260-267 (2006).
*
-
Neuberger J. Liver transplantation for autoimmune liver diseases.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 82-83 (2004). *
-
Neuberger J. Liver transplantation for cholestatic liver disease.
Curr. Treat. Options Gastroenterol. 6: 113-121 (2003).
-
Neuberger J. Recurrence of autoimmune liver diseases after liver transplantation.
Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 47-48. September 12 - 13 (2003). *
-
Neuberger J. Current problems in primary biliary cirrhosis.
Z. Gastroenterol. 31 Suppl. 2: 90-93 (1993).
-
Neuberger J. Transplantation for autoimmune hepatitis.
Semin. Liver Dis. 22: 379-386 (2002).
-
Neuberger J, Jothimani D. Long-term immunosuppression for prevention of nonviral disease recurrence.
Transplant. Proc. 37: 1671-1674 (2005).
*
-
Neurath MF. IL-23: a master regulator in Crohn disease.
Nat. Med. 13: 26-28 (2007).
*
-
Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease.
Gut 44: 625-628 (1999).
*
-
Neveu I, Labrune P, Huguet P, Musset D, Chaussain JL, Odievre M. Sclerosing cholangitis revealing histiocytosis X.
Arch. Fr. Pediatr. 47: 197-199 (1990).
-
Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP; Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
N. Engl. J. Med. 356: 663-675 (2007).
*
-
Newby E, Sawczenko A, Thomas A, Wilson D. Interventions for growth failure in childhood Crohn's disease.
Cochrane Database Syst. Rev. 3: CD003873 (2005).
*
-
Newman AJ, Singer NG. Critical care myopathy in a child.
J. Clin. Rheumatol. 11: 93-97 (2005).
-
Newton JR, Ah-See KW. A review of nasal polyposis.
Ther. Clin. Risk Manag. 4: 507-512 (2008).
-
Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis.
Inflamm. Bowel Dis. 15: 935-950 (2009).
-
Ng SC, Kamm MA. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.
Aliment. Pharmacol. Ther. 28: 815-829 (2008).
*
-
Nguyen DQ, Raman VS, Twomey JM, Luthert P. Keratectasia as a presentation of surgically induced necrotizing sclerokeratitis (SINS).
Eye Contact Lens 33: 332-333 (2007).
-
Nguyen H, Bakshi AK, Kashyap AS, Borum ML. Corticosteroid side effects and counseling in patients with inflammatory bowel disease.
J. Clin. Gastroenterol. Apr 18 [Epub ahead of print] (2009).
-
Nguyen HD, Bakshi AK, Borum ML. The frequency of osteoporosis screening in men with inflammatory bowel disease.
Am. J. Mens Health Feb 2 [Epub ahead of print] (2009).
-
Nielsen AA, Jorgensen LG, Nielsen JN, Eivindson M, Gronbaek H, Vind I, Hougaard DM, Skogstrand K, Jensen S, Munkholm P, Brandslund I, Hey H. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids.
Aliment. Pharmacol. Ther. 22: 1121-1128 (2005).
*
-
Nielsen OH, Andreasson B, Bondesen S, Jacobsen O, Jarnum S. Pregnancy in Crohn's disease.
Scand. J. Gastroenterol. 19: 724-732 (1984).
-
Nijs J, Macken E, Struyf N, Gys T, Bergmans G, Pelckmans P. Autoimmune pancreatitis with evolution to cholangitis: a case report.
Acta Gastroenterol. Belg. 67: 346-350 (2004).
-
Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation.
J. Hepatol. 21: 866-871 (1994).
-
Nikkels AF, Gillard P, Pierard GE. Etanercept in therapy multiresistant overlapping pityriasis lichenoides.
J. Drugs Dermatol. 7: 990-992 (2008).
-
Nikolopoulou VN, Gogos CA, Zoumbos NC. The in vitro effect of corticosteroids on T-lymphocyte subpopulations in patients with ulcerative colitis.
Z. Gastroenterol. 28: 101-103 (1990).
-
Nikolov NP, Smith JA, Patronas NJ, Illei GG. Diagnosis and treatment of vasculitis of the central nervous system in a patient with systemic lupus erythematosus.
Nat. Clin. Pract. Rheumatol. 2: 627-633 (2006).
*
-
Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
Ann. Rheum. Dis. Nov 19 [Epub ahead of print] (2008).
*
-
Nishiyama R, Kanai T, Abe J, Hara R, Watahiki Y, Sakaguchi T, Nakamura S. Hepatocellular carcinoma associated with autoimmune hepatitis.
J. Hepatobiliary Pancreat. Surg. 11: 215-219 (2004).
-
Nissen KR, Fledelius HC, Nissen SM, Pedersen FK, Zak MS. Anti-TNFalpha treatment of juvenile uveitis.
Ugeskr. Laeger. 169: 1309-1312 (2007).
-
No authors listed. Beclometasone Oral - DOR BioPharma: Beclomethasone Oral - DOR BioPharma.
Drugs R. D. 9: 271-276 (2008).
-
No authors listed. Autoimmune pancreatitis.
Arkh. Patol. 70: 46-51 (2008).
-
Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease.
Inflamm. Bowel Dis. 14: 1683-1687 (2008).
*
-
Nogid A, Pham DQ. Role of abatacept in the management of rheumatoid arthritis.
Clin. Ther. 28: 1764-1778 (2006).
-
Nordstrom DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, Ilva K, Kaipiainen-Seppanen O, Malmi T, Yla-Kerttula T, Honkanen V. Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.
Rheumatol. Int. 26: 741-748 (2006).
*
-
Nos Mateu P. Locally acting corticosteroids in inflammatory bowel disease. Are they effective? Are they really less toxic?
Gastroenterol. Hepatol. 31 Suppl. 3: 16-21 (2008).
-
Nos P, Bastida G, Garrigues V, Calvo F, Ponce M, Maroto N, Ponce J. Factors influencing the decision to administer systemic corticosteroids in Crohn's disease.
Gastroenterol. Hepatol. 27: 444-449 (2004).
-
Nos P, Garrigues V, Bastida G, Maroto N, Ponce M, Ponce J. Outcome of patients with nonstenotic, nonfistulizing Crohn's disease.
Dig. Dis. Sci. 49: 1771-1776 (2004).
*
-
Nosti-Escanilla MP, Pena AS. NF-kappa B and inflammatory intestinal diseases.
Rev. Esp. Enferm. Dig. 90: 113-119 (1998).
-
Nozawa T, Hara R, Kinoshita J, Sano F, Miyamae T, Imagawa T, Mori M, Hirokado M, Takahashi K, Inayama Y, Yokota S. Infliximab for a girl with refractory pyoderma gangrenosum.
Nihon Rinsho Meneki Gakkai Kaishi 31: 454-459 (2008).
-
Nunes H, Bouvry D, Soler P, Valeyre D. Sarcoidosis.
Orphanet J. Rare Dis. 2: 46 (2007).
*
-
Nunes H, Soler P, Valeyre D. Pulmonary sarcoidosis.
Allergy 60: 565-582 (2005).
*
-
O'Beirne J, Holmes M, Agarwal B, Bouloux P, Shaw S, Patch D, Burroughs A. Adrenal insufficiency in liver disease - what is the evidence?
J. Hepatol. 47: 418-423 (2007).
*
-
O'Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis.
Hepatology 48: 550-556 (2008).
*
-
O'Connell TX, Nathan LS, Satmary WA, Goldstein AT. Non-neoplastic epithelial disorders of the vulva.
Am. Fam. Physician 77: 321-326 (2008).
*
-
O'Reilly R, Fitzpatrick P, Leen G, Elnazir B, Greally P. Severe bone demineralisation is associated with higher mortality in children with cystic fibrosis.
Ir. Med. J. 102: 47-49 (2009).
-
O'Shea FD, Haroon N, Salonen DC, Inman RD. Clinical and radiographic response to a local infliximab injection in a patient with chronic sacroiliitis.
Nat. Clin. Pract. Rheumatol. 5: 171-173 (2009).
-
O’Shea R, McCullough AJ. Chapter 25. Immunomodulation therapy for alcoholic hepatitis: rationale and efficacy.
In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 323-336 (2007). *
-
O'Sullivan M. Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease'. Nutrition in Crohn's disease.
Proc. Nutr. Soc. 68: 127-134 (2009).
*
-
O'Sullivan M, O'Morain C. Nutrition in inflammatory bowel disease.
Best Pract. Res. Clin. Gastroenterol. 20: 561-573 (2006).
-
O'Sullivan MA, O'Morain CA. Nutritional therapy in Crohn's disease.
Inflamm. Bowel Dis. 4: 45-53 (1998).
*
-
Oberholzer J, Al-Saghier M, Kneteman NM. Steroid avoidance in liver transplantation.
Can. J. Gastroenterol. 18 Suppl. C: 5C-11C (2004).
-
Oeff MK, Seltmann H, Hiroi N, Nastos A, Makrantonaki E, Bornstein SR, Zouboulis CC. Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes.
Dermatology 213: 266 (2006).
-
Oender K, Lanschuetzer C, Laimer M, Klausegger A, Paulweber B, Kofler B, Hintner H, Bauer J. Introducing a fast and simple PCR-RFLP analysis for the detection of mutant thiopurine S-methyltransferase alleles TPMT*3A and TPMT*3C.
J. Eur. Acad. Dermatol. Venereol. 20: 396-400 (2006).
-
Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease.
Curr. Pharm. Des. 9: 1107-1113 (2003).
-
Ogawa Y, Mukai M, Gotoh H, Tanaka S, Takada A, Takenouchi T. A case of thrombotic thrombocytopenic purpura with systemic lupus erythematosus.
Nihon Rinsho Meneki Gakkai Kaishi 29: 342-347 (2006).
-
Ogawa Y, Tominaga T, Ikeda H. Neurosarcoidosis manifesting as tremor of the extremities and severe hypopituitarism: case report.
Neurol. Med. Chir. (Tokyo) 48: 314-317 (2008).
-
Oh DC, Ng TM, Ho J, Leong KP. Systemic lupus erythematosus with concurrent protein-losing enteropathy and primary sclerosing cholangitis: a unique association.
Lupus 15: 102-104 (2006).
-
Oh HE, Chetty R. Eosinophilic gastroenteritis: a review.
J. Gastroenterol. 43: 741-750 (2008).
*
-
Oh WM, Hwang IN, Son HH, Hwang YC. Rapid periapical bone destruction during endodontic treatment of a patient with rheumatoid arthritis.
J. Endod. 34: 1261-1263 (2008).
-
Ohara H, Nakazawa T, Ando T, Joh T. Systemic extrapancreatic lesions associated with autoimmune pancreatitis.
J. Gastroenterol. 42 Suppl. 18: 15-21 (2007).
*
-
Ohara M, Takahashi H, Suzuki C, Yamamoto M, Naishiro Y, Yamamoto H, Saga K, Shinomura Y, Imai K. A case of lupus erythematosus profundus followed by systemic lupus erythematosus presenting with severe intestinal involvement.
Nihon Rinsho Meneki Gakkai Kaishi 30: 48-54 (2007).
-
Oikonomidou O, Vlachoyiannopoulos PG, Kominakis A, Kalofoutis A, Moutsopoulos HM, Moutsatsou P. Glucocorticoid receptor, nuclear factor kappaB, activator protein-1 and C-Jun N-terminal kinase in systemic lupus erythematosus patients.
Neuroimmunomodulation 13: 194-204 (2007).
-
Okada H, Makidono C, Takenaka R, Hiraoka S, Fujiwara A, Kato J, Kawahara Y, Kawamoto H, Mizuno M, Shiratori Y. Therapeutic efficacy of leukocytapheresis in a pregnant woman with severe active ulcerative colitis.
Digestion 74: 15-18 (2006).
*
-
Okada H, Takenaka R, Hiraoka S, Makidono C, Hori SI, Kato J, Okazaki H, Kawamoto H, Mizuno M, Shiratori Y. Centrifugal leukocytapheresis therapy for ulcerative colitis without concurrent corticosteroid administration.
Ther. Apher. Dial. 10: 242-246 (2006).
*
-
Okamoto H, Koizumi K, Kamitsuji S, Inoue E, Hara M, Tomatsu T, Kamatani N, Yamanaka H. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort.
J. Rheumatol. 34: 964-968 (2007).
-
Olesen M, Eriksson S, Bohr J, Jarnerot G, Tysk C. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients.
Gut 53: 536-541 (2004).
*
-
Oliveira MC, Oliveira BM, Murao M, Vieira ZM, Gresta LT, Viana MB. Clinical course of autoimmune hemolytic anemia: an observational study.
J. Pediatr. (Rio J.) 82: 58-62 (2006).
-
Olivieri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome.
Expert Opin. Investig. Drugs 15: 1229-1233 (2006).
-
Olowu WA. Lupus nephropathy and cardiopulmonary and hepatic dysfunctions in a child.
Pediatr. Nephrol. 21: 1318-1322 (2006).
*
-
Olsen NJ. Tailoring arthritis therapy in the wake of the NSAID crisis.
N. Engl. J. Med. 352: 2578-2580 (2005).
*
-
Omagari K. Autoimmune cholangitis: is it an antimitochondrial antibody negative primary biliary cirrhosis?
Acta Medica Nagasakiensia 44: 11-14 (1999). *
-
Oo YH, Neuberger J. Options for treatment of primary biliary cirrhosis.
Drugs 64: 2261-2271 (2004).
-
Ooi CJ, Sands BE. Treatment of ulcerative colitis.
Curr. Opin. Gastroenterol. 15: 298 (1999).
-
Ooi CY, Day AS, Jackson R, Bohane TD, Tobias V, Lemberg DA. Eosinophilic esophagitis in children with celiac disease.
J. Gastroenterol. Hepatol. 23: 1144-1148 (2008).
*
-
Openshaw H, Nash RA, McSweeney PA. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review.
Biol. Blood Marrow Transplant. 8: 233-248 (2002).
-
Orenstein SR. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease.
Curr. Gastroenterol. Rep. 9: 205-207 (2007).
-
Orts Costa J, Zuniga Cabrera A, Alarcon Torres I. Autoimmune hepatitis.
An. Med. Interna. 21: 340-354 (2004).
-
Osaki R, Andoh A, Tsujikawa T, Ogawa A, Koizumi Y, Nakahara T, Hata K, Sasaki M, Saito Y, Fujiyama Y. Acute cytomegalovirus infection superimposed on corticosteroid-naive ulcerative colitis.
Intern. Med. 47: 1341-1344 (2008).
*
-
Osina VA, Kuz'mina TN. Enteral nutrition in therapy of gastrointestinal diseases (according to materials of the European Association of Parenteral and Enteral Nutrition).
Eksp. Klin. Gastroenterol. 3: 92-98, 129 (2007).
-
Otley A, Steinhart A, Otley A. Budesonide for induction of remission in Crohn's disease.
Cochrane Database Syst. Rev. 4: CD000296 (2005).
*
-
Ovadia S, Dror I, Zubkov T, Tanay A, Levy D, Zandman-Goddard G. Churg-Strauss syndrome: a rare presentation with otological and pericardial manifestations: case report and review of the literature.
Clin. Rheumatol. 28 Suppl. 1: S35-S38 (2009).
-
Owczarek D, Cibor D, Szczepanek M, Mach T. Biological therapy of inflammatory bowel disease.
Pol. Arch. Med. Wewn. 119: 84-88 (2009).
*
-
Ozdil S, Akyuz F, Pinarbasi B, Demir K, Karaca C, Boztas G, Kaymakoglu S, Mungan Z, Besisik F, Cakaloglu Y, Okten A. Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission?).
Hepatogastroenterology 51: 768-770 (2004).
-
Ozer I, Birol Bostanci E, Ozogul YB, Ulker A, Temucin T, Akoglu M. Diffuse colorectal angiodysplasia misdiagnosed preoperatively as ulcerative colitis in a child: report of a case.
Surg. Today 38: 731-733 (2008).
-
Packer CD, Hornick TR, Augustine SA. Fatal hemolytic anemia associated with metformin: a case report.
J. Med. Case Reports 2: 300 (2008).
*
-
Padman R, McColley SA, Miller DP, Konstan MW, Morgan WJ, Schechter MS, Ren CL, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function.
Pediatrics 119: e531-e537 (2007).
*
-
Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease.
Inflamm. Bowel Dis. 13: 416-423 (2007).
*
-
Page AV, Liles WC. Tumor necrosis factor-alpha inhibitor-induced lupus-like syndrome presenting as fever of unknown origin in a liver transplant recipient: case report and concise review of the literature.
Transplant. Proc. 40: 1768-1770 (2008).
-
Page M. Nursing care and management of patients with sarcoidosis.
Br. J. Nurs. 17: 252-257 (2008).
-
Pagnoux C. Plasma exchange for systemic lupus erythematosus.
Transfus. Apher. Sci. 36: 187-193 (2007).
-
Pagnoux C. Pregnancy and vasculitides.
Presse. Med. 37: 1657-1665 (2008).
-
Pagnoux C. Wegener's granulomatosis and microscopic polyangiitis.
Rev. Prat. 58: 522-532 (2008).
-
Pagnoux C, Chironi G, Simon A, Guillevin L. Atherosclerosis in ANCA-associated vasculitides.
Ann. N. Y. Acad. Sci. 1107: 11-21 (2007).
*
-
Pagnoux C, Cohen P, Guillevin L. Vasculitides secondary to infections.
Clin. Exp. Rheumatol. 24: S71-S81 (2006).
-
Pagnoux C, Hayem G, Roux F, Palazzo E, Meyer O. Sclerosing cholangitis as a complication of Langerhans' cell histiocytosis.
Rev. Med. Interne. 24: 324-327 (2003).
-
Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L; the French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
N. Engl. J. Med. 359: 2790-2803 (2008).
*
-
Pai SY, Levy O, Jabara HH, Glickman JN, Stoler-Barak L, Sachs J, Nurko S, Orange JS, Geha RS. Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency.
J. Allergy Clin. Immunol. 122: 1113-1118.e1 (2008).
*
-
Palazzi C, D'Angelo S, Olivieri I. Hepatitis C virus-related arthritis.
Autoimmun. Rev. 8: 48-51 (2008).
-
Palermo M, Marazzi MG, Hughes BA, Stewart PM, Clayton PT, Shackleton CH. Human delta(4)-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism.
Steroids 73: 417-423 (2008).
-
Palmen MJ, Dieleman LA, Soesatyo M, Pena AS, Meuwissen SG, van Rees EP. Effects of local budesonide treatment on the cell-mediated immune response in acute and relapsing colitis in rats.
Dig. Dis. Sci. 43: 2518-2525 (1998).
*
-
Palmisano A, Vaglio A. Chronic periaortitis: a fibro-inflammatory disorder.
Best Pract. Res. Clin. Rheumatol. 23: 339-353 (2009).
-
Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximise remission and minimise corticosteroid dependence in patients with inflammatory bowel disease: a time bound approach.
Aliment. Pharmacol. Ther. 28: 674-688 (2008).
*
-
Panes J, Gomollon F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a focus on biologics.
Drugs 67: 2511-2537 (2007).
-
Panes J, Guilera M, Ginard D, Hinojosa J, Gonzalez-Carro P, Gonzalez-Lara V, Varea V, Domenech E, Badia X. Treatment cost of ulcerative colitis. Is apheresis with Adacolumn((R)) cost-effective?
Dig. Liver Dis. 39: 617-625 (2007).
-
Panzer S. Novel approaches in management of immune thrombocytopenia.
Thromb. Res. 123 Suppl. 2: S51-S55 (2009).
-
Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Loane J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
Am. J. Gastroenterol. 100: 75-79 (2005).
*
-
Papaioannou A, Ferko NC, Adachi JD. All patients with inflammatory bowel disease should have bone density assessment: pro.
Inflamm. Bowel Dis. 7: 158-162 (2001).
*
-
Papi C, Festa V, Leandro G, Moretti A, Tanga M, Koch M, Capurso L. Long-term outcome of Crohn's disease following corticosteroid-induced remission.
Am. J. Gastroenterol. 102: 814-819 (2007).
*
-
Paplinska M, Grubek-Jaworska H, Chazan R. Role of eotaxin in the pathophysiology of asthma.
Pneumonol. Alergol. Pol. 75: 180-185 (2007).
-
Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis.
J. Cutan. Med. Surg. 11: 57-66 (2007).
-
Papp KA, Toth D, Rosoph L. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
BMC Dermatol. 6: 9 (2006).
*
-
Parambil JG, Yi ES, Ryu JH. Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases.
Respirology 14: 443-448 (2009).
-
Pardi DS, Loftus EV Jr, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update.
Drugs Aging 19: 355-363 (2002).
-
Paredes J, Barrachina M, Roman J, Moreno-Osset E. Joint disease in inflammatory bowel disease.
Gastroenterol. Hepatol. 28: 240-249 (2005).
-
Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, Lee TY, Seo DW, Lee SK. Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis.
Gastroenterology 134: 440-446 (2008).
*
-
Parkes M, Booth JC, Pillai G, Mee AS. Do steroids help jaundice caused by primary sclerosing cholangitis?
J. Clin. Gastroenterol. 33: 319-322 (2001).
-
Parlak E, Ulker A, Alkim C, Ozderin Y, Disibeyaz S, Tunc B, Dagli U. The course of colonic disease in ulcerative colitis patients with primary sclerosing cholangitis.
Turk. J. Gastroenterol. 13: 134-138 (2002).
*
-
Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O, Muftuoglu E. A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab.
J. Thromb. Thrombolysis 27: 220-222 (2009).
-
Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors?
BioDrugs 19: 211-231 (2005).
-
Patel M, Shah T, Amin A. Therapeutic opportunities in colon-specific drug-delivery systems.
Crit. Rev. Ther. Drug Carrier Syst. 24: 147-202 (2007).
-
Patton T, Korman N. Role of methotrexate in the treatment of bullous pemphigoid in the elderly.
Drugs Aging 25: 623-629 (2008).
-
Pavlovic-Calic N. Ulcerative colitis and Crohn's disease.
Med. Arh. 57 (1 Suppl. 2): 85-86 (2003).
-
Pavy S, Allanore Y, Kahan A. Spondylarthropathies and anti-TNFalpha drugs.
Rev. Med. Interne. 26: 717-724 (2005).
-
Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Gawronska-Szklarz B. Association of cytokine gene polymorphisms and the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone.
Int. Immunopharmacol. 6: 351-357 (2006).
-
Pawlik A, Czerny B, Dabrowska-Zamojcin E, Gornik W, Poziomkowska I, Gawronska-Szklarz B, Herczynska M. The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone.
Pol. Arch. Med. Wewn. 114: 843-847 (2005).
-
Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis.
Int. J. Clin. Pharmacol. Ther. 42: 496-503 (2004).
-
Pawlowska J, Kalicinski P, Jankowska I, Teisseyre M, Teisseyre J, Kaminska D, Nachulewicz P, Markiewicz-Kijewska M, Socha J. Living related liver transplantation - analysis of the first 102 cases.
Med. Wieku. Rozwoj. XI: 93-96 (2007).
-
Payne DN, Adcock IM. Molecular mechanisms of corticosteroid actions.
Paediatr. Respir. Rev. 2: 145-150 (2001).
-
Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.
Ann. N. Y. Acad. Sci. 1068: 543-556 (2006).
*
-
Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB Jr, Feldman SR. Psoriasis treatment in the United States at the end of the 20th century.
Int. J. Dermatol. 45: 370-374 (2006).
*
-
Pearce DJ, Thomas CG, Fleischer AB Jr, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection.
Dermatol. Nurs. 16: 421-428, 432 (2004).
-
Peeters GJ, Cremers CW, Pinckers AJ, Hoefnagels WH. Atypical Cogan's syndrome: an autoimmune disease?
Ann. Otol. Rhinol. Laryngol. 95: 173-175 (1986).
-
Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soule JC. Infliximab treatment for symptomatic Crohn's disease strictures.
Aliment. Pharmacol. Ther. 29: 279-285 (2009).
*
-
Pelletier G, Roulot D, Davion T, Masliah C, Causse X, Oberti F, Raabe JJ, Van Lemmens C, Labadie H, Serfaty L; URSOMAF Group. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice.
Hepatology 37: 887-892 (2003).
*
-
Pena-Sagredo JL, Miro J, Aguayo F, Alvarez C, Berciano J. Primary Sjogren syndrome with involvement of the nervous system. Description of 4 cases.
Neurologia 8: 231-234 (1993).
-
Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis.
J. Hepatol. 14: 325-331 (1992).
-
Pereira J. Comparative analyses between tuberculids and extrapulmonary tuberculosis - another face for Mycobacterium tuberculosis.
Rev. Port. Pneumol. 12: S31-S32 (2006).
-
Perente I, Utine CA, Cakir H, Kaya V, Tutkun IT, Yilmaz OF. Management of ocular complications of Vogt-Koyanagi-Harada syndrome.
Int. Ophthalmol. 29: 33-37 (2009).
*
-
Perini P, Calabrese M, Rinaldi L, Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy.
Expert Opin. Drug Saf. 6: 183-190 (2007).
-
Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation.
Clin. Exp. Immunol. 139: 2-10 (2005).
*
-
Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BA, Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT. Changes in lipid profile during infliximab treatment and corticosteroid therapy in rheumatoid arthritis.
Ann. Rheum. Dis. 66: 958-961 (2007).
*
-
Petkov T, Pehlivanov G, Grozdev I, Kavaklieva S, Tsankov N. Toxic epidermal necrolysis as a dermatological manifestation of drug hypersensitivity syndrome.
Eur. J. Dermatol. 17: 422-427 (2007).
-
Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
Arthritis Rheum. 48: 166-173 (2003).
*
-
Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
Cleve. Clin. J. Med. 69 Suppl. 1: SI31-SI39 (2002).
-
Peuvrel L, Barbarot S, Gagey-Caron V, Tessier MH, Cassagnau E, Stalder JF. Pyodermatitis-pyostomatitis vegetans with nasal involvement.
Ann. Dermatol. Venereol. 135: 753-756 (2008).
-
Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters T, Leleiko N, Hyams J. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms.
J. Pediatr. Gastroenterol. Nutr. 48: 168-174 (2009).
-
Pham CQ, Efros CB, Berardi RR. Cyclosporine for severe ulcerative colitis.
Ann. Pharmacother. 40: 96-101 (2006).
-
Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Ann. Surg. Oncol. 15: 3014-3021 (2008).
*
-
Phillips K, Aliprantis A, Coblyn J. Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis.
Drugs Aging 23: 773-779 (2006).
-
Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis - a randomised clinical trial?
J. Hepatol. 44: 784-790 (2006).
*
-
Pica R, Paoluzi OA, Iacopini F, Marcheggiano A, Crispino P, Rivera M, Bella A, Consolazio A, Paoluzi P. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis.
Inflamm. Bowel Dis. 10: 731-736 (2004).
*
-
Picciotto A, Gesu GP, Schito GC, Testa R, Varagona G, Celle G. Antimycobacterial chemotherapy in inflammatory bowel disease.
Biomed. Pharmacother. 43: 141-143 (1989).
-
Picco MF. Everything old is new again? A fresh look at corticosteroids in ulcerative colitis.
Am. J. Gastroenterol. 103: 2517-2518 (2008).
-
Picco MF, Krishna M, Cangemi JR, Shelton D. Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis.
Inflamm. Bowel Dis. 12: 537-542 (2006).
*
-
Pickartz T, Pickartz H, Lochs H, Ockenga J. Overlap syndrome of autoimmune pancreatitis and cholangitis associated with secondary Sjogren's syndrome.
Eur. J. Gastroenterol. Hepatol. 16: 1295-1299 (2004).
-
Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease.
World J. Gastroenterol. 12: 3657-3667 (2006).
*
-
Pietruszewska W, Olejniczak I, Durko T, Mlynarski W. Role of IFN-gamma and TNF-alpha in etiology of nasal polyps - initial studies.
Otolaryngol. Pol. 62: 54-58 (2008).
-
Pietszkowski NC, Carvalho GA, Souza HN, Werka CR Jr, Borazo LA, Graf H, Carvalho M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune disease induced by propylthiouracil.
Arq. Bras. Endocrinol. Metabol. 51: 136-141 (2007).
-
Pihet M, Carrere J, Cimon B, Chabasse D, Delhaes L, Symoens F, Bouchara JP. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis - a review.
Med. Mycol. 47: 387-397 (2009).
*
-
Pimentel-Nunes P, Dinis-Ribeiro M, Magro F. Systematic review on drug and diet-induced endoscopic remission in Crohn's disease.
Eur. J. Gastroenterol. Hepatol. 21: 491-503 (2009).
-
Pinna AL, Atzori L, Ferreli C, Aste N. Cutaneous Crohn disease in a child.
Pediatr. Dermatol. 23: 49-52 (2006).
*
-
Piquet MA, Gloro R, Justum AM, Reimund JM. Nutritional therapy in inflammatory bowel disease.
Gastroenterol. Clin. Biol. 30: 262-271 (2006).
-
Pishori T, Qureshi AH. Post-colectomy peristomal pyoderma gangrenosum.
J. Coll. Physicians Surg. Pak. 15: 121-122 (2005).
-
Place E, Wenzel JE, Arumugam R, Belani K, Messinger Y. Successful plasmapheresis for extreme hyperbilirubinemia caused by acute Epstein-Barr virus.
J. Pediatr. Hematol. Oncol. 29: 323-326 (2007).
-
Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
Gastroenterology 133: 1414-1422 (2007).
*
-
Plevy SE. Corticosteroid-sparing treatments in patients with Crohn's disease.
Am. J. Gastroenterol. 97: 1607-1617 (2002).
*
-
Pleyer U, Dutescu M. Sympathetic ophthalmia.
Ophthalmologe 106: 167-176 (2009).
-
Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease.
BioDrugs 21: 125-132 (2007).
-
Poindexter G, Morrell DS. Anogenital pruritus: lichen sclerosus in children.
Pediatr. Ann. 36: 785-791 (2007).
-
Polat M, Lenk N, Yalcin B, Gur G, Tamer E, Artuz F, Alli N. Efficacy of erythromycin for psoriasis vulgaris.
Clin. Exp. Dermatol. 32: 295-297 (2007).
*
-
Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus-(FK 506) based immunosuppression in severe systemic lupus erythematosus.
Clin. Nephrol. 62: 49-53 (2004).
-
Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease.
Am. J. Gastroenterol. 93: 1483-1490 (1998).
*
-
Polzer K, Soleiman A, Baum W, Axmann R, Distler J, Redlich K, Kilian A, Kronke G, Schett G, Zwerina J. Selective p38MAPK isoform expression and activation in ANCA-associated crescentic glomerulonephritis: role of p38MAPK alpha.
Ann. Rheum. Dis. 67: 602-608 (2008).
-
Pongratz D. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
J. Neurol. 253 Suppl. 5: v64-v65 (2006).
-
Pooler PA, Duane WC. Effects of bile acid administration on bile acid synthesis and its circadian rhythm in man.
Hepatology 8: 1140-1146 (1988).
-
Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
J. Rheumatol. 36: 724-730 (2009).
-
Poppers DM, Scherl EJ. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.
Inflamm. Bowel Dis. 14: 106-113 (2008).
*
-
Porcelijn L, Huiskes E, Maatman R, de Kreuk A, de Haas M. Acquired Glanzmann's thrombasthenia caused by glycoprotein IIb/IIIa autoantibodies of the immunoglobulin G1 (IgG1), IgG2 or IgG4 subclass: a study in six cases.
Vox. Sang. 95: 324-330 (2008).
-
Porta C, Caporali R, Montecucco C. Autoimmunity in thrombotic thrombocytopenic purpura.
Semin. Thromb. Hemost. 31: 633-640 (2005).
-
Porta G. Autoimmune hepatitis.
J. Pediatr. (Rio. J.) 76: S181-S186 (2000).
*
-
Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy.
World J. Gastroenterol. 11: 7-16 (2005).
*
-
Poupon R. Primary biliary cirrhosis: from ursodeoxycholic acid towards targeting strategies for therapy.
Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 63 (2006). *
-
Poupon R. Primary biliary cirrhosis: clinical aspects.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 62-63 (2005). *
-
Poupon R. Treatment of primary biliary cirrhosis and overlap syndromes: current standards.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 77-78 (2004). *
-
Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases.
J. Hepatol. 32: S129-S140 (2000).
-
Poupon R, Poupon RE. Treatment of primary biliary cirrhosis.
Best Pract. Res. Clin. Gastroenterol. 14: 615-628 (2000).
*
-
Power WJ, Rodriguez A, Pedroza-Seres M, Foster CS. Outcomes in anterior uveitis associated with the HLA-B27 haplotype.
Ophthalmology 105: 1646-1651 (1998).
*
-
Pozler O, Maly J, Bonova O, Dedek P, Fruhauf P, Havlickova A, Janatova T, Jimramovsky F, Klimova L, Klusacek D, Kocourkova D, Kolek A, Kotalova R, Marx D, Nevoral J, Petro R, Petru O, Plasilova I, Seidl Z, Sekyrova I, Semendak N, Schreierova I, et al. Incidence of Crohn disease in the Czech Republic in the years 1990 to 2001 and assessment of pediatric population with inflammatory bowel disease.
J. Pediatr. Gastroenterol. Nutr. 42: 186-189 (2006).
*
-
Pozzi C. Treatment of IgA nephropathy with chronic renal failure.
G. Ital. Nefrol. 25 Suppl. 44: 83-87 (2008).
-
Prajapati DN, Kim JP, Spinelli KS, Sudakoff G, Stewart ET, Komorowski RA, Telford GL, Binion DG. Case report: "popcorn" dystrophic ileal calcification in a patient with Crohn's disease.
Inflamm. Bowel Dis. 9: 25-27 (2003).
*
-
Prajapati DN, Newcomer JR, Emmons J, Abu-Hajir M, Binion DG. Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin.
Inflamm. Bowel Dis. 8: 192-195 (2002).
*
-
Prall RT, Lindor KD, Wiesner RH, LaRusso NF. Current therapies and clinical controversies in the management of primary sclerosing cholangitis.
Curr. Gastroenterol. Rep. 2: 99-103 (2000).
-
Prantera C, Scribano ML, Berto E, Zannoni F. Antibiotic use in Crohn's disease: why and how?
BioDrugs 8: 293-306 (1997).
-
Pranzatelli MR, Tate ED, Hoefgen ER, Swan JA, Colliver JA. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.
Cytokine 44: 26-32 (2008).
-
Pras E, Neumann R, Zandman-Goddard G, Levy Y, Assia EI, Shoenfeld Y, Langevitz P. Intraocular inflammation in autoimmune diseases.
Semin. Arthritis Rheum. 34: 602-609 (2004).
*
-
Prasad R, Ibanez D, Gladman D, Urowitz M. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus.
Lupus 15: 285-291 (2006).
-
Prescott WA Jr, Johnson CE. Antiinflammatory therapies for cystic fibrosis: past, present, and future.
Pharmacotherapy 25: 555-573 (2005).
-
Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis.
Cochrane Database Syst. Rev. 2: CD003778 (2005).
*
-
Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.
Ann. Rheum. Dis. 63: 318-320 (2004).
*
-
Prodanovic EM, Korman NJ. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
J. Dermatolog. Treat. 19: 1-3 (2008).
-
Prpic-Massari L, Kastelan M, Brajac I, Cabrijan L, Zamolo G, Massari D. Bowel-associated dermatosis-arthritis syndrome in a patient with appendicitis.
Med. Sci. Monit. 13: CS97-CS100 (2007).
*
-
Puebla Maestu A, Martin-Lorente JL, Lopez-Morante A, Garcia-Moran S, Yuguero Del Moral L, Arauzo Gonzalez A. Ulcerative colitis associated with idiopathic thrombocytopenic purpura.
Gastroenterol. Hepatol. 26: 545-548 (2003).
-
Puechal X. Non antibiotic treatments of Lyme borreliosis.
Med. Mal. Infect. 37: 473-478 (2007).
-
Pulitano C, Aldrighetti L, Arru M, Finazzi R, Soldini L, Catena M, Ferla G. Prospective randomized study of the benefits of preoperative corticosteroid administration on hepatic ischemia-reperfusion injury and cytokine response in patients undergoing hepatic resection.
HPB (Oxford) 9: 183-189 (2007).
*
-
Pulsatelli L, Dolzani P, Silvestri T, De Giorgio R, Salvarani C, Macchioni P, Frizziero L, Meliconi R. Synovial expression of vasoactive intestinal peptide in polymyalgia rheumatica.
Clin. Exp. Rheumatol. 24: 562-566 (2006).
-
Punati J, Markowitz J, Lerer T, Hyams J, Kugathasan S, Griffiths A, Otley A, Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, Keljo D, Crandall W; Pediatric IBD Collaborative Research Group. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
Inflamm. Bowel Dis. 14: 949-954 (2008).
-
Qing Y, Zhou JG, Yuan G. Systemic lupus erythematosus presenting as hypoglycaemia with insulin receptor antibodies and insulin autoantibodies.
Lupus 18: 457-459 (2009).
-
Quallich LG, Greenson J, Haftel HM, Fontana RJ. Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.
BMC Gastroenterol. 1: 8 (2001).
*
-
Queiro R, Torre JC, Belzunegui J, González C, De Dios JR, Unanue F, Figueroa M. Clinical features and predictive factors in psoriatic arthritis-related uveitis.
Semin. Arthritis Rheum. 31: 264-270 (2002).
*
-
Quiniou C, Sapieha P, Lahaie I, Hou X, Brault S, Beauchamp M, Leduc M, Rihakova L, Joyal JS, Nadeau S, Heveker N, Lubell W, Sennlaub F, Gobeil F Jr, Miller G, Pshezhetsky AV, Chemtob S. Development of a novel noncompetitive antagonist of IL-1 receptor.
J. Immunol. 180: 6977-6987 (2008).
*
-
Quondamcarlo C, Valentini G, Ruggeri M, Forlini G, Fenderico P, Rossi Z. Campylobacter jejuni enterocolitis presenting as inflammatory bowel disease.
Tech. Coloproctol. 7: 173-177 (2003).
-
Radford-Smith G. Ulcerative colitis: an immunological disease?
Baillieres Clin. Gastroenterol. 11: 35-52 (1997).
-
Rafeey M, Kianrad M, Hasani A. Autoimmune hepatitis in Iranian children.
Indian J. Gastroenterol. 26: 11-13 (2007).
*
-
Raffa S, Manzi P, Sottili S, Grassi M. Current therapeutic methods in primary sclerosing cholangitis.
Clin. Ter. 148: 249-256 (1997).
-
Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids.
Med. Sci. Monit. 13: PI13-PI18 (2007).
*
-
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis.
Dig. Dis. Sci. 52: 2920-2925 (2007).
*
-
Raina A, Krasinskas AM, Greer JB, Lamb J, Fink E, Moser AJ, Zeh HJ 3rd, Slivka A, Whitcomb DC. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis.
Arch. Pathol. Lab. Med. 132: 48-53 (2008).
*
-
Raithel M, Winterkamp S, Weidenhiller M, Muller S, Hahn EG. Combination therapy using fexofenadine, disodium cromoglycate, and a hypoallergenic amino acid-based formula induced remission in a patient with steroid-dependent, chronically active ulcerative colitis.
Int. J. Colorectal Dis. 22: 833-839 (2007).
*
-
Rajapakse R, Korelitz BI. Inflammatory bowel disease during pregnancy.
Curr. Treat. Options Gastroenterol. 4: 245-251 (2001).
-
Rakkhit T, Panko JM, Christensen TE, Wong B, Nelson T, Papenfuss J, Hansen CB, Callis-Duffin K, Krueger GG. Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response.
Br. J. Dermatol. 160: 1083-1089 (2009).
*
-
Rallis E, Anyfantakis V. Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy.
Skinmed. 7: 101-102 (2008).
-
Ramos-Casals M, Brito-Zeron P, Siso A, Vargas A, Ros E, Bove A, Belenguer R, Plaza J, Benavent J, Font J. High prevalence of serum metabolic alterations in primary Sjogren's syndrome: influence on clinical and immunological expression.
J. Rheumatol. 34: 754-761 (2007).
-
Rampton DS, Collins CE. Review article: thromboxanes in inflammatory bowel disease - pathogenic and therapeutic implications.
Aliment. Pharmacol. Ther. 7: 357-367 (1993).
-
Ranque B, Authier FJ, Le-Guern V, Pagnoux C, Berezne A, Allanore Y, Launay D, Hachulla E, Kahan A, Cabane J, Gherardi R, Guillevin L, Mouthon L. A descriptive and prognostic study of systemic sclerosis-associated myopathies.
Ann. Rheum. Dis. Dec 3 [Epub ahead of print] (2008).
-
Rao V, Gallagher M, Bhat P, Foster CS. Sensorineural hearing loss in a patient with HLA-B27 sclero-uveitis.
Br. J. Ophthalmol. 92: 425 (2008).
-
Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine.
Int. J. Dermatol. 47: 850-852 (2008).
-
Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV Jr. Inflammatory bowel disease in the setting of autoimmune pancreatitis.
Inflamm. Bowel Dis. Feb 23 [Epub ahead of print] (2009).
-
Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease.
J. Pediatr. Gastroenterol. Nutr. 44: 427-430 (2007).
*
-
Raynaud JJ, Bechade D, Desrame J, Algayres JP. Corticotherapy and giant hemangioma of the liver. Return to the normal values of cytokines.
Gastroenterol. Clin. Biol. 30: 907-909 (2006).
-
Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis.
Aliment. Pharmacol. Ther. 18: 303-308 (2003).
*
-
Read AE, Sherlock S, Harrison CV. Active 'juvenile' cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy.
Gut 4: 378-393 (1963).
*
-
Rech J, Hueber AJ, Leipe J, Manger B, Schett G, Kallert S. A case report of plasma exchange, steroids, mycophenolate mofetil and cyclophosphamide in acquired factor VIII inhibitors.
Ther. Apher. Dial. 12: 406-408 (2008).
-
Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory bowel disease receiving optimal care?
Am. J. Gastroenterol. 100: 1357-1361 (2005).
*
-
Reddymasu SC, Bonino J, McCallum R. Gastroparesis secondary to a demyelinating disease: a case series.
BMC Gastroenterol. 7: 3 (2007).
*
-
Reding R, Gras J, Sokal E, Otte JB, Davies HF. Steroid-free liver transplantation in children.
Lancet 362: 2068-2070 (2003).
*
-
Rednic S, Marinescu C, Chira R, Rogojan L, Rednic N. Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease.
J. Gastrointestin. Liver Dis. 15: 379-382 (2006).
*
-
Reed CA, Nichols DL, Bonnick SL, DiMarco NM. Bone mineral density and dietary intake in patients with Crohn's disease.
J. Clin. Densitom. 1: 33-40 (1998).
-
Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP. Bone density improves with disease remission in patients with inflammatory bowel disease.
Eur. J. Gastroenterol. Hepatol. 15: 1267-1273 (2003).
-
Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis.
J. Clin. Gastroenterol. 40: 476-481 (2006).
-
Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement.
Inflamm. Bowel Dis. 12: 972-978 (2006).
*
-
Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.
Inflamm. Bowel Dis. 12: 979-994 (2006).
*
-
Regueiro MD. Update in medical treatment of Crohn's disease.
J. Clin. Gastroenterol. 31: 282-291 (2000).
-
Regueiro MD. Diagnosis and treatment of ulcerative proctitis.
J. Clin. Gastroenterol. 38: 733-740 (2004).
-
Reguiai Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in pyoderma gangrenosum associated with inflammatory bowel disease.
Am. J. Clin. Dermatol. 8: 67-77 (2007).
-
Reguiai Z, Tchen T, Perceau G, Bernard P. Efficacy of rituximab in a case of refractory bullous pemphigoid.
Ann. Dermatol. Venereol. 136: 431-434 (2009).
-
Reinisch W, Haas T, Kaser A, Petritsch W, Vogelsang H, Feichtenschlager T, Novacek G, Siebert F, Tilg H, Knoflach P. Adalimumab for the treatment of Crohn's disease - Consensus Paper of the Working Group "Chronic Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology.
Z. Gastroenterol. 47: 372-380 (2009).
-
Reneses S, Pestana L, Fernandez-Suarez A, Criado R, Wichmann I, Garcia A, Nunez-Roldan A. A recent onset inflammatory polyarthritis register in Spain: factors that predict remission.
Scand. J. Rheumatol. 36: 378-385 (2007).
-
Rennebohm RM, Egan RA, Susac JO. Treatment of Susac's syndrome.
Curr. Treat. Options Neurol. 10: 67-74 (2008).
-
Requena L, Sanchez Yus E. Erythema nodosum.
Semin. Cutan. Med. Surg. 26: 114-125 (2007).
-
Rho YH, Chung CP, Oeser A, Solus J, Raggi P, Gebretsadik T, Shintani A, Stein CM. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus.
J. Rheumatol. 35: 1789-1794 (2008).
-
Rhodes JM, Robinson R, Beales I, Pugh S, Dickinson R, Dronfield M, Speirs CJ, Wilkinson P, Wilkinson SP. Clinical trial: oral prednisolone metasulfobenzoate (predocol) versus oral prednisolone for active ulcerative colitis.
Aliment. Pharmacol. Ther. 27: 228-240 (2008).
*
-
Ricart E, Garcia-Bosch O, Ordas I, Panes J. Are we giving biologics too late? The case for early versus late use.
World J. Gastroenterol. 14: 5523-5527 (2008).
*
-
Richaud-Patin Y, Vega-Boada F, Vidaller A, Llorente L. Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients.
Biomed. Pharmacother. 58: 320-324 (2004).
-
Richer O, Ulinski T, Lemelle I, Ranchin B, Loirat C, Piette JC, Pillet P, Quartier P, Salomon R, Bader-Meunier B. Abdominal manifestations in childhood-onset systemic lupus erythematosus.
Ann. Rheum. Dis. 66: 174-178 (2007).
*
-
Richetta AG, Maiani E, Carboni V, Carlomagno V, Cimillo M, Mattozzi C, Calvieri S. Pyoderma gangrenosum: case series.
Clin. Ter. 158: 325-329 (2007).
-
Rider LG. The heterogeneity of juvenile myositis.
Autoimmun. Rev. 6: 241-247 (2007).
-
Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV Jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.
Inflamm. Bowel Dis. 8: 186-191 (2002).
*
-
Rijnierse A, Koster AS, Nijkamp FP, Kraneveld AD. TNF-alpha is crucial for the development of mast-cell dependent colitis in mice.
Am. J. Physiol. Gastrointest. Liver Physiol. 291: G969-G976 (2006).
*
-
Rimal J, Sumanth KN, Ongole R, George T, Chatterjee S. A rare presentation of oral pemphigus vulgaris as multiple pustules.
Kathmandu Univ. Med. J (KUMJ) 5: 541-545 (2007).
-
Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis.
Am. Fam. Physician 72: 1037-1047 (2005).
*
-
Ringheanu M, Markowitz J. Inflammatory bowel disease in children.
Curr. Treat. Options Gastroenterol. 5: 181-196 (2002).
-
Rizzello F, Campieri M, Tambasco R, Straforini G, Brugnera R, Poggioli G, Gionchetti P. Medical treatment and management of severe ulcerative colitis.
Dig. Liver Dis. 40 Suppl. 2: S280-S284 (2008).
-
Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. Review article: the management of refractory Crohn's disease.
Aliment. Pharmacol. Ther. 16 Suppl. 4: 40-47 (2002).
*
-
Rizzi R, Pastore D, Liso A, Liuzzi GM, Dalena AM, Specchia G, Ricco R, Liso V. Autoimmune myelofibrosis: report of three cases and review of the literature.
Leuk. Lymphoma 45: 561-566 (2004).
-
Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation.
Curr. Opin. Pharmacol. 6: 421-427 (2006).
-
Rjeibi I, Zeglaoui F, El Fekih N, Ezzine N, Fazaa B, Kamoun MR. Sweet's syndrome: report of 5 cases.
Rev. Med. Liege 61: 834-836 (2006).
-
Robak E, Sysa-Jedrzejowska A, Wozniacka A. Progress and perspectives in the treatment of systemic lupus erythematosus.
Przegl. Lek. 62: 894-899 (2005).
-
Roberts EA. Autoimmune hepatitis.
Indian J. Pediatr. 62: 525-531 (1995).
-
Roberts JR, Finger DR. Catastrophic antiphospholipid syndrome; a "CATASTROPHIC" case of systemic lupus erythematosus.
Hawaii Med. J. 63: 362-364 (2004).
-
Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.
Gastroenterology 110: 848-857 (1996).
*
-
Robinson M. Medical therapy of inflammatory bowel disease for the 21st century.
Eur. J. Surg. Suppl. 582: 90-98 (1998).
-
Robinson M. Optimizing therapy for inflammatory bowel disease.
Am. J. Gastroenterol. 92: 12S-17S (1997).
-
Roblin X, Phelip JM, Genevois M, Ducros V, Bonaz B. Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn's disease.
Aliment. Pharmacol. Ther. 25: 797-804 (2007).
*
-
Roblot F. Management of Pneumocystis pneumonia in patients with inflammatory disorders.
Expert Rev. Anti. Infect. Ther. 3: 435-444 (2005).
-
Rodrigues AF, Johnson T, Davies P, Murphy MS. Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn's disease.
Arch. Dis. Child. 92: 767-770 (2007).
*
-
Rodriguez-D'Jesus A, Casellas F, Malagelada JR. Epidemiology of inflammatory bowel disease in the elderly.
Gastroenterol. Hepatol. 31: 269-273 (2008).
-
Rodriguez-Moranta F, Soriano-Izquierdo A, Guardiola J.. Current status of treatment of inflammatory bowel disease.
Cir. Esp. 82: 254-259 (2007).
-
Roganovic B, Milutinovic C, Usaj S. Chronic persistent hepatitis with an atypical clinical course.
Vojnosanit. Pregl. 55: 225-227 (1998).
-
Rogler G. Indications for use of infliximab.
Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 54-55 (2006). *
-
Rogler G, Holler E. Can NOD2/CARD15 mutations predict intestinal graft-versus-host disease and aid our understanding of Crohn’s disease?
Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 62-63 (2004).
*
-
Rogler G, Meinel A, Lingauer A, Michl J, Zietz B, Gross V, Lang B, Andus T, Scholmerich J, Palitzsch KD. Glucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease.
Eur. J. Clin. Invest. 29: 330-336 (1999).
*
-
Rogozina VA, Rumiantsev VG. Comparative efficacy of mezakol and sulfasalazine in treating chronic relapsing ulcerative colitis.
Eksp. Klin. Gastroenterol. 1: 58-9, 183 (2003).
-
Roka R, Ait-Belgnaoui A, Salvador-Cartier C, Garcia-Villar R, Fioramonti J, Eutamene H, Bueno L. Dexamethasone prevents visceral hyparalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats.
Gut 56: 1072-1078 (2007).
*
-
Rollini P, Fournier RE. A 370-kb cosmid contig of the serpin gene cluster on human chromosome 14q32.1: molecular linkage of the genes encoding alpha 1-antichymotrypsin, protein C inhibitor, kallistatin, alpha 1-antitrypsin, and corticosteroid-binding globulin.
Genomics 46: 409-415 (1997).
*
-
Rollini P, Fournier RE. Molecular linkage of the human alpha 1-antitrypsin and corticosteroid-binding globulin genes on chromosome 14q32.1.
Mamm. Genome 8: 913-916 (1997).
*
-
Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis.
Osteoarthritis Cartilage 14: 839-848 (2006).
-
Romanelli RG, La Villa G, Almerigogna F, Vizzutti F, Di Pietro E, Fedi V, Gentilini P, Laffi G. Uveitis in autoimmune hepatitis: a case report.
World J. Gastroenterol. 12: 1637-1640 (2006).
*
-
Romano A, De Santis A, Romito A, Di Fonso M, Venuti A, Gasbarrini GB, Manna R. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes.
Ann. Allergy Asthma Immunol. 80: 433-437 (1998).
*
-
Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection, a risk factor for cirrhosis and hepatocellular carcinoma.
Gastroenterology 136: 1629-1638 (2009).
*
-
Romero M, Perez-Grueso MJ, Repiso A, de la Cruz G, Garcia Vela A, Martín Escobedo R, Gonzalez de Frutos C, Carrobles JM. Autoimmune pancreatitis associated with retroperitoneal fibrosis: outcome after 24 months of follow-up.
Rev. Esp. Enferm. Dig. 100: 648-651 (2008).
-
Ronchi F, Cecchi P, Falcioni F, Marsciani A, Minak G, Muratori G, Tazzari PL, Beverini S. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine.
Arch. Dis. Child. 78: 273-274 (1998).
*
-
Rosen T, Unkefer RP. Treatment of pyoderma faciale with isotretinoin in a patient with ulcerative colitis.
Cutis 64: 107-109 (1999).
-
Rosenberg JL, Edlow D, Sneider R. Liver disease and vasculitis in a patient taking cromolyn.
Arch. Intern. Med. 138: 989-991 (1978).
-
Rosenblatt RL. Lung transplantation in cystic fibrosis.
Respir. Care 54: 777-787 (2009).
-
Ross AS, Cohen RD. Medical therapy for ulcerative colitis: the state of the art and beyond.
Curr. Gastroenterol. Rep. 6: 488-495 (2004).
-
Ross KR, Chmiel JF, Konstan MW. The role of inhaled corticosteroids in the management of cystic fibrosis.
Paediatr. Drugs 11: 101-113 (2009).
-
Rossini M, Viapiana O, Del Marco A, de Terlizzi F, Gatti D, Adami S. Quantitative ultrasound in adults with cystic fibrosis: correlation with bone mineral density and risk of vertebral fractures.
Calcif. Tissue Int. 80: 44-49 (2007).
*
-
Rowin J. Etanercept treatment in myasthenia gravis.
Ann. N. Y. Acad. Sci. 1132: 300-304 (2008).
*
-
Rozin AP, Schapira D, Braun-Moscovici Y, Markovits D, Vlodavsky E, Balbir-Gurman A. Ultrasound imaging of fasciitis due to body-building supplement.
Am. J. Med. Sci. 335: 242-245 (2008).
-
Rozkova D, Horvath R, Bartunkova J, Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors.
Clin. Immunol. 120: 260-271 (2006).
*
-
Ruckert A, Glimm H, Lubbert M, Grullich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up.
Lupus 17: 757-760 (2008).
-
Ruderman EM. Evaluation and management of psoriatic arthritis: the role of biologic therapy.
J. Am. Acad. Dermatol. 49 (2 Suppl.): S125-S132 (2003).
-
Ruf G. Toxic megacolon - surgical point of view.
Schweiz. Rundsch. Med. Prax. 95: 1727-1730 (2006).
-
Rufer A, Brodmann D, Gregor M, Kremer Hovinga JA, Lammle B, Wuillemin WA. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature.
Swiss Med. Wkly. 137: 518-524 (2007).
*
-
Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children.
Paediatr. Drugs 8: 279-302 (2006).
-
Ruiz JF, Radics G, Windle H, Serra HO, Simplício AL, Kedziora K, Fallon PG, Kelleher DP, Gilmer JF. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease.
J. Med. Chem. 52: 3205-3211 (2009).
*
-
Ruiz Montes F, Rene Espinet JM, Rubio Caballero M. Eosinophilic gastroenteritis: review of the published cases in Spain and comparison with foreign literature.
Rev. Esp. Enferm. Dig. 81: 270-279 (1992).
-
Ruocco E, Cuomo A, Salerno R, Ruocco V, Romano M, Baroni A. Crohn's disease and its mucocutaneous involvement.
Skinmed. 6: 179-185 (2007).
*
-
Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases.
World J. Gastroenterol. 14: 3368-3373 (2008).
*
-
Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Clin. Rev. Allergy Immunol. 28: 135-146 (2005).
*
-
Rutgeerts P. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
Mediators Inflamm. 7: 137-140 (1998).
*
-
Rutgeerts P. Medical therapy of inflammatory bowel disease.
Digestion 59: 453-469 (1998).
-
Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease.
Gastroenterology 126: 1593-1610 (2004).
*
-
Rutgeerts PJ. Conventional treatment of Crohn's disease: objectives and outcomes.
Inflamm. Bowel Dis. 7 Suppl. 1: S2-S8 (2001).
*
-
Rutgeerts PJ. An historical overview of the treatment of Crohn's disease: why do we need biological therapies?
Rev. Gastroenterol. Disord. 4 Suppl. 3: S3-S9 (2004).
*
-
Ruuska T, Wewer V, Lindgren F, Malmborg P, Lindquist M, Marthinsen L, Browaldh L, Casswall T, Kalliomaki M, Gronlund J. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives.
Inflamm. Bowel Dis. 15: 1049-1054 (2009).
-
Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A, Bissonnette R, Varjonen E, Hollo P, Cambazard F, Lahfa M, Elsner P, Nyberg F, Svensson A, Brown TC, Harsch M, Maares J. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.
Br. J. Dermatol. 158: 808-817 (2008).
*
-
Ryan JG, Morgan RK, Lavin PJ, Murray FE, O'Connell PG. Current management of corticosteroid-induced osteoporosis: variations in awareness and management.
Ir. J. Med. Sci. 173: 20-22 (2004).
-
Sa MJ. Acute transverse myelitis: a practical reappraisal.
Autoimmun. Rev. Apr 20 [Epub ahead of print] (2009).
-
Sack DM, Peppercorn MA. Drug therapy of inflammatory bowel disease.
Pharmacotherapy 3: 158-176 (1983).
-
Saeed SA, Crandall WV. Managing Crohn disease in children and adolescents: focus on tumor necrosis factor antagonists.
Paediatr. Drugs 10: 31-38 (2008).
-
Saeki H, Watanabe A, Tada Y, Kakinuma T, Komine M, Ihn H, Asahina A, Etoh T, Kitanaka S, Sato U, Kano H, Igarashi T, Tamaki K. Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid.
J. Dermatol. 35: 601-603 (2008).
-
Saha S, Fichera A, Bales G, Greenberg E, Kane S. Metastatic Crohn's disease of the bladder.
Inflamm. Bowel Dis. 14: 140-142 (2008).
*
-
Sahani DV, Sainani NI, Deshpande V, Shaikh MS, Frinkelberg DL, Fernandez-Del Castillo C. Autoimmune pancreatitis: disease evolution, staging, response assessment, and CT features that predict response to corticosteroid therapy.
Radiology 250: 118-129 (2009).
-
Sakai M, Ohashi K, Ohta K, Yamashita T, Akiyama H, Kisida S, Kamata N, Sakamaki H. Immune-mediated myelopathy following allogeneic stem cell transplantation.
Int. J. Hematol. 84: 272-275 (2006).
-
Sako M, Kimura H, Arai K, Koganei K, Kito F, Sugita A, Fukushima T. Restorative proctocolectomy for pediatric patients with ulcerative colitis.
Surg. Today 36: 162-165 (2006).
*
-
Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation.
Nat. Clin. Pract. Nephrol. 2: 221-230 (2006).
*
-
Saleem B, Mackie S, Quinn M, Nizam S, Hensor E, Jarrett S, Conaghan PG, Emery P. Does the use of TNF antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
Ann. Rheum. Dis. 67: 1178-1180 (2008).
-
Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis?
Clin. Exp. Rheumatol. 24: S033-S036 (2006).
*
-
Saleh F, Ko HH, Davis JE, Apiratpracha W, Powell JJ, Erb SR, Yoshida EM. Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis.
Ann. Hepatol. 6: 186-189 (2007).
*
-
Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, Grillo-Lopez AJ, LoBuglio AF. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
Semin. Oncol. 27: S99-S103 (2000).
-
Saltik Temizel IN, Eren M, Demir H, Uslu N, Usta Y, Ozen H, Gurakan F, Yuce A. Bone mineralization in children with inflammatory bowel disease: what is the role of zinc?
Turk. J. Gastroenterol. 19: 234-238 (2008).
*
-
Sample C, Bailey RJ, Todoruk D, Sadowski D, Gramlich L, Milan M, Cherry R, Ma M, Lalor E, McKaigney J, Sherbaniuk R, Matic K, Switzer C, Fedorak RN. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.
Can. J. Gastroenterol. 16: 165-170 (2002).
-
Sanchez Carazo JL, Mahiques Santos L, Oliver Martinez V. Safety of etanercept in psoriasis: a critical review.
Drug Saf. 29: 675-685 (2006).
-
Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis.
Hepatology 15: 215-221 (1992).
-
Sand E, Themner-Persson A, Ekblad E. Mast cells reduce survival of myenteric neurons in culture.
Neuropharmacology 56: 522-530 (2009).
-
Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.
Curr. Gastroenterol. Rep. 5: 501-505 (2003).
-
Sandborn WJ. Evidence-based treatment algorithm for mild to moderate Crohn's disease.
Am. J. Gastroenterol. 98: S1-S5 (2003).
*
-
Sandborn WJ. Transcending conventional therapies: the role of biologic and other novel therapies.
Inflamm. Bowel Dis. 7 Suppl. 1: S9-S16 (2001).
*
-
Sandborn WJ. Steroid-dependent Crohn's disease.
Can. J. Gastroenterol. 14 Suppl. C: 17C-22C (2000).
-
Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn's disease - defining the basis for a new treatment algorithm.
Aliment. Pharmacol. Ther. 18: 263-277 (2003).
*
-
Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Aliment. Pharmacol. Ther. 26: 987-1003 (2007).
*
-
Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Am. J. Gastroenterol. 97: 2962-2972 (2002).
*
-
Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Am. J. Gastroenterol. 100: 1780-1787 (2005).
*
-
Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease.
Mayo Clin. Proc. 67: 981-990 (1992).
-
Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
Rheumatology (Oxford) 45: 724-729 (2006).
*
-
Sandhu BS, Luketic VA. Management of primary sclerosing cholangitis.
Gastroenterology & Hepatology 2: 843-849 (2006). *
-
Sandmeier D, Bouzourene H. Microscopic colitis with giant cells: a rare new histopathologic subtype?
Int. J. Surg. Pathol. 12: 45-48 (2004).
-
Sands BE. Therapy of inflammatory bowel disease.
Gastroenterology 118: S68-S82 (2000).
-
Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?
Gut 55: 437-441 (2006).
*
-
Sands BE. Biological therapies for ulcerative colitis.
Acta Gastroenterol. Belg. 64: 205-209 (2001).
-
Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
Inflamm. Bowel Dis. 7: 83-88 (2001).
*
-
Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.
Aliment. Pharmacol. Ther. 16: 399-406 (2002).
*
-
Sane SP, Bhatt AD. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
J. Assoc. Physicians India 48: 999-1003 (2000).
-
Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities.
BioDrugs 18: 269-278 (2004).
-
Santos ES, Arosemena LR, Raez LE, O'brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature.
Liver Int. 26: 625-629 (2006).
*
-
Sari I, Kocyigit I, Altuntas F, Kaynar L, Eser B. An unusal case of acute brucellosis presenting with Coombs-positive autoimmune hemolytic anemia.
Intern. Med. 47: 1043-1045 (2008).
*
-
Sarir H, Henricks PA, van Houwelingen AH, Nijkamp FP, Folkerts G. Cells, mediators and Toll-like receptors in COPD.
Eur. J. Pharmacol. 585: 346-353 (2008).
-
Saritas U, Aydin B, Ustundag Y. Plasmapheresis and corticosteroid treatment for persistent jaundice after successful drainage of common bile duct stones by endoscopic retrograde cholangiography.
World J. Gastroenterol. 13: 4152-4153 (2007).
*
-
Sarkar PK, Patel N, Furie RA, Talwar A. Pulmonary manifestations of primary Sjogren's syndrome.
Indian J. Chest Dis. Allied Sci. 51: 93-101 (2009).
-
Sarker PC, Khandker HH, Sarker CR, Khatoon M. Clinico-laboratory profile of 45 filarial arthritis cases.
Mymensingh. Med. J. 16: S7-S11 (2007).
-
Sarkhy A, Persad R, Tarnopolsky M. Muscle weakness in a girl with autoimmune hepatitis and Graves' disease.
Eur. J. Pediatr. 168: 241-243 (2009).
*
-
Sarkissian T, Beyenne J, Feldman B, Adeli K, Silverman E. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus.
Arthritis Rheum. 54: 1283-1290 (2006).
*
-
Sartor RB. Clinical applications of advances in the genetics of IBD.
Rev. Gastroenterol. Disord. 3 Suppl. 1: S9-S17 (2003).
*
-
Satoh T, Hirakata M, Yoshida T, Matsumura M, Miyachi K, Mimori T, Akizuki M. Systemic lupus erythmatosus associated with autoimmune hepatitis two cases with novel autoantibodies to transfer RNA-related antigens.
Clin. Rheumatol. 16: 305-309 (1997).
-
Sauder DN. Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions.
J. Cutan. Med. Surg. 8 Suppl. 3: 3-12 (2004).
*
-
Sawabe T, Imafuku S. Cyclosporin-induced cortical blindness in a patient with dermatomyositis.
Mod. Rheumatol. 14: 271-273 (2004).
-
Sawada K. Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease.
Dis. Colon Rectum 46: S66-S77 (2003).
-
Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
Am. J. Gastroenterol. 100: 1362-1369 (2005).
*
-
Schedel J, Mayer S, Woenckhaus M, Kiss E, Scholmerich J, Rogler G. Autoimmune cholangitis with vasculitic ulcers, rheumatoid arthritis and IgA glomerulonephritis.
Dtsch. Med. Wochenschr. 129: 2409-2412 (2004).
-
Schiller LR. Diagnosis and management of microscopic colitis syndrome.
J. Clin. Gastroenterol. 38: S27-S30 (2004).
-
Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout.
Cochrane Database Syst. Rev. 4: CD006190 (2006).
*
-
Schmassmann A, Halter F. Local or systemic treatment of inflammatory bowel diseases?
Ther. Umsch. 50: 94-99 (1993).
-
Schmeling H, Seliger E, Horneff G. Growth reconstitution in juvenile idiopathic arthritis treated with etanercept.
Clin. Exp. Rheumatol. 21: 779-784 (2003).
-
Schmidt E. Optimizing therapy in patients with severe autoimmune blistering skin diseases.
Hautarzt. Jun 19 [Epub ahead of print] (2009).
-
Schmidt E, Brocker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Clin. Rev. Allergy Immunol. 34: 56-64 (2008).
*
-
Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Aliment. Pharmacol. Ther. May 6 [Epub ahead of print] (2009).
*
-
Schnelldorfer T, Lewin DN, Adams DB. Long-term results after surgery for autoimmune sclerosing pancreatitis.
J. Gastrointest. Surg. 11: 56-58 (2007).
*
-
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
Inflamm. Bowel Dis. Apr 1 [Epub ahead of print] (2009).
-
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts PJ. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort.
Gut 58: 492-500 (2009).
*
-
Schnitzler L, Verret JL, Caron C, Tuchais E, Soret JY, Salaun Y. Multifocal fibrosclerosis (retroperitoneal, mediastinal, mesenteric and pelvic involvement) associated with vasculitis and revealed by a livedo: clinical, histopathological and ultrastructural study in a case.
Ann. Dermatol. Venereol. 105: 943-956 (1978).
-
Scholmerich J. Management of extraintestinal disease in IBD.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 38-39 (2005). *
-
Scholmerich J, Gerok W. Drug therapy of chronic inflammatory intestinal diseases - current status of 5-aminosalicylic acid.
Wien. Klin. Wochenschr. 98: 762-769 (1986).
-
Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Hapten-White L, Graffner H, Bianchi Porro G, Vatn M, Stockbrugger RW. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
Clin. Gastroenterol. Hepatol. 3: 113-121 (2005).
*
-
Schoonbroodt D, Horsmans Y, Laka A, Geubel AP, Hoang P. Eosinophilic gastroenteritis presenting with colitis and cholangitis.
Dig. Dis. Sci. 40: 308-314 (1995).
-
Schrander-van der Meer AM, Vogten AJ. Estimation of survival probability in cirrhotics. Evaluation of a computer model applicable for decision-making.
Neth. J. Med. 40: 183-189 (1992).
-
Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease.
Gut 42: 477-484 (1998).
*
-
Schreibman I, Regev A. Recurrent primary biliary cirrhosis after liver transplantation - the disease and its management.
MedGenMed. 8: 30 (2006).
*
-
Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far?
Transpl. Int. 22: 144-152 (2009).
*
-
Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease.
Inflamm. Bowel Dis. 4: 268-275 (1998).
*
-
Schulte CM. Bone disease in inflammatory bowel disease.
Aliment. Pharmacol. Ther. 20 Suppl. 4: 43-49 (2004).
*
-
Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease.
Gastroenterology 119: 909-920 (2000).
*
-
Schulze J, Bader P, Henke U, Rose MA, Zielen S. Severe bullous pemphigoid in an infant - successful treatment with rituximab.
Pediatr. Dermatol. 4: 462-465 (2008).
-
Schwartz D, Ferguson JR. Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis.
Curr. Med. Res. Opin. 23: 2715-2728 (2007).
-
Schwartz DA, Connolley CD, Koyama T, Wise PE, Herline AJ. Calcaneal ultrasound bone densitometry is not a useful tool to screen patients with inflammatory bowel disease at high risk for metabolic bone disease.
Inflamm. Bowel Dis. 11: 749-754 (2005).
*
-
Schwartz DA, Pardi DS, Murray JA. Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis.
Dig. Dis. Sci. 46: 1787-1790 (2001).
*
-
Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease.
Curr. Gastroenterol. Rep. 10: 585-590 (2008).
-
Schwarzer A, Ricciardelli I, Kirkham S, Binnie K, Shah N, Elawad MA, Hill SM, Furman M, Smith VV, Sebire N, Milla PJ, Londei M, Lindley KJ. Management of fulminating ulcerative colitis in childhood with chimeric anti-CD25 antibody.
J. Pediatr. Gastroenterol. Nutr. 42: 245-248 (2006).
*
-
Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients.
Arch. Neurol. 64: 691-696 (2007).
-
Scribano M, Prantera C. Review article: medical treatment of moderate to severe Crohn's disease.
Aliment. Pharmacol. Ther. 17 Suppl. 2: 23-30 (2003).
-
Scribano ML, Prantera C. Review article: medical treatment of active Crohn's disease.
Aliment. Pharmacol. Ther. 16 Suppl. 4: 35-39 (2002).
*
-
Scudeletti M, Musselli C, Lanza L, Peirano L, Puppo F, Indiveri F. The immunological activity of corticosteroids.
Recenti Prog. Med. 87: 508-515 (1996).
-
Scully C, Mignogna M. Oral mucosal disease: pemphigus.
Br. J. Oral Maxillofac. Surg. 46: 272-277 (2008).
-
Segarra Canton O, Infante Pina D, Tormo Carnice R. Infliximab therapy for inflammatory bowel disease: seven years on.
An. Pediatr. (Barc.) 67: 344-351 (2007).
-
Sehlstedt M, Andersen GN, Nilsson K, Blomberg A, Mincheva-Nilsson L, Waldenstrom A, Rantapaa-Dahlqvist S, Sandstrom T. Suppressed signal transduction in the bronchial epithelium of patients with systemic sclerosis.
Respir. Med. 103: 301-308 (2009).
-
Seite S, Khemis A, Rougier A, Ortonne JP. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis.
Exp. Dermatol. May 14 [Epub ahead of print] (2009).
-
Sejismundo LP. Vasculitis and biologic infusion therapies: implications for nursing.
J. Infus. Nurs. 29: 272-282 (2006).
-
Sejvar JJ. Acute disseminated encephalomyelitis.
Curr. Infect. Dis. Rep. 10: 307-314 (2008).
-
Selby W. Pathogenesis and therapeutic aspects of Crohn's disease.
Vet. Microbiol. 77: 505-511 (2000).
*
-
Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D; Antibiotics in Crohn’s Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.
Gastroenterology 132: 2313-2319 (2007).
*
-
Selby WS, Jewell DP. T lymphocyte subsets in inflammatory bowel disease: peripheral blood.
Gut 24: 99-105 (1983).
*
-
Selenko-Gebauer N, Karlhofer F, Stingl G. Efalizumab in routine use: a clinical experience.
Br. J. Dermatol. 156: S1-S6 (2007).
-
Selimoglu MA, Ertekin V. Autoimmune hepatitis triggered by Brucella infection or doxycycline or both.
Int. J. Clin. Pract. 57: 639-641 (2003).
-
Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.
J. Am. Coll. Surg. 204: 956-962 (2007).
-
Semkova K, Black M. Pemphigoid gestationis: current insights into pathogenesis and treatment.
Eur. J. Obstet. Gynecol. Reprod. Biol. Jun 9 [Epub ahead of print] (2009).
-
Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease.
Cochrane Database Syst. Rev. 3: CD000296 (2008).
*
-
Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
Ann. N. Y. Acad. Sci. 1069: 414-419 (2006).
*
-
Sermet-Gaudelus I, Souberbielle JC, Ruiz JC, Vrielynck S, Heuillon B, Azhar I, Cazenave A, Lawson-Body E, Chedevergne F, Lenoir G. Low bone mineral density in young children with cystic fibrosis.
Am. J. Respir. Crit. Care Med. 175: 951-957 (2007).
*
-
Serrao VV, Feio AB. Localized abdominal idiopathic lipodystrophy.
Dermatol. Online J. 14: 15 (2008).
*
-
Serrao VV, Organ V, Pereira L, Vale E, Correia S. Annular lichen planus in association with Crohn disease.
Dermatol. Online J. 14: 5 (2008).
-
Seve P, Bourdillon L, Sarrot-Reynauld F, Ruivard M, Jaussaud R, Bouhour D, Bonotte B, Gardembas M, Poindron V, Thiercelin MF, Broussolle C, Oksenhendler E; The DEF-I Study Group. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients.
Medicine (Baltimore) 87: 177-184 (2008).
-
Seve P, Gachon E, Petiot P, Stankovic K, Charhon A, Broussolle C. Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjogren's syndrome.
Rheumatol. Int. 28: 175-177 (2007).
*
-
Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease.
Dig. Liver Dis. 34: 22-28 (2002).
-
Shah SB, Hanauer SB. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions.
Rev. Gastroenterol. Disord. 7 Suppl. 3: S3-S10 (2007).
-
Shah SM, Rabbani MA, Gul A, Ahmad A. Unusual presentations of Wegener's granulomatosis: pitfalls in early diagnosis.
Saudi J. Kidney Dis. Transpl. 14: 177-185 (2003).
-
Shakeri R, Zamani F, Sotoudehmanesh R, Amiri A, Mohamadnejad M, Davatchi F, Mohammadi Karakani A, Malekzadeh R, Shahram F. Gluten sensitivity enteropathy in patients with recurrent aphthous stomatitis.
BMC Gastroenterol. 9: 44 (2009).
*
-
Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Mayo Clin. Proc. 78: 1340-1346 (2003).
*
-
Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB. Immunosuppression: evolution in practice and trends, 1993-2003.
Am. J. Transplant. 5: 874-886 (2005).
-
Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis.
J. Clin. Gastroenterol. 38: 741-745 (2004).
-
Sherlock S. Immunosuppressive therapy in chronic liver disease.
Minerva Med. 69: 2605-2609 (1978).
-
Shetty AK, Gedalia A. Childhood sarcoidosis: a rare but fascinating disorder.
Pediatr. Rheumatol. Online J. 6: 16 (2008).
*
-
Shibata M, Morizane T, Tanaka A, Onozuka Y, Uchida T, Gershwin ME, Mitamura K. A case of autoimmune hepatitis with a high titer of antimitochondrial antibody and normal gamma-globulinemia.
J. Gastroenterol. Hepatol. 16: 830-835 (2001).
*
-
Shibata S, Ubara Y, Sawa N, Tagami T, Hosino J, Yokota M, Katori H, Takemoto F, Hara S, Takaichi K, Fujii A, Murata H, Nishi T. Severe interstitial cystitis associated with Sjogren's syndrome.
Intern. Med. 43: 248-252 (2004).
*
-
Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis.
Cochrane Database Syst. Rev. 1: CD004277 (2005).
-
Shibolet O, Regushevskaya ER, Hershko AYH, Soares-Weiser K, Brezis M. Cyclosporine A for induction of remission in steroid refractory ulcerative colitis.
Cochrane Database Syst. Rev. 2: CD000302 (2004). *
-
Shibuya A, Satomich A, Nagaba S, Endoh H, Kuwao S, Saigenji K. Thrombotic thrombocytopenic purpura in autoimmune hepatitis.
J. Gastroenterol. 36: 569-573 (2001).
*
-
Shiels MT, Czaja AJ, Ludwig J, McCullough AJ, Jones JD, Go VL. Diagnostic and prognostic implications of plasma amino acid determinations in chronic active hepatitis.
Dig. Dis. Sci. 30: 819-823 (1985).
-
Shih A, Jackson Ii KC. Role of corticosteroids in palliative care.
J. Pain Palliat. Care Pharmacother. 21: 69-76 (2007).
-
Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
Br. J. Dermatol. 158: 382-388 (2008).
*
-
Shimomura I, Takase Y, Matsumoto S, Kuyama J, Nakajima T, Maeda H, Sugase T, Hata A, Hanada M, Okuno M. Primary sclerosing cholangitis associated with increased peripheral eosinophils and serum IgE.
J. Gastroenterol. 31: 737-741 (1996).
-
Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis.
Clin. Rheumatol. 26: 1871-1875 (2007).
*
-
Shoda H, Kanda H, Tanaka R, Komagata Y, Misaki Y, Yamamoto K. Wegener's granulomatosis with eosinophilia.
Intern. Med. 44: 750-753 (2005).
*
-
Shojaiefard A, Mousavi SA, Faghihi SH, Abdollahzade S. Prediction of response to splenectomy in patients with idiopathic thrombocytopenic purpura.
World J. Surg. 32: 488-493 (2008).
*
-
Shteyer E, Wilschanski M. Novel therapeutic modalities in pediatric inflammatory bowel disease.
Isr. Med. Assoc. J. 10: 816-820 (2008).
*
-
Shvidel L, Shtalrid M, Duek A, Haran M, Berrebi A, Sigler E. Direct antiglobulin test reactive with complement only in warm type autoimmune hemolytic anemia.
Int. J. Lab. Hematol. 30: 494-498 (2008).
*
-
Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Seinhart H, Greenberg G. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease.
Inflamm. Bowel Dis. 10: 220-228 (2004).
*
-
Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
Clin. Gastroenterol. Hepatol. 3: 122-132 (2005).
*
-
Siffledeen JS, Siminoski K, Jen H, Fedorak RN. Vertebral fractures and role of low bone mineral density in Crohn's disease.
Clin. Gastroenterol. Hepatol. 5: 721-728 (2007).
-
Sigal LH. Basic science for the clinician 44. Atherosclerosis: an immunologically mediated (autoimmune?) disease.
J. Clin. Rheumatol. 13: 160-168 (2007).
-
Sigurbjornsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD.
Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 509-516 (2008).
-
Sijssens KM, Rijkers GT, Rothova A, Stilma JS, Schellekens PA, de Boer JH. Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis.
Exp. Eye Res. 85: 443-449 (2007).
-
Sijssens KM, Rothova A, Van De Vijver DA, Stilma JS, De Boer JH. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis.
Am. J. Ophthalmol. 144: 574-579 (2007).
*
-
Sikorska-Wisniewska G, Liberek A, Bako W, Gora-Gebka M, Szlagatys-Sidorkiewicz A, Jankowska A, Zagierski M. Vasculitis in children.
Med. Wieku. Rozwoj. 11: 429-434 (2007).
-
Silva MA, Lopez CB, Riverin F, Oligny L, Menezes J, Seidman EG. Characterization and distribution of colonic dendritic cells in Crohn's disease.
Inflamm. Bowel Dis. 10: 504-512 (2004).
*
-
Silvana B, Antonella LM, Basilia P, Trombetta D, Saija A, Salpietro C. Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome.
Pediatr. Transplant. 11: 552-556 (2007).
-
Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease.
Gut 37: 71-76 (1995).
*
-
Silverman AK, Ellis CN, Voorhees JJ. Hypervitaminosis A syndrome: a paradigm of retinoid side effects.
J. Am. Acad. Dermatol. 16: 1027-1039 (1987).
-
Simma W, Wayand U, Lederer B, Brucke P. Two cases of primary sclerosing cholangitis.
Wien. Klin. Wochenschr. 91: 257-261 (1979).
-
Simmonds NJ, Millar AD, Blake DR, Rampton DS. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.
Aliment. Pharmacol. Ther. 13: 363-372 (1999).
*
-
Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based, nested, case-control study.
Gastroenterology 136: 451-458 (2009).
*
-
Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.
Arthritis Rheum. 54: 1595-1601 (2006).
*
-
Sinha A, Bagga A. Pulse steroid therapy.
Indian J. Pediatr. 75: 1057-1066 (2008).
-
Sinkovic A, Koren M, Skok P, Potrc S. Acute pancreatitis following azathioprine therapy of Crohn's disease - a case report and the overview of the literature.
Acta Med. Croatica 62: 81-84 (2008).
-
Sivak MV Jr, Farmer RG, Lalli AF. Sclerosing cholangitis: its increasing frequency of recognition and association with inflammatory bowel disease.
J. Clin. Gastroenterol. 3: 261-266 (1981).
-
Siveke JT, Egert J, Sitter T, Schiemann U, Walcher P, Torok HP, Glas J, Folwaczny C. 5-ASA therapy and renal function in inflammatory bowel disease.
Am. J. Gastroenterol. 100: 501 (2005).
*
-
Sixdorf U, Bauer H, Marker-Hermann E. Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil.
Dtsch. Med. Wochenschr. 131: 2266-2269 (2006).
-
Skalova S, Minxova L, Slezak R. Hypokalaemic paralysis revealing Sjogren's syndrome in a 16-year old girl.
Ghana Med. J. 42: 124-128 (2008).
*
-
Skorjanec S, Dolovski Z, Kocman I, Brcic L, Blagaic Boban A, Batelja L, Coric M, Sever M, Klicek R, Berkopic L, Radic B, Drmic D, Kolenc D, Ilic S, Cesarec V, Tonkic A, Zoricic I, Mise S, Staresinic M, Ivica M, Lovric Bencic M, Anic T, Seiwerth S, et al. Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole.
Dig. Dis. Sci. 54: 46-56 (2009).
*
-
Small AJ, Loftus CG, Smyrk TC, Baron TH. A case of IgG4-associated cholangitis and autoimmune pancreatitis responsive to corticosteroids.
Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 707-712 (2008).
*
-
Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
Clin. Cancer Res. 13: 1810-1815 (2007).
*
-
Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundstrom C, Akerman M, Melbye M, Glimelius B, Adami HO. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.
J. Natl. Cancer Inst. 98: 51-60 (2006).
*
-
Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma.
N. Engl. J. Med. 352: 2163-2173 (2005).
*
-
Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
Arthritis Rheum. 53: 18-23 (2005).
*
-
Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease.
Nat. Clin. Pract. Rheumatol. 3: 219-226 (2007).
*
-
Smith PA. Nutritional therapy for active Crohn's disease.
World J. Gastroenterol. 14: 4420-4423 (2008).
*
-
Smolen JS. What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials.
J. Rheumatol. Suppl. 79: 15-20 (2007).
*
-
Sninsky CA. Altering the natural history of Crohn's disease?
Inflamm. Bowel Dis. 7 Suppl. 1: S34-S39 (2001).
*
-
Snyder MC, Cappell MS. Clinical presentation, diagnosis and management of autoimmune pancreatitis.
Minerva Gastroenterol. Dietol. 54: 389-405 (2008).
-
Soderlin MK, Lindroth Y, Jacobsson LT. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
Rheumatology (Oxford) 46: 1355-1358 (2007).
*
-
Sogo T, Fujisawa T, Inui A, Komatsu H, Etani Y, Tajiri H, Waki K, Shimizu Y, Nakashima S, Imagawa T, Yokota S. Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis.
Hepatol. Res. 34: 187-192 (2006).
-
Sohi S, Cohen RD. Management of refractory ulcerative colitis.
Curr. Treat. Options Gastroenterol. 9: 234-245 (2006).
-
Solau-Gervais E, Legrand JL, Cortet B, Duquesnoy B, Flipo RM. Magnetic resonance imaging of the hand for the diagnosis of rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide antibodies: a prospective study.
J. Rheumatol. 33: 1760-1765 (2006).
-
Soloway RD, Hewlett AT. The medical treatment for autoimmune hepatitis through corticosteroid to new immunosuppressive agents: a concise review.
Ann. Hepatol. 6: 204-207 (2007).
*
-
Soltesz S, Mencke T, Mey C, Rohrig S, Diefenbach C, Molter GP. Influence of a continuous prednisolone medication on the time course of neuromuscular block of atracurium in patients with chronic inflammatory bowel disease.
Br. J. Anaesth. 100: 798-802 (2008).
-
Soltner E, Neel A, Tiab M, Varin S, Cormier G, Maisonneuve H, Maugars Y, Tanguy G, Hamidou M, Berthelot JM. Chronic, eventually fatal, Kawasaki-like disease in an adult with spondylarthropathy responding to IVIG therapy.
Joint Bone Spine May 20 [Epub ahead of print] (2009).
*
-
Soltys J, Goyal PK, Wakelin D. Cellular immune responses in mice infected with the intestinal nematode Trichuris muris.
Exp. Parasitol. 92: 40-47 (1999).
*
-
Sonomoto K, Miyamura T, Watanabe H, Takahama S, Nakamura M, Ando H, Minami R, Yamamoto M, Saito T, Imayama S, Hosokawa C, Suematsu E. A case of polyarteritis nodosa successfully treated by rituximab.
Nihon Rinsho Meneki Gakkai Kaishi 31: 119-123 (2008).
-
Sorce M, Arico M, Bongiorno MR. Rituximab in refractory pemphigus vulgaris.
Dermatol. Ther. 21 Suppl. 1: S6-S9 (2008).
-
Sorensen RU, Kallick MD. Clinical uses of intravenous immune globulin: immunoglobulin replacement therapy and treatment of autoimmune cytopenias.
J. Clin. Apher. 4: 97-103 (1988).
-
Soria A, Matichard E, Descamps V, Crickx B. Bullous pemphigoid and acquired hemophilia.
Ann. Dermatol. Venereol. 134: 353-356 (2007).
-
Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.
J. Rheumatol. 33: 1422-1430 (2006).
-
Soska V. Secondary dyslipidemias and their treatment.
Vnitr. Lek. 53: 396-400 (2007).
-
Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease.
Am. J. Ophthalmol. 118: 601-611 (1994).
-
Soultati AS, Dourakis SP, Asvesti K, Nezi V, Alexopoulou A, Archimandritis AJ. Autoimmune blistering disease in a patient with Graves disease and vitiligo.
Am. J. Med. Sci. 333: 309-312 (2007).
-
Soy M, Oktun MT, Tuncbilek N, Ermantas N, Okten O, Altinay G, Turgut B. Nocardiosis in a patient with primary anti-phospholipid syndrome.
Rheumatol. Int. 26: 461-464 (2006).
*
-
Soy M, Pamuk ON, Gerenli M, Celik Y. A primary Sjogren's syndrome patient with distal renal tubular acidosis, who presented with symptoms of hypokalemic periodic paralysis. Report of a case study and review of the literature.
Rheumatol. Int. 26: 86-89 (2005).
*
-
Soyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L, Helland S, Middelfart K, Odu S, Falk ES, Solvoll K, Bjorneboe GA, Drevon CA. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis.
N. Engl. J. Med. 328: 1812-1816 (1993).
-
Spada M, Petz W, Bertani A, Riva S, Sonzogni A, Giovannelli M, Torri E, Torre G, Colledan M, Gridelli B. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression.
Am. J. Transplant. 6: 1913-1921 (2006).
*
-
Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Clin. Gastroenterol. Hepatol. 5: 209-214 (2007).
-
Sparsa A, Loustaud-Ratti V, Mousset-Hovaere M, De Vencay
| |
